This Robotics Growth Stock Could Turn $1,000 Into $4,000 by 2029

68
28
Favorite

This Robotics Growth Stock Could Turn $1,000 Into $4,000 by 2029

Motley Fool2021-09-09

Doing business as usual will be more than enough to make this company a strong investment. Key Points Companies with regularly recurring revenue have an easier time posting consistent revenue growth....

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment（28）

Tanyl
·2021-09-09
Try to buy ISRG & CAGR
Reply
1
Report
kevinlaisq
·2021-09-09
Pls like
Reply
1
Report
CTLT
·2021-09-09
Per share is so high now..
Reply
1
Report
Al385
·2021-09-09
?
Reply
3
Report
Potato11
·2021-09-09
Oh
Reply
2
Report
moliya
·2021-09-09
Really
Reply
4
Report
Fold Replies
- moliya:
  yeah yeah...
  2021-09-09
  Reply
  Report
Kczx
·2021-09-09
Go go go
Reply
4
Report
Fold Replies
- SeC:
  ?
  2021-09-11
  Reply
  Report
lyokel
·2021-09-09
Ok
Reply
4
Report
Rteo
·2021-09-09
X4 ?
Reply
2
Report
Andr3
·2021-09-09
Like please
Reply
5
Report
Fold Replies
- lyokel:
  done
  2021-09-09
  Reply
  Report
- Andr3:
  comment
  2021-09-09
  Reply
  Report
Boonseong
·2021-09-09
[財迷]
Reply
5
Report
Fold Replies
- Rteo:
  ?
  2021-09-09
  Reply
  Report
Kiattt
·2021-09-09
Like
Reply
4
Report
KMK
·2021-09-09
Plz like
Reply
5
Report
SillyOldBear
·2021-09-09
Like pls
Reply
5
Report
Fold Replies
- Kiattt:
  K
  2021-09-09
  Reply
  Report
clare288
·2021-09-09
Wow
Reply
7
Report
Fold Replies
- Vonz:
  oo
  2021-09-09
  Reply
  Report
- sncx00:
  oo
  2021-09-09
  Reply
  Report
thuiching
·2021-09-09
Like
Reply
7
Report
Fold Replies
- Expert126:
  ok
  2021-09-09
  Reply
  Report
Saintrade
·2021-09-09
Like and comments ty
Reply
6
Report
Fold Replies
- Saintrade:
  Ok
  2021-09-09
  Reply
  Report
StaceyLiew
·2021-09-09
Comment and like
Reply
10
Report
Fold Replies
- xoxoll:
  Ok
  2021-09-09
  Reply
  Report
- StaceyLiew:
  [强]
  2021-09-09
  Reply
  Report
xoxoll
·2021-09-09
Help me like
Reply
6
Report
Fold Replies
- thuiching:
  [微笑]
  2021-09-09
  Reply
  Report
Jrrr92
·2021-09-09
Good
Reply
6
Report
Fold Replies
- Darrs21:
  K
  2021-09-09
  Reply
  Report

Most Discussed

7x24

All

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/2166312201?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2021-09-09 19:41","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2166312201","market":"us","top_or_hot":-1,"title":"This Robotics Growth Stock Could Turn $1,000 Into $4,000 by 2029","media":"Motley Fool","content":"<div>\n<p>Doing business as usual will be more than enough to make this company a strong investment.\nKey Points\n\nCompanies with regularly recurring revenue have an easier time posting consistent revenue growth....</p>\n\n<a href=\"https://www.fool.com/investing/2021/09/09/this-robotics-growth-stock-could-turn-1000-into-40/\">Source Link</a>\n\n</div>\n","source":"fool_stock","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>This Robotics Growth Stock Could Turn $1,000 Into $4,000 by 2029</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThis Robotics Growth Stock Could Turn $1,000 Into $4,000 by 2029\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-09 19:41 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/09/09/this-robotics-growth-stock-could-turn-1000-into-40/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Doing business as usual will be more than enough to make this company a strong investment.\nKey Points\n\nCompanies with regularly recurring revenue have an easier time posting consistent revenue growth....</p>\n\n<a href=\"https://www.fool.com/investing/2021/09/09/this-robotics-growth-stock-could-turn-1000-into-40/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ISRG","symbol_name":"直觉外科公司","start_time":0,"source_url":"https://www.fool.com/investing/2021/09/09/this-robotics-growth-stock-could-turn-1000-into-40/","article_id":"2166312201","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2166312201","pubTimestamp":1631187660,"sourceInfo":{"source_id":"fool_stock","name":"Motley Fool"},"weMediaInfo":null,"summary":"Doing business as usual will be more than enough to make this company a strong investment.","collect":0,"end_time":0,"defaultTopTitle":"fool.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"ISRG":"直觉外科公司"},"translate_title":"到2029年，这支机器人成长股可能会将1000美元变成4000美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ISRG":0.9},"content_text":"Doing business as usual will be more than enough to make this company a strong investment.\nKey Points\n\nCompanies with regularly recurring revenue have an easier time posting consistent revenue growth.\nMaking products that are platforms for complex tasks is one way to build a recurring revenue base.\nSurgical robots are likely to be in demand in the coming years, just like they have been for the past decade.\n\nYou've probably heard that robots are the future for everything from manufacturing to retail distribution. But have you ever considered that they might be lucrative investments in the present?\nIntuitive Surgical(NASDAQ:ISRG) sits at the intersection of high-tech robotics and healthcare, and that's one of the many reasons why it's an exciting growth stock. Still, with a market cap in excess of $123 billion, investors are right to be skeptical about the stock's prospects for triple-digit percentage growth. Could Intuitive Surgical be a powerhouse for your portfolio with a relatively small initial investment, or is this stock's growth story approaching stagnation? Let's investigate by taking a look at its business model to start.\n\nImage source: Getty Images.\nBig growth is more than feasible\nOverall, Intuitive Surgical is primed to experience consistent and significant growth because of how it makes its income.\nIn case you aren't familiar, its main product is the da Vinci line of robotic surgical suites, which surgeons control from a station in the operating room. It also sells maintenance contracts and an ever-increasing selection of robotic surgical tools to use in conjunction with its da Vinci units. In total, these three product categories made the company $5.16 billion in trailing revenue, 77% of which is recurring.\nFor investors seeking growth stocks, there's nothing sweeter than a rock-solid revenue base. Importantly, there are a few different things that contribute to Intuitive's aggressive expansion of that base.\nThe most obvious is sales of its surgical suites, but that's just the start. Once a hospital has purchased a da Vinci unit and trained its surgeons, it's safe to say that it won't be buying a similar unit from competitors.\nSo, when Intuitive develops new surgical tools to expand the range of procedures performable with the robot, existing customers are highly likely to be interested in expanding the capabilities of the platform they own. Likewise, the more a hospital utilizes its surgical robotics, the more it'll need maintenance and a steady supply of replacement parts.\nAll of the above means that each newly installed surgical suite will render a significant amount of revenue over its lifetime, and the company is constantly installing more with each quarter. In the second quarter of 2021, there were 10% more da Vinci systems installed globally than in Q2 of 2020. Assuming that the business will continue to deploy its products at a similar rate, it'll have a massive pool of future sales opportunities to draw from over the next decade.\nBut will it make investors richer?\nI'm of the view that Intuitive's stock will multiply in value well before 2029.\nOver the next seven years, a $1,000 investment made today could grow to reach $4,000 in value if the stock expands with a compound annual growth rate (CAGR) of 21.9%. Let's take a closer look at why the stock is likely to grow by at least that much on an annual basis for the next few years.\nFirst, Intuitive's stock has been rising rapidly at an even faster rate over the past seven years. Since August 2014, the stock has grown by 567.5%, giving it a CAGR of about 31.5%. While skeptics might argue that the such a strong performance is unlikely to be repeated on a consistent basis, there is little evidence to suggest that growth is slowing.\nEven when including for the sharp drop in income and earnings that occurred when hospitals stopped performing elective surgeries during the first peak of the pandemic, the past three years have seen the company's quarterly revenue rise by nearly 59%, with quarterly earnings before interest, taxes, depreciation, and amortization (EBITDA) increasing by just over 70% in the same period. Likewise, its quarterly free cash flow (FCF) has grown by slightly more than 84% in the last five years, so its financial strength has been steadily increasing over time.\n\nISRG Revenue (Quarterly) data by YCharts\nThus, Intuitive doesn't need to change its business model or optimize its operations to keep expanding. And that means its prospects for being a winning growth stock are secure.\nWhen's the right time to buy?\nIn my view, there's little doubt that this stock could juice a $1,000 investment today into $4,000 over the next seven years, even if growth does end up slowing slightly. Still, there remains the question of when to make a purchase.\nGiven the company's ongoing efforts to develop new surgical tools, expand its portfolio of eligible procedures, and deploy more machines internationally, there's a smattering of catalysts for Intuitive's stock between now and 2029. At the same time, there's little chance of a competitor stealing revenue from accessory sales and maintenance for the established base of installed systems.\nSo, there isn't much to hold investors back from buying the stock today.","kind":null,"is_publish_news":true,"is_publish_highlight":true,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":883918943,"gmtCreate":1631195832382,"gmtModify":1676530493646,"author":{"id":"4087109808120260","authorId":"4087109808120260","name":"Tanyl","avatar":"https://static.tigerbbs.com/174329973340cf0f5b68791ee5b08afd","vip":1,"crmLevel":8,"crmLevelSwitch":1},"htmlText":"Try to buy ISRG &amp; CAGR","listText":"Try to buy ISRG &amp; CAGR","text":"Try to buy ISRG & CAGR","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/883918943","repostId":2166312201,"repostType":4,"repost":{"id":"2166312201","pubTimestamp":1631187660,"share":"https://www.laohu8.com/m/news/2166312201?lang=&edition=full","pubTime":"2021-09-09 19:41","market":"us","language":"en","title":"This Robotics Growth Stock Could Turn $1,000 Into $4,000 by 2029","url":"https://stock-news.laohu8.com/highlight/detail?id=2166312201","media":"Motley Fool","summary":"Doing business as usual will be more than enough to make this company a strong investment.","content":"<p>Doing business as usual will be more than enough to make this company a strong investment.</p>\n<p><b>Key Points</b></p>\n<ul>\n <li>Companies with regularly recurring revenue have an easier time posting consistent revenue growth.</li>\n <li>Making products that are platforms for complex tasks is one way to build a recurring revenue base.</li>\n <li>Surgical robots are likely to be in demand in the coming years, just like they have been for the past decade.</li>\n</ul>\n<p>You've probably heard that robots are the future for everything from manufacturing to retail distribution. But have you ever considered that they might be lucrative investments in the present?</p>\n<p><b>Intuitive Surgical</b>(NASDAQ:ISRG) sits at the intersection of high-tech robotics and healthcare, and that's <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the many reasons why it's an exciting growth stock. Still, with a market cap in excess of $123 billion, investors are right to be skeptical about the stock's prospects for triple-digit percentage growth. Could Intuitive Surgical be a powerhouse for your portfolio with a relatively small initial investment, or is this stock's growth story approaching stagnation? Let's investigate by taking a look at its business model to start.</p>\n<p><img src=\"https://static.tigerbbs.com/a92230e2013b2ec95bc9649c43631081\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: Getty Images.</p>\n<p><b>Big growth is more than feasible</b></p>\n<p>Overall, Intuitive Surgical is primed to experience consistent and significant growth because of how it makes its income.</p>\n<p>In case you aren't familiar, its main product is the da Vinci line of robotic surgical suites, which surgeons control from a station in the operating room. It also sells maintenance contracts and an ever-increasing selection of robotic surgical tools to use in conjunction with its da Vinci units. In total, these three product categories made the company $5.16 billion in trailing revenue, 77% of which is recurring.</p>\n<p>For investors seeking growth stocks, there's nothing sweeter than a rock-solid revenue base. Importantly, there are a few different things that contribute to Intuitive's aggressive expansion of that base.</p>\n<p>The most obvious is sales of its surgical suites, but that's just the start. Once a hospital has purchased a da Vinci unit and trained its surgeons, it's safe to say that it won't be buying a similar unit from competitors.</p>\n<p>So, when Intuitive develops new surgical tools to expand the range of procedures performable with the robot, existing customers are highly likely to be interested in expanding the capabilities of the platform they own. Likewise, the more a hospital utilizes its surgical robotics, the more it'll need maintenance and a steady supply of replacement parts.</p>\n<p>All of the above means that each newly installed surgical suite will render a significant amount of revenue over its lifetime, and the company is constantly installing more with each quarter. In the second quarter of 2021, there were 10% more da Vinci systems installed globally than in Q2 of 2020. Assuming that the business will continue to deploy its products at a similar rate, it'll have a massive pool of future sales opportunities to draw from over the next decade.</p>\n<p><b>But will it make investors richer?</b></p>\n<p>I'm of the view that Intuitive's stock will multiply in value well before 2029.</p>\n<p>Over the next seven years, a $1,000 investment made today could grow to reach $4,000 in value if the stock expands with a compound annual growth rate (CAGR) of 21.9%. Let's take a closer look at why the stock is likely to grow by at least that much on an annual basis for the next few years.</p>\n<p>First, Intuitive's stock has been rising rapidly at an even faster rate over the past seven years. Since August 2014, the stock has grown by 567.5%, giving it a CAGR of about 31.5%. While skeptics might argue that the such a strong performance is unlikely to be repeated on a consistent basis, there is little evidence to suggest that growth is slowing.</p>\n<p>Even when including for the sharp drop in income and earnings that occurred when hospitals stopped performing elective surgeries during the first peak of the pandemic, the past three years have seen the company's quarterly revenue rise by nearly 59%, with quarterly earnings before interest, taxes, depreciation, and amortization (EBITDA) increasing by just over 70% in the same period. Likewise, its quarterly free cash flow (FCF) has grown by slightly more than 84% in the last five years, so its financial strength has been steadily increasing over time.</p>\n<p><img src=\"https://static.tigerbbs.com/23c1a7a479389e7ae5416faa90fb0002\" tg-width=\"720\" tg-height=\"387\" referrerpolicy=\"no-referrer\"></p>\n<p>ISRG Revenue (Quarterly) data by YCharts</p>\n<p>Thus, Intuitive doesn't need to change its business model or optimize its operations to keep expanding. And that means its prospects for being a winning growth stock are secure.</p>\n<p><b>When's the right time to buy?</b></p>\n<p>In my view, there's little doubt that this stock could juice a $1,000 investment today into $4,000 over the next seven years, even if growth does end up slowing slightly. Still, there remains the question of when to make a purchase.</p>\n<p>Given the company's ongoing efforts to develop new surgical tools, expand its portfolio of eligible procedures, and deploy more machines internationally, there's a smattering of catalysts for Intuitive's stock between now and 2029. At the same time, there's little chance of a competitor stealing revenue from accessory sales and maintenance for the established base of installed systems.</p>\n<p>So, there isn't much to hold investors back from buying the stock today.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>This Robotics Growth Stock Could Turn $1,000 Into $4,000 by 2029</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThis Robotics Growth Stock Could Turn $1,000 Into $4,000 by 2029\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-09 19:41 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/09/09/this-robotics-growth-stock-could-turn-1000-into-40/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Doing business as usual will be more than enough to make this company a strong investment.\nKey Points\n\nCompanies with regularly recurring revenue have an easier time posting consistent revenue growth....</p>\n\n<a href=\"https://www.fool.com/investing/2021/09/09/this-robotics-growth-stock-could-turn-1000-into-40/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ISRG":"直觉外科公司"},"source_url":"https://www.fool.com/investing/2021/09/09/this-robotics-growth-stock-could-turn-1000-into-40/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2166312201","content_text":"Doing business as usual will be more than enough to make this company a strong investment.\nKey Points\n\nCompanies with regularly recurring revenue have an easier time posting consistent revenue growth.\nMaking products that are platforms for complex tasks is one way to build a recurring revenue base.\nSurgical robots are likely to be in demand in the coming years, just like they have been for the past decade.\n\nYou've probably heard that robots are the future for everything from manufacturing to retail distribution. But have you ever considered that they might be lucrative investments in the present?\nIntuitive Surgical(NASDAQ:ISRG) sits at the intersection of high-tech robotics and healthcare, and that's one of the many reasons why it's an exciting growth stock. Still, with a market cap in excess of $123 billion, investors are right to be skeptical about the stock's prospects for triple-digit percentage growth. Could Intuitive Surgical be a powerhouse for your portfolio with a relatively small initial investment, or is this stock's growth story approaching stagnation? Let's investigate by taking a look at its business model to start.\n\nImage source: Getty Images.\nBig growth is more than feasible\nOverall, Intuitive Surgical is primed to experience consistent and significant growth because of how it makes its income.\nIn case you aren't familiar, its main product is the da Vinci line of robotic surgical suites, which surgeons control from a station in the operating room. It also sells maintenance contracts and an ever-increasing selection of robotic surgical tools to use in conjunction with its da Vinci units. In total, these three product categories made the company $5.16 billion in trailing revenue, 77% of which is recurring.\nFor investors seeking growth stocks, there's nothing sweeter than a rock-solid revenue base. Importantly, there are a few different things that contribute to Intuitive's aggressive expansion of that base.\nThe most obvious is sales of its surgical suites, but that's just the start. Once a hospital has purchased a da Vinci unit and trained its surgeons, it's safe to say that it won't be buying a similar unit from competitors.\nSo, when Intuitive develops new surgical tools to expand the range of procedures performable with the robot, existing customers are highly likely to be interested in expanding the capabilities of the platform they own. Likewise, the more a hospital utilizes its surgical robotics, the more it'll need maintenance and a steady supply of replacement parts.\nAll of the above means that each newly installed surgical suite will render a significant amount of revenue over its lifetime, and the company is constantly installing more with each quarter. In the second quarter of 2021, there were 10% more da Vinci systems installed globally than in Q2 of 2020. Assuming that the business will continue to deploy its products at a similar rate, it'll have a massive pool of future sales opportunities to draw from over the next decade.\nBut will it make investors richer?\nI'm of the view that Intuitive's stock will multiply in value well before 2029.\nOver the next seven years, a $1,000 investment made today could grow to reach $4,000 in value if the stock expands with a compound annual growth rate (CAGR) of 21.9%. Let's take a closer look at why the stock is likely to grow by at least that much on an annual basis for the next few years.\nFirst, Intuitive's stock has been rising rapidly at an even faster rate over the past seven years. Since August 2014, the stock has grown by 567.5%, giving it a CAGR of about 31.5%. While skeptics might argue that the such a strong performance is unlikely to be repeated on a consistent basis, there is little evidence to suggest that growth is slowing.\nEven when including for the sharp drop in income and earnings that occurred when hospitals stopped performing elective surgeries during the first peak of the pandemic, the past three years have seen the company's quarterly revenue rise by nearly 59%, with quarterly earnings before interest, taxes, depreciation, and amortization (EBITDA) increasing by just over 70% in the same period. Likewise, its quarterly free cash flow (FCF) has grown by slightly more than 84% in the last five years, so its financial strength has been steadily increasing over time.\n\nISRG Revenue (Quarterly) data by YCharts\nThus, Intuitive doesn't need to change its business model or optimize its operations to keep expanding. And that means its prospects for being a winning growth stock are secure.\nWhen's the right time to buy?\nIn my view, there's little doubt that this stock could juice a $1,000 investment today into $4,000 over the next seven years, even if growth does end up slowing slightly. Still, there remains the question of when to make a purchase.\nGiven the company's ongoing efforts to develop new surgical tools, expand its portfolio of eligible procedures, and deploy more machines internationally, there's a smattering of catalysts for Intuitive's stock between now and 2029. At the same time, there's little chance of a competitor stealing revenue from accessory sales and maintenance for the established base of installed systems.\nSo, there isn't much to hold investors back from buying the stock today.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":883022546,"gmtCreate":1631191405385,"gmtModify":1676530491962,"author":{"id":"3572874548548490","authorId":"3572874548548490","name":"kevinlaisq","avatar":"https://static.tigerbbs.com/329de1199f764a89b7cadf50308e183d","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"Pls like","listText":"Pls like","text":"Pls like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/883022546","repostId":2166312201,"repostType":4,"repost":{"id":"2166312201","pubTimestamp":1631187660,"share":"https://www.laohu8.com/m/news/2166312201?lang=&edition=full","pubTime":"2021-09-09 19:41","market":"us","language":"en","title":"This Robotics Growth Stock Could Turn $1,000 Into $4,000 by 2029","url":"https://stock-news.laohu8.com/highlight/detail?id=2166312201","media":"Motley Fool","summary":"Doing business as usual will be more than enough to make this company a strong investment.","content":"<p>Doing business as usual will be more than enough to make this company a strong investment.</p>\n<p><b>Key Points</b></p>\n<ul>\n <li>Companies with regularly recurring revenue have an easier time posting consistent revenue growth.</li>\n <li>Making products that are platforms for complex tasks is one way to build a recurring revenue base.</li>\n <li>Surgical robots are likely to be in demand in the coming years, just like they have been for the past decade.</li>\n</ul>\n<p>You've probably heard that robots are the future for everything from manufacturing to retail distribution. But have you ever considered that they might be lucrative investments in the present?</p>\n<p><b>Intuitive Surgical</b>(NASDAQ:ISRG) sits at the intersection of high-tech robotics and healthcare, and that's <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the many reasons why it's an exciting growth stock. Still, with a market cap in excess of $123 billion, investors are right to be skeptical about the stock's prospects for triple-digit percentage growth. Could Intuitive Surgical be a powerhouse for your portfolio with a relatively small initial investment, or is this stock's growth story approaching stagnation? Let's investigate by taking a look at its business model to start.</p>\n<p><img src=\"https://static.tigerbbs.com/a92230e2013b2ec95bc9649c43631081\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: Getty Images.</p>\n<p><b>Big growth is more than feasible</b></p>\n<p>Overall, Intuitive Surgical is primed to experience consistent and significant growth because of how it makes its income.</p>\n<p>In case you aren't familiar, its main product is the da Vinci line of robotic surgical suites, which surgeons control from a station in the operating room. It also sells maintenance contracts and an ever-increasing selection of robotic surgical tools to use in conjunction with its da Vinci units. In total, these three product categories made the company $5.16 billion in trailing revenue, 77% of which is recurring.</p>\n<p>For investors seeking growth stocks, there's nothing sweeter than a rock-solid revenue base. Importantly, there are a few different things that contribute to Intuitive's aggressive expansion of that base.</p>\n<p>The most obvious is sales of its surgical suites, but that's just the start. Once a hospital has purchased a da Vinci unit and trained its surgeons, it's safe to say that it won't be buying a similar unit from competitors.</p>\n<p>So, when Intuitive develops new surgical tools to expand the range of procedures performable with the robot, existing customers are highly likely to be interested in expanding the capabilities of the platform they own. Likewise, the more a hospital utilizes its surgical robotics, the more it'll need maintenance and a steady supply of replacement parts.</p>\n<p>All of the above means that each newly installed surgical suite will render a significant amount of revenue over its lifetime, and the company is constantly installing more with each quarter. In the second quarter of 2021, there were 10% more da Vinci systems installed globally than in Q2 of 2020. Assuming that the business will continue to deploy its products at a similar rate, it'll have a massive pool of future sales opportunities to draw from over the next decade.</p>\n<p><b>But will it make investors richer?</b></p>\n<p>I'm of the view that Intuitive's stock will multiply in value well before 2029.</p>\n<p>Over the next seven years, a $1,000 investment made today could grow to reach $4,000 in value if the stock expands with a compound annual growth rate (CAGR) of 21.9%. Let's take a closer look at why the stock is likely to grow by at least that much on an annual basis for the next few years.</p>\n<p>First, Intuitive's stock has been rising rapidly at an even faster rate over the past seven years. Since August 2014, the stock has grown by 567.5%, giving it a CAGR of about 31.5%. While skeptics might argue that the such a strong performance is unlikely to be repeated on a consistent basis, there is little evidence to suggest that growth is slowing.</p>\n<p>Even when including for the sharp drop in income and earnings that occurred when hospitals stopped performing elective surgeries during the first peak of the pandemic, the past three years have seen the company's quarterly revenue rise by nearly 59%, with quarterly earnings before interest, taxes, depreciation, and amortization (EBITDA) increasing by just over 70% in the same period. Likewise, its quarterly free cash flow (FCF) has grown by slightly more than 84% in the last five years, so its financial strength has been steadily increasing over time.</p>\n<p><img src=\"https://static.tigerbbs.com/23c1a7a479389e7ae5416faa90fb0002\" tg-width=\"720\" tg-height=\"387\" referrerpolicy=\"no-referrer\"></p>\n<p>ISRG Revenue (Quarterly) data by YCharts</p>\n<p>Thus, Intuitive doesn't need to change its business model or optimize its operations to keep expanding. And that means its prospects for being a winning growth stock are secure.</p>\n<p><b>When's the right time to buy?</b></p>\n<p>In my view, there's little doubt that this stock could juice a $1,000 investment today into $4,000 over the next seven years, even if growth does end up slowing slightly. Still, there remains the question of when to make a purchase.</p>\n<p>Given the company's ongoing efforts to develop new surgical tools, expand its portfolio of eligible procedures, and deploy more machines internationally, there's a smattering of catalysts for Intuitive's stock between now and 2029. At the same time, there's little chance of a competitor stealing revenue from accessory sales and maintenance for the established base of installed systems.</p>\n<p>So, there isn't much to hold investors back from buying the stock today.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>This Robotics Growth Stock Could Turn $1,000 Into $4,000 by 2029</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThis Robotics Growth Stock Could Turn $1,000 Into $4,000 by 2029\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-09 19:41 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/09/09/this-robotics-growth-stock-could-turn-1000-into-40/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Doing business as usual will be more than enough to make this company a strong investment.\nKey Points\n\nCompanies with regularly recurring revenue have an easier time posting consistent revenue growth....</p>\n\n<a href=\"https://www.fool.com/investing/2021/09/09/this-robotics-growth-stock-could-turn-1000-into-40/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ISRG":"直觉外科公司"},"source_url":"https://www.fool.com/investing/2021/09/09/this-robotics-growth-stock-could-turn-1000-into-40/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2166312201","content_text":"Doing business as usual will be more than enough to make this company a strong investment.\nKey Points\n\nCompanies with regularly recurring revenue have an easier time posting consistent revenue growth.\nMaking products that are platforms for complex tasks is one way to build a recurring revenue base.\nSurgical robots are likely to be in demand in the coming years, just like they have been for the past decade.\n\nYou've probably heard that robots are the future for everything from manufacturing to retail distribution. But have you ever considered that they might be lucrative investments in the present?\nIntuitive Surgical(NASDAQ:ISRG) sits at the intersection of high-tech robotics and healthcare, and that's one of the many reasons why it's an exciting growth stock. Still, with a market cap in excess of $123 billion, investors are right to be skeptical about the stock's prospects for triple-digit percentage growth. Could Intuitive Surgical be a powerhouse for your portfolio with a relatively small initial investment, or is this stock's growth story approaching stagnation? Let's investigate by taking a look at its business model to start.\n\nImage source: Getty Images.\nBig growth is more than feasible\nOverall, Intuitive Surgical is primed to experience consistent and significant growth because of how it makes its income.\nIn case you aren't familiar, its main product is the da Vinci line of robotic surgical suites, which surgeons control from a station in the operating room. It also sells maintenance contracts and an ever-increasing selection of robotic surgical tools to use in conjunction with its da Vinci units. In total, these three product categories made the company $5.16 billion in trailing revenue, 77% of which is recurring.\nFor investors seeking growth stocks, there's nothing sweeter than a rock-solid revenue base. Importantly, there are a few different things that contribute to Intuitive's aggressive expansion of that base.\nThe most obvious is sales of its surgical suites, but that's just the start. Once a hospital has purchased a da Vinci unit and trained its surgeons, it's safe to say that it won't be buying a similar unit from competitors.\nSo, when Intuitive develops new surgical tools to expand the range of procedures performable with the robot, existing customers are highly likely to be interested in expanding the capabilities of the platform they own. Likewise, the more a hospital utilizes its surgical robotics, the more it'll need maintenance and a steady supply of replacement parts.\nAll of the above means that each newly installed surgical suite will render a significant amount of revenue over its lifetime, and the company is constantly installing more with each quarter. In the second quarter of 2021, there were 10% more da Vinci systems installed globally than in Q2 of 2020. Assuming that the business will continue to deploy its products at a similar rate, it'll have a massive pool of future sales opportunities to draw from over the next decade.\nBut will it make investors richer?\nI'm of the view that Intuitive's stock will multiply in value well before 2029.\nOver the next seven years, a $1,000 investment made today could grow to reach $4,000 in value if the stock expands with a compound annual growth rate (CAGR) of 21.9%. Let's take a closer look at why the stock is likely to grow by at least that much on an annual basis for the next few years.\nFirst, Intuitive's stock has been rising rapidly at an even faster rate over the past seven years. Since August 2014, the stock has grown by 567.5%, giving it a CAGR of about 31.5%. While skeptics might argue that the such a strong performance is unlikely to be repeated on a consistent basis, there is little evidence to suggest that growth is slowing.\nEven when including for the sharp drop in income and earnings that occurred when hospitals stopped performing elective surgeries during the first peak of the pandemic, the past three years have seen the company's quarterly revenue rise by nearly 59%, with quarterly earnings before interest, taxes, depreciation, and amortization (EBITDA) increasing by just over 70% in the same period. Likewise, its quarterly free cash flow (FCF) has grown by slightly more than 84% in the last five years, so its financial strength has been steadily increasing over time.\n\nISRG Revenue (Quarterly) data by YCharts\nThus, Intuitive doesn't need to change its business model or optimize its operations to keep expanding. And that means its prospects for being a winning growth stock are secure.\nWhen's the right time to buy?\nIn my view, there's little doubt that this stock could juice a $1,000 investment today into $4,000 over the next seven years, even if growth does end up slowing slightly. Still, there remains the question of when to make a purchase.\nGiven the company's ongoing efforts to develop new surgical tools, expand its portfolio of eligible procedures, and deploy more machines internationally, there's a smattering of catalysts for Intuitive's stock between now and 2029. At the same time, there's little chance of a competitor stealing revenue from accessory sales and maintenance for the established base of installed systems.\nSo, there isn't much to hold investors back from buying the stock today.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":883067679,"gmtCreate":1631190852191,"gmtModify":1676530491736,"author":{"id":"3575034880210493","authorId":"3575034880210493","name":"CTLT","avatar":"https://static.tigerbbs.com/7281d38ef945e595e240f73b0b57e538","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"Per share is so high now..","listText":"Per share is so high now..","text":"Per share is so high now..","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/883067679","repostId":2166312201,"repostType":4,"repost":{"id":"2166312201","pubTimestamp":1631187660,"share":"https://www.laohu8.com/m/news/2166312201?lang=&edition=full","pubTime":"2021-09-09 19:41","market":"us","language":"en","title":"This Robotics Growth Stock Could Turn $1,000 Into $4,000 by 2029","url":"https://stock-news.laohu8.com/highlight/detail?id=2166312201","media":"Motley Fool","summary":"Doing business as usual will be more than enough to make this company a strong investment.","content":"<p>Doing business as usual will be more than enough to make this company a strong investment.</p>\n<p><b>Key Points</b></p>\n<ul>\n <li>Companies with regularly recurring revenue have an easier time posting consistent revenue growth.</li>\n <li>Making products that are platforms for complex tasks is one way to build a recurring revenue base.</li>\n <li>Surgical robots are likely to be in demand in the coming years, just like they have been for the past decade.</li>\n</ul>\n<p>You've probably heard that robots are the future for everything from manufacturing to retail distribution. But have you ever considered that they might be lucrative investments in the present?</p>\n<p><b>Intuitive Surgical</b>(NASDAQ:ISRG) sits at the intersection of high-tech robotics and healthcare, and that's <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the many reasons why it's an exciting growth stock. Still, with a market cap in excess of $123 billion, investors are right to be skeptical about the stock's prospects for triple-digit percentage growth. Could Intuitive Surgical be a powerhouse for your portfolio with a relatively small initial investment, or is this stock's growth story approaching stagnation? Let's investigate by taking a look at its business model to start.</p>\n<p><img src=\"https://static.tigerbbs.com/a92230e2013b2ec95bc9649c43631081\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: Getty Images.</p>\n<p><b>Big growth is more than feasible</b></p>\n<p>Overall, Intuitive Surgical is primed to experience consistent and significant growth because of how it makes its income.</p>\n<p>In case you aren't familiar, its main product is the da Vinci line of robotic surgical suites, which surgeons control from a station in the operating room. It also sells maintenance contracts and an ever-increasing selection of robotic surgical tools to use in conjunction with its da Vinci units. In total, these three product categories made the company $5.16 billion in trailing revenue, 77% of which is recurring.</p>\n<p>For investors seeking growth stocks, there's nothing sweeter than a rock-solid revenue base. Importantly, there are a few different things that contribute to Intuitive's aggressive expansion of that base.</p>\n<p>The most obvious is sales of its surgical suites, but that's just the start. Once a hospital has purchased a da Vinci unit and trained its surgeons, it's safe to say that it won't be buying a similar unit from competitors.</p>\n<p>So, when Intuitive develops new surgical tools to expand the range of procedures performable with the robot, existing customers are highly likely to be interested in expanding the capabilities of the platform they own. Likewise, the more a hospital utilizes its surgical robotics, the more it'll need maintenance and a steady supply of replacement parts.</p>\n<p>All of the above means that each newly installed surgical suite will render a significant amount of revenue over its lifetime, and the company is constantly installing more with each quarter. In the second quarter of 2021, there were 10% more da Vinci systems installed globally than in Q2 of 2020. Assuming that the business will continue to deploy its products at a similar rate, it'll have a massive pool of future sales opportunities to draw from over the next decade.</p>\n<p><b>But will it make investors richer?</b></p>\n<p>I'm of the view that Intuitive's stock will multiply in value well before 2029.</p>\n<p>Over the next seven years, a $1,000 investment made today could grow to reach $4,000 in value if the stock expands with a compound annual growth rate (CAGR) of 21.9%. Let's take a closer look at why the stock is likely to grow by at least that much on an annual basis for the next few years.</p>\n<p>First, Intuitive's stock has been rising rapidly at an even faster rate over the past seven years. Since August 2014, the stock has grown by 567.5%, giving it a CAGR of about 31.5%. While skeptics might argue that the such a strong performance is unlikely to be repeated on a consistent basis, there is little evidence to suggest that growth is slowing.</p>\n<p>Even when including for the sharp drop in income and earnings that occurred when hospitals stopped performing elective surgeries during the first peak of the pandemic, the past three years have seen the company's quarterly revenue rise by nearly 59%, with quarterly earnings before interest, taxes, depreciation, and amortization (EBITDA) increasing by just over 70% in the same period. Likewise, its quarterly free cash flow (FCF) has grown by slightly more than 84% in the last five years, so its financial strength has been steadily increasing over time.</p>\n<p><img src=\"https://static.tigerbbs.com/23c1a7a479389e7ae5416faa90fb0002\" tg-width=\"720\" tg-height=\"387\" referrerpolicy=\"no-referrer\"></p>\n<p>ISRG Revenue (Quarterly) data by YCharts</p>\n<p>Thus, Intuitive doesn't need to change its business model or optimize its operations to keep expanding. And that means its prospects for being a winning growth stock are secure.</p>\n<p><b>When's the right time to buy?</b></p>\n<p>In my view, there's little doubt that this stock could juice a $1,000 investment today into $4,000 over the next seven years, even if growth does end up slowing slightly. Still, there remains the question of when to make a purchase.</p>\n<p>Given the company's ongoing efforts to develop new surgical tools, expand its portfolio of eligible procedures, and deploy more machines internationally, there's a smattering of catalysts for Intuitive's stock between now and 2029. At the same time, there's little chance of a competitor stealing revenue from accessory sales and maintenance for the established base of installed systems.</p>\n<p>So, there isn't much to hold investors back from buying the stock today.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>This Robotics Growth Stock Could Turn $1,000 Into $4,000 by 2029</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThis Robotics Growth Stock Could Turn $1,000 Into $4,000 by 2029\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-09 19:41 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/09/09/this-robotics-growth-stock-could-turn-1000-into-40/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Doing business as usual will be more than enough to make this company a strong investment.\nKey Points\n\nCompanies with regularly recurring revenue have an easier time posting consistent revenue growth....</p>\n\n<a href=\"https://www.fool.com/investing/2021/09/09/this-robotics-growth-stock-could-turn-1000-into-40/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ISRG":"直觉外科公司"},"source_url":"https://www.fool.com/investing/2021/09/09/this-robotics-growth-stock-could-turn-1000-into-40/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2166312201","content_text":"Doing business as usual will be more than enough to make this company a strong investment.\nKey Points\n\nCompanies with regularly recurring revenue have an easier time posting consistent revenue growth.\nMaking products that are platforms for complex tasks is one way to build a recurring revenue base.\nSurgical robots are likely to be in demand in the coming years, just like they have been for the past decade.\n\nYou've probably heard that robots are the future for everything from manufacturing to retail distribution. But have you ever considered that they might be lucrative investments in the present?\nIntuitive Surgical(NASDAQ:ISRG) sits at the intersection of high-tech robotics and healthcare, and that's one of the many reasons why it's an exciting growth stock. Still, with a market cap in excess of $123 billion, investors are right to be skeptical about the stock's prospects for triple-digit percentage growth. Could Intuitive Surgical be a powerhouse for your portfolio with a relatively small initial investment, or is this stock's growth story approaching stagnation? Let's investigate by taking a look at its business model to start.\n\nImage source: Getty Images.\nBig growth is more than feasible\nOverall, Intuitive Surgical is primed to experience consistent and significant growth because of how it makes its income.\nIn case you aren't familiar, its main product is the da Vinci line of robotic surgical suites, which surgeons control from a station in the operating room. It also sells maintenance contracts and an ever-increasing selection of robotic surgical tools to use in conjunction with its da Vinci units. In total, these three product categories made the company $5.16 billion in trailing revenue, 77% of which is recurring.\nFor investors seeking growth stocks, there's nothing sweeter than a rock-solid revenue base. Importantly, there are a few different things that contribute to Intuitive's aggressive expansion of that base.\nThe most obvious is sales of its surgical suites, but that's just the start. Once a hospital has purchased a da Vinci unit and trained its surgeons, it's safe to say that it won't be buying a similar unit from competitors.\nSo, when Intuitive develops new surgical tools to expand the range of procedures performable with the robot, existing customers are highly likely to be interested in expanding the capabilities of the platform they own. Likewise, the more a hospital utilizes its surgical robotics, the more it'll need maintenance and a steady supply of replacement parts.\nAll of the above means that each newly installed surgical suite will render a significant amount of revenue over its lifetime, and the company is constantly installing more with each quarter. In the second quarter of 2021, there were 10% more da Vinci systems installed globally than in Q2 of 2020. Assuming that the business will continue to deploy its products at a similar rate, it'll have a massive pool of future sales opportunities to draw from over the next decade.\nBut will it make investors richer?\nI'm of the view that Intuitive's stock will multiply in value well before 2029.\nOver the next seven years, a $1,000 investment made today could grow to reach $4,000 in value if the stock expands with a compound annual growth rate (CAGR) of 21.9%. Let's take a closer look at why the stock is likely to grow by at least that much on an annual basis for the next few years.\nFirst, Intuitive's stock has been rising rapidly at an even faster rate over the past seven years. Since August 2014, the stock has grown by 567.5%, giving it a CAGR of about 31.5%. While skeptics might argue that the such a strong performance is unlikely to be repeated on a consistent basis, there is little evidence to suggest that growth is slowing.\nEven when including for the sharp drop in income and earnings that occurred when hospitals stopped performing elective surgeries during the first peak of the pandemic, the past three years have seen the company's quarterly revenue rise by nearly 59%, with quarterly earnings before interest, taxes, depreciation, and amortization (EBITDA) increasing by just over 70% in the same period. Likewise, its quarterly free cash flow (FCF) has grown by slightly more than 84% in the last five years, so its financial strength has been steadily increasing over time.\n\nISRG Revenue (Quarterly) data by YCharts\nThus, Intuitive doesn't need to change its business model or optimize its operations to keep expanding. And that means its prospects for being a winning growth stock are secure.\nWhen's the right time to buy?\nIn my view, there's little doubt that this stock could juice a $1,000 investment today into $4,000 over the next seven years, even if growth does end up slowing slightly. Still, there remains the question of when to make a purchase.\nGiven the company's ongoing efforts to develop new surgical tools, expand its portfolio of eligible procedures, and deploy more machines internationally, there's a smattering of catalysts for Intuitive's stock between now and 2029. At the same time, there's little chance of a competitor stealing revenue from accessory sales and maintenance for the established base of installed systems.\nSo, there isn't much to hold investors back from buying the stock today.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":883062735,"gmtCreate":1631190733827,"gmtModify":1676530491687,"author":{"id":"3563863691814974","authorId":"3563863691814974","name":"Al385","avatar":"https://static.tigerbbs.com/51b962289811e9774fd45f1320a21259","vip":1,"crmLevel":3,"crmLevelSwitch":0},"htmlText":"?","listText":"?","text":"?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/883062735","repostId":2166312201,"repostType":4,"repost":{"id":"2166312201","pubTimestamp":1631187660,"share":"https://www.laohu8.com/m/news/2166312201?lang=&edition=full","pubTime":"2021-09-09 19:41","market":"us","language":"en","title":"This Robotics Growth Stock Could Turn $1,000 Into $4,000 by 2029","url":"https://stock-news.laohu8.com/highlight/detail?id=2166312201","media":"Motley Fool","summary":"Doing business as usual will be more than enough to make this company a strong investment.","content":"<p>Doing business as usual will be more than enough to make this company a strong investment.</p>\n<p><b>Key Points</b></p>\n<ul>\n <li>Companies with regularly recurring revenue have an easier time posting consistent revenue growth.</li>\n <li>Making products that are platforms for complex tasks is one way to build a recurring revenue base.</li>\n <li>Surgical robots are likely to be in demand in the coming years, just like they have been for the past decade.</li>\n</ul>\n<p>You've probably heard that robots are the future for everything from manufacturing to retail distribution. But have you ever considered that they might be lucrative investments in the present?</p>\n<p><b>Intuitive Surgical</b>(NASDAQ:ISRG) sits at the intersection of high-tech robotics and healthcare, and that's <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the many reasons why it's an exciting growth stock. Still, with a market cap in excess of $123 billion, investors are right to be skeptical about the stock's prospects for triple-digit percentage growth. Could Intuitive Surgical be a powerhouse for your portfolio with a relatively small initial investment, or is this stock's growth story approaching stagnation? Let's investigate by taking a look at its business model to start.</p>\n<p><img src=\"https://static.tigerbbs.com/a92230e2013b2ec95bc9649c43631081\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: Getty Images.</p>\n<p><b>Big growth is more than feasible</b></p>\n<p>Overall, Intuitive Surgical is primed to experience consistent and significant growth because of how it makes its income.</p>\n<p>In case you aren't familiar, its main product is the da Vinci line of robotic surgical suites, which surgeons control from a station in the operating room. It also sells maintenance contracts and an ever-increasing selection of robotic surgical tools to use in conjunction with its da Vinci units. In total, these three product categories made the company $5.16 billion in trailing revenue, 77% of which is recurring.</p>\n<p>For investors seeking growth stocks, there's nothing sweeter than a rock-solid revenue base. Importantly, there are a few different things that contribute to Intuitive's aggressive expansion of that base.</p>\n<p>The most obvious is sales of its surgical suites, but that's just the start. Once a hospital has purchased a da Vinci unit and trained its surgeons, it's safe to say that it won't be buying a similar unit from competitors.</p>\n<p>So, when Intuitive develops new surgical tools to expand the range of procedures performable with the robot, existing customers are highly likely to be interested in expanding the capabilities of the platform they own. Likewise, the more a hospital utilizes its surgical robotics, the more it'll need maintenance and a steady supply of replacement parts.</p>\n<p>All of the above means that each newly installed surgical suite will render a significant amount of revenue over its lifetime, and the company is constantly installing more with each quarter. In the second quarter of 2021, there were 10% more da Vinci systems installed globally than in Q2 of 2020. Assuming that the business will continue to deploy its products at a similar rate, it'll have a massive pool of future sales opportunities to draw from over the next decade.</p>\n<p><b>But will it make investors richer?</b></p>\n<p>I'm of the view that Intuitive's stock will multiply in value well before 2029.</p>\n<p>Over the next seven years, a $1,000 investment made today could grow to reach $4,000 in value if the stock expands with a compound annual growth rate (CAGR) of 21.9%. Let's take a closer look at why the stock is likely to grow by at least that much on an annual basis for the next few years.</p>\n<p>First, Intuitive's stock has been rising rapidly at an even faster rate over the past seven years. Since August 2014, the stock has grown by 567.5%, giving it a CAGR of about 31.5%. While skeptics might argue that the such a strong performance is unlikely to be repeated on a consistent basis, there is little evidence to suggest that growth is slowing.</p>\n<p>Even when including for the sharp drop in income and earnings that occurred when hospitals stopped performing elective surgeries during the first peak of the pandemic, the past three years have seen the company's quarterly revenue rise by nearly 59%, with quarterly earnings before interest, taxes, depreciation, and amortization (EBITDA) increasing by just over 70% in the same period. Likewise, its quarterly free cash flow (FCF) has grown by slightly more than 84% in the last five years, so its financial strength has been steadily increasing over time.</p>\n<p><img src=\"https://static.tigerbbs.com/23c1a7a479389e7ae5416faa90fb0002\" tg-width=\"720\" tg-height=\"387\" referrerpolicy=\"no-referrer\"></p>\n<p>ISRG Revenue (Quarterly) data by YCharts</p>\n<p>Thus, Intuitive doesn't need to change its business model or optimize its operations to keep expanding. And that means its prospects for being a winning growth stock are secure.</p>\n<p><b>When's the right time to buy?</b></p>\n<p>In my view, there's little doubt that this stock could juice a $1,000 investment today into $4,000 over the next seven years, even if growth does end up slowing slightly. Still, there remains the question of when to make a purchase.</p>\n<p>Given the company's ongoing efforts to develop new surgical tools, expand its portfolio of eligible procedures, and deploy more machines internationally, there's a smattering of catalysts for Intuitive's stock between now and 2029. At the same time, there's little chance of a competitor stealing revenue from accessory sales and maintenance for the established base of installed systems.</p>\n<p>So, there isn't much to hold investors back from buying the stock today.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>This Robotics Growth Stock Could Turn $1,000 Into $4,000 by 2029</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThis Robotics Growth Stock Could Turn $1,000 Into $4,000 by 2029\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-09 19:41 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/09/09/this-robotics-growth-stock-could-turn-1000-into-40/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Doing business as usual will be more than enough to make this company a strong investment.\nKey Points\n\nCompanies with regularly recurring revenue have an easier time posting consistent revenue growth....</p>\n\n<a href=\"https://www.fool.com/investing/2021/09/09/this-robotics-growth-stock-could-turn-1000-into-40/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ISRG":"直觉外科公司"},"source_url":"https://www.fool.com/investing/2021/09/09/this-robotics-growth-stock-could-turn-1000-into-40/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2166312201","content_text":"Doing business as usual will be more than enough to make this company a strong investment.\nKey Points\n\nCompanies with regularly recurring revenue have an easier time posting consistent revenue growth.\nMaking products that are platforms for complex tasks is one way to build a recurring revenue base.\nSurgical robots are likely to be in demand in the coming years, just like they have been for the past decade.\n\nYou've probably heard that robots are the future for everything from manufacturing to retail distribution. But have you ever considered that they might be lucrative investments in the present?\nIntuitive Surgical(NASDAQ:ISRG) sits at the intersection of high-tech robotics and healthcare, and that's one of the many reasons why it's an exciting growth stock. Still, with a market cap in excess of $123 billion, investors are right to be skeptical about the stock's prospects for triple-digit percentage growth. Could Intuitive Surgical be a powerhouse for your portfolio with a relatively small initial investment, or is this stock's growth story approaching stagnation? Let's investigate by taking a look at its business model to start.\n\nImage source: Getty Images.\nBig growth is more than feasible\nOverall, Intuitive Surgical is primed to experience consistent and significant growth because of how it makes its income.\nIn case you aren't familiar, its main product is the da Vinci line of robotic surgical suites, which surgeons control from a station in the operating room. It also sells maintenance contracts and an ever-increasing selection of robotic surgical tools to use in conjunction with its da Vinci units. In total, these three product categories made the company $5.16 billion in trailing revenue, 77% of which is recurring.\nFor investors seeking growth stocks, there's nothing sweeter than a rock-solid revenue base. Importantly, there are a few different things that contribute to Intuitive's aggressive expansion of that base.\nThe most obvious is sales of its surgical suites, but that's just the start. Once a hospital has purchased a da Vinci unit and trained its surgeons, it's safe to say that it won't be buying a similar unit from competitors.\nSo, when Intuitive develops new surgical tools to expand the range of procedures performable with the robot, existing customers are highly likely to be interested in expanding the capabilities of the platform they own. Likewise, the more a hospital utilizes its surgical robotics, the more it'll need maintenance and a steady supply of replacement parts.\nAll of the above means that each newly installed surgical suite will render a significant amount of revenue over its lifetime, and the company is constantly installing more with each quarter. In the second quarter of 2021, there were 10% more da Vinci systems installed globally than in Q2 of 2020. Assuming that the business will continue to deploy its products at a similar rate, it'll have a massive pool of future sales opportunities to draw from over the next decade.\nBut will it make investors richer?\nI'm of the view that Intuitive's stock will multiply in value well before 2029.\nOver the next seven years, a $1,000 investment made today could grow to reach $4,000 in value if the stock expands with a compound annual growth rate (CAGR) of 21.9%. Let's take a closer look at why the stock is likely to grow by at least that much on an annual basis for the next few years.\nFirst, Intuitive's stock has been rising rapidly at an even faster rate over the past seven years. Since August 2014, the stock has grown by 567.5%, giving it a CAGR of about 31.5%. While skeptics might argue that the such a strong performance is unlikely to be repeated on a consistent basis, there is little evidence to suggest that growth is slowing.\nEven when including for the sharp drop in income and earnings that occurred when hospitals stopped performing elective surgeries during the first peak of the pandemic, the past three years have seen the company's quarterly revenue rise by nearly 59%, with quarterly earnings before interest, taxes, depreciation, and amortization (EBITDA) increasing by just over 70% in the same period. Likewise, its quarterly free cash flow (FCF) has grown by slightly more than 84% in the last five years, so its financial strength has been steadily increasing over time.\n\nISRG Revenue (Quarterly) data by YCharts\nThus, Intuitive doesn't need to change its business model or optimize its operations to keep expanding. And that means its prospects for being a winning growth stock are secure.\nWhen's the right time to buy?\nIn my view, there's little doubt that this stock could juice a $1,000 investment today into $4,000 over the next seven years, even if growth does end up slowing slightly. Still, there remains the question of when to make a purchase.\nGiven the company's ongoing efforts to develop new surgical tools, expand its portfolio of eligible procedures, and deploy more machines internationally, there's a smattering of catalysts for Intuitive's stock between now and 2029. At the same time, there's little chance of a competitor stealing revenue from accessory sales and maintenance for the established base of installed systems.\nSo, there isn't much to hold investors back from buying the stock today.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":883066472,"gmtCreate":1631190563196,"gmtModify":1676530491660,"author":{"id":"3563765020637097","authorId":"3563765020637097","name":"Potato11","avatar":"https://static.tigerbbs.com/90745aebd82041ad3402ae7268e01714","vip":1,"crmLevel":3,"crmLevelSwitch":0},"htmlText":"Oh","listText":"Oh","text":"Oh","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/883066472","repostId":2166312201,"repostType":4,"repost":{"id":"2166312201","pubTimestamp":1631187660,"share":"https://www.laohu8.com/m/news/2166312201?lang=&edition=full","pubTime":"2021-09-09 19:41","market":"us","language":"en","title":"This Robotics Growth Stock Could Turn $1,000 Into $4,000 by 2029","url":"https://stock-news.laohu8.com/highlight/detail?id=2166312201","media":"Motley Fool","summary":"Doing business as usual will be more than enough to make this company a strong investment.","content":"<p>Doing business as usual will be more than enough to make this company a strong investment.</p>\n<p><b>Key Points</b></p>\n<ul>\n <li>Companies with regularly recurring revenue have an easier time posting consistent revenue growth.</li>\n <li>Making products that are platforms for complex tasks is one way to build a recurring revenue base.</li>\n <li>Surgical robots are likely to be in demand in the coming years, just like they have been for the past decade.</li>\n</ul>\n<p>You've probably heard that robots are the future for everything from manufacturing to retail distribution. But have you ever considered that they might be lucrative investments in the present?</p>\n<p><b>Intuitive Surgical</b>(NASDAQ:ISRG) sits at the intersection of high-tech robotics and healthcare, and that's <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the many reasons why it's an exciting growth stock. Still, with a market cap in excess of $123 billion, investors are right to be skeptical about the stock's prospects for triple-digit percentage growth. Could Intuitive Surgical be a powerhouse for your portfolio with a relatively small initial investment, or is this stock's growth story approaching stagnation? Let's investigate by taking a look at its business model to start.</p>\n<p><img src=\"https://static.tigerbbs.com/a92230e2013b2ec95bc9649c43631081\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: Getty Images.</p>\n<p><b>Big growth is more than feasible</b></p>\n<p>Overall, Intuitive Surgical is primed to experience consistent and significant growth because of how it makes its income.</p>\n<p>In case you aren't familiar, its main product is the da Vinci line of robotic surgical suites, which surgeons control from a station in the operating room. It also sells maintenance contracts and an ever-increasing selection of robotic surgical tools to use in conjunction with its da Vinci units. In total, these three product categories made the company $5.16 billion in trailing revenue, 77% of which is recurring.</p>\n<p>For investors seeking growth stocks, there's nothing sweeter than a rock-solid revenue base. Importantly, there are a few different things that contribute to Intuitive's aggressive expansion of that base.</p>\n<p>The most obvious is sales of its surgical suites, but that's just the start. Once a hospital has purchased a da Vinci unit and trained its surgeons, it's safe to say that it won't be buying a similar unit from competitors.</p>\n<p>So, when Intuitive develops new surgical tools to expand the range of procedures performable with the robot, existing customers are highly likely to be interested in expanding the capabilities of the platform they own. Likewise, the more a hospital utilizes its surgical robotics, the more it'll need maintenance and a steady supply of replacement parts.</p>\n<p>All of the above means that each newly installed surgical suite will render a significant amount of revenue over its lifetime, and the company is constantly installing more with each quarter. In the second quarter of 2021, there were 10% more da Vinci systems installed globally than in Q2 of 2020. Assuming that the business will continue to deploy its products at a similar rate, it'll have a massive pool of future sales opportunities to draw from over the next decade.</p>\n<p><b>But will it make investors richer?</b></p>\n<p>I'm of the view that Intuitive's stock will multiply in value well before 2029.</p>\n<p>Over the next seven years, a $1,000 investment made today could grow to reach $4,000 in value if the stock expands with a compound annual growth rate (CAGR) of 21.9%. Let's take a closer look at why the stock is likely to grow by at least that much on an annual basis for the next few years.</p>\n<p>First, Intuitive's stock has been rising rapidly at an even faster rate over the past seven years. Since August 2014, the stock has grown by 567.5%, giving it a CAGR of about 31.5%. While skeptics might argue that the such a strong performance is unlikely to be repeated on a consistent basis, there is little evidence to suggest that growth is slowing.</p>\n<p>Even when including for the sharp drop in income and earnings that occurred when hospitals stopped performing elective surgeries during the first peak of the pandemic, the past three years have seen the company's quarterly revenue rise by nearly 59%, with quarterly earnings before interest, taxes, depreciation, and amortization (EBITDA) increasing by just over 70% in the same period. Likewise, its quarterly free cash flow (FCF) has grown by slightly more than 84% in the last five years, so its financial strength has been steadily increasing over time.</p>\n<p><img src=\"https://static.tigerbbs.com/23c1a7a479389e7ae5416faa90fb0002\" tg-width=\"720\" tg-height=\"387\" referrerpolicy=\"no-referrer\"></p>\n<p>ISRG Revenue (Quarterly) data by YCharts</p>\n<p>Thus, Intuitive doesn't need to change its business model or optimize its operations to keep expanding. And that means its prospects for being a winning growth stock are secure.</p>\n<p><b>When's the right time to buy?</b></p>\n<p>In my view, there's little doubt that this stock could juice a $1,000 investment today into $4,000 over the next seven years, even if growth does end up slowing slightly. Still, there remains the question of when to make a purchase.</p>\n<p>Given the company's ongoing efforts to develop new surgical tools, expand its portfolio of eligible procedures, and deploy more machines internationally, there's a smattering of catalysts for Intuitive's stock between now and 2029. At the same time, there's little chance of a competitor stealing revenue from accessory sales and maintenance for the established base of installed systems.</p>\n<p>So, there isn't much to hold investors back from buying the stock today.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>This Robotics Growth Stock Could Turn $1,000 Into $4,000 by 2029</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThis Robotics Growth Stock Could Turn $1,000 Into $4,000 by 2029\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-09 19:41 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/09/09/this-robotics-growth-stock-could-turn-1000-into-40/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Doing business as usual will be more than enough to make this company a strong investment.\nKey Points\n\nCompanies with regularly recurring revenue have an easier time posting consistent revenue growth....</p>\n\n<a href=\"https://www.fool.com/investing/2021/09/09/this-robotics-growth-stock-could-turn-1000-into-40/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ISRG":"直觉外科公司"},"source_url":"https://www.fool.com/investing/2021/09/09/this-robotics-growth-stock-could-turn-1000-into-40/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2166312201","content_text":"Doing business as usual will be more than enough to make this company a strong investment.\nKey Points\n\nCompanies with regularly recurring revenue have an easier time posting consistent revenue growth.\nMaking products that are platforms for complex tasks is one way to build a recurring revenue base.\nSurgical robots are likely to be in demand in the coming years, just like they have been for the past decade.\n\nYou've probably heard that robots are the future for everything from manufacturing to retail distribution. But have you ever considered that they might be lucrative investments in the present?\nIntuitive Surgical(NASDAQ:ISRG) sits at the intersection of high-tech robotics and healthcare, and that's one of the many reasons why it's an exciting growth stock. Still, with a market cap in excess of $123 billion, investors are right to be skeptical about the stock's prospects for triple-digit percentage growth. Could Intuitive Surgical be a powerhouse for your portfolio with a relatively small initial investment, or is this stock's growth story approaching stagnation? Let's investigate by taking a look at its business model to start.\n\nImage source: Getty Images.\nBig growth is more than feasible\nOverall, Intuitive Surgical is primed to experience consistent and significant growth because of how it makes its income.\nIn case you aren't familiar, its main product is the da Vinci line of robotic surgical suites, which surgeons control from a station in the operating room. It also sells maintenance contracts and an ever-increasing selection of robotic surgical tools to use in conjunction with its da Vinci units. In total, these three product categories made the company $5.16 billion in trailing revenue, 77% of which is recurring.\nFor investors seeking growth stocks, there's nothing sweeter than a rock-solid revenue base. Importantly, there are a few different things that contribute to Intuitive's aggressive expansion of that base.\nThe most obvious is sales of its surgical suites, but that's just the start. Once a hospital has purchased a da Vinci unit and trained its surgeons, it's safe to say that it won't be buying a similar unit from competitors.\nSo, when Intuitive develops new surgical tools to expand the range of procedures performable with the robot, existing customers are highly likely to be interested in expanding the capabilities of the platform they own. Likewise, the more a hospital utilizes its surgical robotics, the more it'll need maintenance and a steady supply of replacement parts.\nAll of the above means that each newly installed surgical suite will render a significant amount of revenue over its lifetime, and the company is constantly installing more with each quarter. In the second quarter of 2021, there were 10% more da Vinci systems installed globally than in Q2 of 2020. Assuming that the business will continue to deploy its products at a similar rate, it'll have a massive pool of future sales opportunities to draw from over the next decade.\nBut will it make investors richer?\nI'm of the view that Intuitive's stock will multiply in value well before 2029.\nOver the next seven years, a $1,000 investment made today could grow to reach $4,000 in value if the stock expands with a compound annual growth rate (CAGR) of 21.9%. Let's take a closer look at why the stock is likely to grow by at least that much on an annual basis for the next few years.\nFirst, Intuitive's stock has been rising rapidly at an even faster rate over the past seven years. Since August 2014, the stock has grown by 567.5%, giving it a CAGR of about 31.5%. While skeptics might argue that the such a strong performance is unlikely to be repeated on a consistent basis, there is little evidence to suggest that growth is slowing.\nEven when including for the sharp drop in income and earnings that occurred when hospitals stopped performing elective surgeries during the first peak of the pandemic, the past three years have seen the company's quarterly revenue rise by nearly 59%, with quarterly earnings before interest, taxes, depreciation, and amortization (EBITDA) increasing by just over 70% in the same period. Likewise, its quarterly free cash flow (FCF) has grown by slightly more than 84% in the last five years, so its financial strength has been steadily increasing over time.\n\nISRG Revenue (Quarterly) data by YCharts\nThus, Intuitive doesn't need to change its business model or optimize its operations to keep expanding. And that means its prospects for being a winning growth stock are secure.\nWhen's the right time to buy?\nIn my view, there's little doubt that this stock could juice a $1,000 investment today into $4,000 over the next seven years, even if growth does end up slowing slightly. Still, there remains the question of when to make a purchase.\nGiven the company's ongoing efforts to develop new surgical tools, expand its portfolio of eligible procedures, and deploy more machines internationally, there's a smattering of catalysts for Intuitive's stock between now and 2029. At the same time, there's little chance of a competitor stealing revenue from accessory sales and maintenance for the established base of installed systems.\nSo, there isn't much to hold investors back from buying the stock today.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":883063516,"gmtCreate":1631190271335,"gmtModify":1676530491576,"author":{"id":"3552850525395609","authorId":"3552850525395609","name":"moliya","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"hat":"https://static.tigerbbs.com/7b75ce0c34afff716602792a5d0929dd","crmLevel":3,"crmLevelSwitch":1},"htmlText":"Really","listText":"Really","text":"Really","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/883063516","repostId":2166312201,"repostType":4,"repost":{"id":"2166312201","pubTimestamp":1631187660,"share":"https://www.laohu8.com/m/news/2166312201?lang=&edition=full","pubTime":"2021-09-09 19:41","market":"us","language":"en","title":"This Robotics Growth Stock Could Turn $1,000 Into $4,000 by 2029","url":"https://stock-news.laohu8.com/highlight/detail?id=2166312201","media":"Motley Fool","summary":"Doing business as usual will be more than enough to make this company a strong investment.","content":"<p>Doing business as usual will be more than enough to make this company a strong investment.</p>\n<p><b>Key Points</b></p>\n<ul>\n <li>Companies with regularly recurring revenue have an easier time posting consistent revenue growth.</li>\n <li>Making products that are platforms for complex tasks is one way to build a recurring revenue base.</li>\n <li>Surgical robots are likely to be in demand in the coming years, just like they have been for the past decade.</li>\n</ul>\n<p>You've probably heard that robots are the future for everything from manufacturing to retail distribution. But have you ever considered that they might be lucrative investments in the present?</p>\n<p><b>Intuitive Surgical</b>(NASDAQ:ISRG) sits at the intersection of high-tech robotics and healthcare, and that's <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the many reasons why it's an exciting growth stock. Still, with a market cap in excess of $123 billion, investors are right to be skeptical about the stock's prospects for triple-digit percentage growth. Could Intuitive Surgical be a powerhouse for your portfolio with a relatively small initial investment, or is this stock's growth story approaching stagnation? Let's investigate by taking a look at its business model to start.</p>\n<p><img src=\"https://static.tigerbbs.com/a92230e2013b2ec95bc9649c43631081\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: Getty Images.</p>\n<p><b>Big growth is more than feasible</b></p>\n<p>Overall, Intuitive Surgical is primed to experience consistent and significant growth because of how it makes its income.</p>\n<p>In case you aren't familiar, its main product is the da Vinci line of robotic surgical suites, which surgeons control from a station in the operating room. It also sells maintenance contracts and an ever-increasing selection of robotic surgical tools to use in conjunction with its da Vinci units. In total, these three product categories made the company $5.16 billion in trailing revenue, 77% of which is recurring.</p>\n<p>For investors seeking growth stocks, there's nothing sweeter than a rock-solid revenue base. Importantly, there are a few different things that contribute to Intuitive's aggressive expansion of that base.</p>\n<p>The most obvious is sales of its surgical suites, but that's just the start. Once a hospital has purchased a da Vinci unit and trained its surgeons, it's safe to say that it won't be buying a similar unit from competitors.</p>\n<p>So, when Intuitive develops new surgical tools to expand the range of procedures performable with the robot, existing customers are highly likely to be interested in expanding the capabilities of the platform they own. Likewise, the more a hospital utilizes its surgical robotics, the more it'll need maintenance and a steady supply of replacement parts.</p>\n<p>All of the above means that each newly installed surgical suite will render a significant amount of revenue over its lifetime, and the company is constantly installing more with each quarter. In the second quarter of 2021, there were 10% more da Vinci systems installed globally than in Q2 of 2020. Assuming that the business will continue to deploy its products at a similar rate, it'll have a massive pool of future sales opportunities to draw from over the next decade.</p>\n<p><b>But will it make investors richer?</b></p>\n<p>I'm of the view that Intuitive's stock will multiply in value well before 2029.</p>\n<p>Over the next seven years, a $1,000 investment made today could grow to reach $4,000 in value if the stock expands with a compound annual growth rate (CAGR) of 21.9%. Let's take a closer look at why the stock is likely to grow by at least that much on an annual basis for the next few years.</p>\n<p>First, Intuitive's stock has been rising rapidly at an even faster rate over the past seven years. Since August 2014, the stock has grown by 567.5%, giving it a CAGR of about 31.5%. While skeptics might argue that the such a strong performance is unlikely to be repeated on a consistent basis, there is little evidence to suggest that growth is slowing.</p>\n<p>Even when including for the sharp drop in income and earnings that occurred when hospitals stopped performing elective surgeries during the first peak of the pandemic, the past three years have seen the company's quarterly revenue rise by nearly 59%, with quarterly earnings before interest, taxes, depreciation, and amortization (EBITDA) increasing by just over 70% in the same period. Likewise, its quarterly free cash flow (FCF) has grown by slightly more than 84% in the last five years, so its financial strength has been steadily increasing over time.</p>\n<p><img src=\"https://static.tigerbbs.com/23c1a7a479389e7ae5416faa90fb0002\" tg-width=\"720\" tg-height=\"387\" referrerpolicy=\"no-referrer\"></p>\n<p>ISRG Revenue (Quarterly) data by YCharts</p>\n<p>Thus, Intuitive doesn't need to change its business model or optimize its operations to keep expanding. And that means its prospects for being a winning growth stock are secure.</p>\n<p><b>When's the right time to buy?</b></p>\n<p>In my view, there's little doubt that this stock could juice a $1,000 investment today into $4,000 over the next seven years, even if growth does end up slowing slightly. Still, there remains the question of when to make a purchase.</p>\n<p>Given the company's ongoing efforts to develop new surgical tools, expand its portfolio of eligible procedures, and deploy more machines internationally, there's a smattering of catalysts for Intuitive's stock between now and 2029. At the same time, there's little chance of a competitor stealing revenue from accessory sales and maintenance for the established base of installed systems.</p>\n<p>So, there isn't much to hold investors back from buying the stock today.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>This Robotics Growth Stock Could Turn $1,000 Into $4,000 by 2029</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThis Robotics Growth Stock Could Turn $1,000 Into $4,000 by 2029\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-09 19:41 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/09/09/this-robotics-growth-stock-could-turn-1000-into-40/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Doing business as usual will be more than enough to make this company a strong investment.\nKey Points\n\nCompanies with regularly recurring revenue have an easier time posting consistent revenue growth....</p>\n\n<a href=\"https://www.fool.com/investing/2021/09/09/this-robotics-growth-stock-could-turn-1000-into-40/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ISRG":"直觉外科公司"},"source_url":"https://www.fool.com/investing/2021/09/09/this-robotics-growth-stock-could-turn-1000-into-40/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2166312201","content_text":"Doing business as usual will be more than enough to make this company a strong investment.\nKey Points\n\nCompanies with regularly recurring revenue have an easier time posting consistent revenue growth.\nMaking products that are platforms for complex tasks is one way to build a recurring revenue base.\nSurgical robots are likely to be in demand in the coming years, just like they have been for the past decade.\n\nYou've probably heard that robots are the future for everything from manufacturing to retail distribution. But have you ever considered that they might be lucrative investments in the present?\nIntuitive Surgical(NASDAQ:ISRG) sits at the intersection of high-tech robotics and healthcare, and that's one of the many reasons why it's an exciting growth stock. Still, with a market cap in excess of $123 billion, investors are right to be skeptical about the stock's prospects for triple-digit percentage growth. Could Intuitive Surgical be a powerhouse for your portfolio with a relatively small initial investment, or is this stock's growth story approaching stagnation? Let's investigate by taking a look at its business model to start.\n\nImage source: Getty Images.\nBig growth is more than feasible\nOverall, Intuitive Surgical is primed to experience consistent and significant growth because of how it makes its income.\nIn case you aren't familiar, its main product is the da Vinci line of robotic surgical suites, which surgeons control from a station in the operating room. It also sells maintenance contracts and an ever-increasing selection of robotic surgical tools to use in conjunction with its da Vinci units. In total, these three product categories made the company $5.16 billion in trailing revenue, 77% of which is recurring.\nFor investors seeking growth stocks, there's nothing sweeter than a rock-solid revenue base. Importantly, there are a few different things that contribute to Intuitive's aggressive expansion of that base.\nThe most obvious is sales of its surgical suites, but that's just the start. Once a hospital has purchased a da Vinci unit and trained its surgeons, it's safe to say that it won't be buying a similar unit from competitors.\nSo, when Intuitive develops new surgical tools to expand the range of procedures performable with the robot, existing customers are highly likely to be interested in expanding the capabilities of the platform they own. Likewise, the more a hospital utilizes its surgical robotics, the more it'll need maintenance and a steady supply of replacement parts.\nAll of the above means that each newly installed surgical suite will render a significant amount of revenue over its lifetime, and the company is constantly installing more with each quarter. In the second quarter of 2021, there were 10% more da Vinci systems installed globally than in Q2 of 2020. Assuming that the business will continue to deploy its products at a similar rate, it'll have a massive pool of future sales opportunities to draw from over the next decade.\nBut will it make investors richer?\nI'm of the view that Intuitive's stock will multiply in value well before 2029.\nOver the next seven years, a $1,000 investment made today could grow to reach $4,000 in value if the stock expands with a compound annual growth rate (CAGR) of 21.9%. Let's take a closer look at why the stock is likely to grow by at least that much on an annual basis for the next few years.\nFirst, Intuitive's stock has been rising rapidly at an even faster rate over the past seven years. Since August 2014, the stock has grown by 567.5%, giving it a CAGR of about 31.5%. While skeptics might argue that the such a strong performance is unlikely to be repeated on a consistent basis, there is little evidence to suggest that growth is slowing.\nEven when including for the sharp drop in income and earnings that occurred when hospitals stopped performing elective surgeries during the first peak of the pandemic, the past three years have seen the company's quarterly revenue rise by nearly 59%, with quarterly earnings before interest, taxes, depreciation, and amortization (EBITDA) increasing by just over 70% in the same period. Likewise, its quarterly free cash flow (FCF) has grown by slightly more than 84% in the last five years, so its financial strength has been steadily increasing over time.\n\nISRG Revenue (Quarterly) data by YCharts\nThus, Intuitive doesn't need to change its business model or optimize its operations to keep expanding. And that means its prospects for being a winning growth stock are secure.\nWhen's the right time to buy?\nIn my view, there's little doubt that this stock could juice a $1,000 investment today into $4,000 over the next seven years, even if growth does end up slowing slightly. Still, there remains the question of when to make a purchase.\nGiven the company's ongoing efforts to develop new surgical tools, expand its portfolio of eligible procedures, and deploy more machines internationally, there's a smattering of catalysts for Intuitive's stock between now and 2029. At the same time, there's little chance of a competitor stealing revenue from accessory sales and maintenance for the established base of installed systems.\nSo, there isn't much to hold investors back from buying the stock today.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5806556,"gmtCreate":1631190289583,"gmtModify":1663233620025,"authorId":3552850525395609,"author":{"id":3552850525395609,"authorId":3552850525395609,"name":"moliya","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":3,"crmLevelSwitch":1,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":883063516,"type":1,"supId":0,"prevId":0,"content":"yeah yeah...","text":"yeah yeah...","html":"yeah yeah..."}],"langContent":"EN"},{"id":883063640,"gmtCreate":1631190167580,"gmtModify":1676530491576,"author":{"id":"4089856301721210","authorId":"4089856301721210","name":"Kczx","avatar":"https://static.tigerbbs.com/f4e2ec76e0922c883fecf5ff8b259010","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"Go go go&nbsp;","listText":"Go go go&nbsp;","text":"Go go go","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/883063640","repostId":2166312201,"repostType":4,"repost":{"id":"2166312201","pubTimestamp":1631187660,"share":"https://www.laohu8.com/m/news/2166312201?lang=&edition=full","pubTime":"2021-09-09 19:41","market":"us","language":"en","title":"This Robotics Growth Stock Could Turn $1,000 Into $4,000 by 2029","url":"https://stock-news.laohu8.com/highlight/detail?id=2166312201","media":"Motley Fool","summary":"Doing business as usual will be more than enough to make this company a strong investment.","content":"<p>Doing business as usual will be more than enough to make this company a strong investment.</p>\n<p><b>Key Points</b></p>\n<ul>\n <li>Companies with regularly recurring revenue have an easier time posting consistent revenue growth.</li>\n <li>Making products that are platforms for complex tasks is one way to build a recurring revenue base.</li>\n <li>Surgical robots are likely to be in demand in the coming years, just like they have been for the past decade.</li>\n</ul>\n<p>You've probably heard that robots are the future for everything from manufacturing to retail distribution. But have you ever considered that they might be lucrative investments in the present?</p>\n<p><b>Intuitive Surgical</b>(NASDAQ:ISRG) sits at the intersection of high-tech robotics and healthcare, and that's <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the many reasons why it's an exciting growth stock. Still, with a market cap in excess of $123 billion, investors are right to be skeptical about the stock's prospects for triple-digit percentage growth. Could Intuitive Surgical be a powerhouse for your portfolio with a relatively small initial investment, or is this stock's growth story approaching stagnation? Let's investigate by taking a look at its business model to start.</p>\n<p><img src=\"https://static.tigerbbs.com/a92230e2013b2ec95bc9649c43631081\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: Getty Images.</p>\n<p><b>Big growth is more than feasible</b></p>\n<p>Overall, Intuitive Surgical is primed to experience consistent and significant growth because of how it makes its income.</p>\n<p>In case you aren't familiar, its main product is the da Vinci line of robotic surgical suites, which surgeons control from a station in the operating room. It also sells maintenance contracts and an ever-increasing selection of robotic surgical tools to use in conjunction with its da Vinci units. In total, these three product categories made the company $5.16 billion in trailing revenue, 77% of which is recurring.</p>\n<p>For investors seeking growth stocks, there's nothing sweeter than a rock-solid revenue base. Importantly, there are a few different things that contribute to Intuitive's aggressive expansion of that base.</p>\n<p>The most obvious is sales of its surgical suites, but that's just the start. Once a hospital has purchased a da Vinci unit and trained its surgeons, it's safe to say that it won't be buying a similar unit from competitors.</p>\n<p>So, when Intuitive develops new surgical tools to expand the range of procedures performable with the robot, existing customers are highly likely to be interested in expanding the capabilities of the platform they own. Likewise, the more a hospital utilizes its surgical robotics, the more it'll need maintenance and a steady supply of replacement parts.</p>\n<p>All of the above means that each newly installed surgical suite will render a significant amount of revenue over its lifetime, and the company is constantly installing more with each quarter. In the second quarter of 2021, there were 10% more da Vinci systems installed globally than in Q2 of 2020. Assuming that the business will continue to deploy its products at a similar rate, it'll have a massive pool of future sales opportunities to draw from over the next decade.</p>\n<p><b>But will it make investors richer?</b></p>\n<p>I'm of the view that Intuitive's stock will multiply in value well before 2029.</p>\n<p>Over the next seven years, a $1,000 investment made today could grow to reach $4,000 in value if the stock expands with a compound annual growth rate (CAGR) of 21.9%. Let's take a closer look at why the stock is likely to grow by at least that much on an annual basis for the next few years.</p>\n<p>First, Intuitive's stock has been rising rapidly at an even faster rate over the past seven years. Since August 2014, the stock has grown by 567.5%, giving it a CAGR of about 31.5%. While skeptics might argue that the such a strong performance is unlikely to be repeated on a consistent basis, there is little evidence to suggest that growth is slowing.</p>\n<p>Even when including for the sharp drop in income and earnings that occurred when hospitals stopped performing elective surgeries during the first peak of the pandemic, the past three years have seen the company's quarterly revenue rise by nearly 59%, with quarterly earnings before interest, taxes, depreciation, and amortization (EBITDA) increasing by just over 70% in the same period. Likewise, its quarterly free cash flow (FCF) has grown by slightly more than 84% in the last five years, so its financial strength has been steadily increasing over time.</p>\n<p><img src=\"https://static.tigerbbs.com/23c1a7a479389e7ae5416faa90fb0002\" tg-width=\"720\" tg-height=\"387\" referrerpolicy=\"no-referrer\"></p>\n<p>ISRG Revenue (Quarterly) data by YCharts</p>\n<p>Thus, Intuitive doesn't need to change its business model or optimize its operations to keep expanding. And that means its prospects for being a winning growth stock are secure.</p>\n<p><b>When's the right time to buy?</b></p>\n<p>In my view, there's little doubt that this stock could juice a $1,000 investment today into $4,000 over the next seven years, even if growth does end up slowing slightly. Still, there remains the question of when to make a purchase.</p>\n<p>Given the company's ongoing efforts to develop new surgical tools, expand its portfolio of eligible procedures, and deploy more machines internationally, there's a smattering of catalysts for Intuitive's stock between now and 2029. At the same time, there's little chance of a competitor stealing revenue from accessory sales and maintenance for the established base of installed systems.</p>\n<p>So, there isn't much to hold investors back from buying the stock today.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>This Robotics Growth Stock Could Turn $1,000 Into $4,000 by 2029</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThis Robotics Growth Stock Could Turn $1,000 Into $4,000 by 2029\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-09 19:41 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/09/09/this-robotics-growth-stock-could-turn-1000-into-40/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Doing business as usual will be more than enough to make this company a strong investment.\nKey Points\n\nCompanies with regularly recurring revenue have an easier time posting consistent revenue growth....</p>\n\n<a href=\"https://www.fool.com/investing/2021/09/09/this-robotics-growth-stock-could-turn-1000-into-40/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ISRG":"直觉外科公司"},"source_url":"https://www.fool.com/investing/2021/09/09/this-robotics-growth-stock-could-turn-1000-into-40/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2166312201","content_text":"Doing business as usual will be more than enough to make this company a strong investment.\nKey Points\n\nCompanies with regularly recurring revenue have an easier time posting consistent revenue growth.\nMaking products that are platforms for complex tasks is one way to build a recurring revenue base.\nSurgical robots are likely to be in demand in the coming years, just like they have been for the past decade.\n\nYou've probably heard that robots are the future for everything from manufacturing to retail distribution. But have you ever considered that they might be lucrative investments in the present?\nIntuitive Surgical(NASDAQ:ISRG) sits at the intersection of high-tech robotics and healthcare, and that's one of the many reasons why it's an exciting growth stock. Still, with a market cap in excess of $123 billion, investors are right to be skeptical about the stock's prospects for triple-digit percentage growth. Could Intuitive Surgical be a powerhouse for your portfolio with a relatively small initial investment, or is this stock's growth story approaching stagnation? Let's investigate by taking a look at its business model to start.\n\nImage source: Getty Images.\nBig growth is more than feasible\nOverall, Intuitive Surgical is primed to experience consistent and significant growth because of how it makes its income.\nIn case you aren't familiar, its main product is the da Vinci line of robotic surgical suites, which surgeons control from a station in the operating room. It also sells maintenance contracts and an ever-increasing selection of robotic surgical tools to use in conjunction with its da Vinci units. In total, these three product categories made the company $5.16 billion in trailing revenue, 77% of which is recurring.\nFor investors seeking growth stocks, there's nothing sweeter than a rock-solid revenue base. Importantly, there are a few different things that contribute to Intuitive's aggressive expansion of that base.\nThe most obvious is sales of its surgical suites, but that's just the start. Once a hospital has purchased a da Vinci unit and trained its surgeons, it's safe to say that it won't be buying a similar unit from competitors.\nSo, when Intuitive develops new surgical tools to expand the range of procedures performable with the robot, existing customers are highly likely to be interested in expanding the capabilities of the platform they own. Likewise, the more a hospital utilizes its surgical robotics, the more it'll need maintenance and a steady supply of replacement parts.\nAll of the above means that each newly installed surgical suite will render a significant amount of revenue over its lifetime, and the company is constantly installing more with each quarter. In the second quarter of 2021, there were 10% more da Vinci systems installed globally than in Q2 of 2020. Assuming that the business will continue to deploy its products at a similar rate, it'll have a massive pool of future sales opportunities to draw from over the next decade.\nBut will it make investors richer?\nI'm of the view that Intuitive's stock will multiply in value well before 2029.\nOver the next seven years, a $1,000 investment made today could grow to reach $4,000 in value if the stock expands with a compound annual growth rate (CAGR) of 21.9%. Let's take a closer look at why the stock is likely to grow by at least that much on an annual basis for the next few years.\nFirst, Intuitive's stock has been rising rapidly at an even faster rate over the past seven years. Since August 2014, the stock has grown by 567.5%, giving it a CAGR of about 31.5%. While skeptics might argue that the such a strong performance is unlikely to be repeated on a consistent basis, there is little evidence to suggest that growth is slowing.\nEven when including for the sharp drop in income and earnings that occurred when hospitals stopped performing elective surgeries during the first peak of the pandemic, the past three years have seen the company's quarterly revenue rise by nearly 59%, with quarterly earnings before interest, taxes, depreciation, and amortization (EBITDA) increasing by just over 70% in the same period. Likewise, its quarterly free cash flow (FCF) has grown by slightly more than 84% in the last five years, so its financial strength has been steadily increasing over time.\n\nISRG Revenue (Quarterly) data by YCharts\nThus, Intuitive doesn't need to change its business model or optimize its operations to keep expanding. And that means its prospects for being a winning growth stock are secure.\nWhen's the right time to buy?\nIn my view, there's little doubt that this stock could juice a $1,000 investment today into $4,000 over the next seven years, even if growth does end up slowing slightly. Still, there remains the question of when to make a purchase.\nGiven the company's ongoing efforts to develop new surgical tools, expand its portfolio of eligible procedures, and deploy more machines internationally, there's a smattering of catalysts for Intuitive's stock between now and 2029. At the same time, there's little chance of a competitor stealing revenue from accessory sales and maintenance for the established base of installed systems.\nSo, there isn't much to hold investors back from buying the stock today.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5829963,"gmtCreate":1631341640239,"gmtModify":1663233722141,"authorId":3582371848241817,"author":{"id":3582371848241817,"authorId":3582371848241817,"name":"SeC","avatar":"https://static.tigerbbs.com/a226cf90d6854e9178341c90697ce373","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":883063640,"type":1,"supId":0,"prevId":0,"content":"?","text":"?","html":"?"}],"langContent":"EN"},{"id":883084418,"gmtCreate":1631189778634,"gmtModify":1676530491497,"author":{"id":"3563941452424650","authorId":"3563941452424650","name":"lyokel","avatar":"https://community-static.tradeup.com/news/a0bd3f0fc07966cf561519ba8ef67d7e","vip":1,"crmLevel":6,"crmLevelSwitch":0},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/883084418","repostId":2166312201,"repostType":4,"repost":{"id":"2166312201","pubTimestamp":1631187660,"share":"https://www.laohu8.com/m/news/2166312201?lang=&edition=full","pubTime":"2021-09-09 19:41","market":"us","language":"en","title":"This Robotics Growth Stock Could Turn $1,000 Into $4,000 by 2029","url":"https://stock-news.laohu8.com/highlight/detail?id=2166312201","media":"Motley Fool","summary":"Doing business as usual will be more than enough to make this company a strong investment.","content":"<p>Doing business as usual will be more than enough to make this company a strong investment.</p>\n<p><b>Key Points</b></p>\n<ul>\n <li>Companies with regularly recurring revenue have an easier time posting consistent revenue growth.</li>\n <li>Making products that are platforms for complex tasks is one way to build a recurring revenue base.</li>\n <li>Surgical robots are likely to be in demand in the coming years, just like they have been for the past decade.</li>\n</ul>\n<p>You've probably heard that robots are the future for everything from manufacturing to retail distribution. But have you ever considered that they might be lucrative investments in the present?</p>\n<p><b>Intuitive Surgical</b>(NASDAQ:ISRG) sits at the intersection of high-tech robotics and healthcare, and that's <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the many reasons why it's an exciting growth stock. Still, with a market cap in excess of $123 billion, investors are right to be skeptical about the stock's prospects for triple-digit percentage growth. Could Intuitive Surgical be a powerhouse for your portfolio with a relatively small initial investment, or is this stock's growth story approaching stagnation? Let's investigate by taking a look at its business model to start.</p>\n<p><img src=\"https://static.tigerbbs.com/a92230e2013b2ec95bc9649c43631081\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: Getty Images.</p>\n<p><b>Big growth is more than feasible</b></p>\n<p>Overall, Intuitive Surgical is primed to experience consistent and significant growth because of how it makes its income.</p>\n<p>In case you aren't familiar, its main product is the da Vinci line of robotic surgical suites, which surgeons control from a station in the operating room. It also sells maintenance contracts and an ever-increasing selection of robotic surgical tools to use in conjunction with its da Vinci units. In total, these three product categories made the company $5.16 billion in trailing revenue, 77% of which is recurring.</p>\n<p>For investors seeking growth stocks, there's nothing sweeter than a rock-solid revenue base. Importantly, there are a few different things that contribute to Intuitive's aggressive expansion of that base.</p>\n<p>The most obvious is sales of its surgical suites, but that's just the start. Once a hospital has purchased a da Vinci unit and trained its surgeons, it's safe to say that it won't be buying a similar unit from competitors.</p>\n<p>So, when Intuitive develops new surgical tools to expand the range of procedures performable with the robot, existing customers are highly likely to be interested in expanding the capabilities of the platform they own. Likewise, the more a hospital utilizes its surgical robotics, the more it'll need maintenance and a steady supply of replacement parts.</p>\n<p>All of the above means that each newly installed surgical suite will render a significant amount of revenue over its lifetime, and the company is constantly installing more with each quarter. In the second quarter of 2021, there were 10% more da Vinci systems installed globally than in Q2 of 2020. Assuming that the business will continue to deploy its products at a similar rate, it'll have a massive pool of future sales opportunities to draw from over the next decade.</p>\n<p><b>But will it make investors richer?</b></p>\n<p>I'm of the view that Intuitive's stock will multiply in value well before 2029.</p>\n<p>Over the next seven years, a $1,000 investment made today could grow to reach $4,000 in value if the stock expands with a compound annual growth rate (CAGR) of 21.9%. Let's take a closer look at why the stock is likely to grow by at least that much on an annual basis for the next few years.</p>\n<p>First, Intuitive's stock has been rising rapidly at an even faster rate over the past seven years. Since August 2014, the stock has grown by 567.5%, giving it a CAGR of about 31.5%. While skeptics might argue that the such a strong performance is unlikely to be repeated on a consistent basis, there is little evidence to suggest that growth is slowing.</p>\n<p>Even when including for the sharp drop in income and earnings that occurred when hospitals stopped performing elective surgeries during the first peak of the pandemic, the past three years have seen the company's quarterly revenue rise by nearly 59%, with quarterly earnings before interest, taxes, depreciation, and amortization (EBITDA) increasing by just over 70% in the same period. Likewise, its quarterly free cash flow (FCF) has grown by slightly more than 84% in the last five years, so its financial strength has been steadily increasing over time.</p>\n<p><img src=\"https://static.tigerbbs.com/23c1a7a479389e7ae5416faa90fb0002\" tg-width=\"720\" tg-height=\"387\" referrerpolicy=\"no-referrer\"></p>\n<p>ISRG Revenue (Quarterly) data by YCharts</p>\n<p>Thus, Intuitive doesn't need to change its business model or optimize its operations to keep expanding. And that means its prospects for being a winning growth stock are secure.</p>\n<p><b>When's the right time to buy?</b></p>\n<p>In my view, there's little doubt that this stock could juice a $1,000 investment today into $4,000 over the next seven years, even if growth does end up slowing slightly. Still, there remains the question of when to make a purchase.</p>\n<p>Given the company's ongoing efforts to develop new surgical tools, expand its portfolio of eligible procedures, and deploy more machines internationally, there's a smattering of catalysts for Intuitive's stock between now and 2029. At the same time, there's little chance of a competitor stealing revenue from accessory sales and maintenance for the established base of installed systems.</p>\n<p>So, there isn't much to hold investors back from buying the stock today.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>This Robotics Growth Stock Could Turn $1,000 Into $4,000 by 2029</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThis Robotics Growth Stock Could Turn $1,000 Into $4,000 by 2029\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-09 19:41 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/09/09/this-robotics-growth-stock-could-turn-1000-into-40/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Doing business as usual will be more than enough to make this company a strong investment.\nKey Points\n\nCompanies with regularly recurring revenue have an easier time posting consistent revenue growth....</p>\n\n<a href=\"https://www.fool.com/investing/2021/09/09/this-robotics-growth-stock-could-turn-1000-into-40/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ISRG":"直觉外科公司"},"source_url":"https://www.fool.com/investing/2021/09/09/this-robotics-growth-stock-could-turn-1000-into-40/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2166312201","content_text":"Doing business as usual will be more than enough to make this company a strong investment.\nKey Points\n\nCompanies with regularly recurring revenue have an easier time posting consistent revenue growth.\nMaking products that are platforms for complex tasks is one way to build a recurring revenue base.\nSurgical robots are likely to be in demand in the coming years, just like they have been for the past decade.\n\nYou've probably heard that robots are the future for everything from manufacturing to retail distribution. But have you ever considered that they might be lucrative investments in the present?\nIntuitive Surgical(NASDAQ:ISRG) sits at the intersection of high-tech robotics and healthcare, and that's one of the many reasons why it's an exciting growth stock. Still, with a market cap in excess of $123 billion, investors are right to be skeptical about the stock's prospects for triple-digit percentage growth. Could Intuitive Surgical be a powerhouse for your portfolio with a relatively small initial investment, or is this stock's growth story approaching stagnation? Let's investigate by taking a look at its business model to start.\n\nImage source: Getty Images.\nBig growth is more than feasible\nOverall, Intuitive Surgical is primed to experience consistent and significant growth because of how it makes its income.\nIn case you aren't familiar, its main product is the da Vinci line of robotic surgical suites, which surgeons control from a station in the operating room. It also sells maintenance contracts and an ever-increasing selection of robotic surgical tools to use in conjunction with its da Vinci units. In total, these three product categories made the company $5.16 billion in trailing revenue, 77% of which is recurring.\nFor investors seeking growth stocks, there's nothing sweeter than a rock-solid revenue base. Importantly, there are a few different things that contribute to Intuitive's aggressive expansion of that base.\nThe most obvious is sales of its surgical suites, but that's just the start. Once a hospital has purchased a da Vinci unit and trained its surgeons, it's safe to say that it won't be buying a similar unit from competitors.\nSo, when Intuitive develops new surgical tools to expand the range of procedures performable with the robot, existing customers are highly likely to be interested in expanding the capabilities of the platform they own. Likewise, the more a hospital utilizes its surgical robotics, the more it'll need maintenance and a steady supply of replacement parts.\nAll of the above means that each newly installed surgical suite will render a significant amount of revenue over its lifetime, and the company is constantly installing more with each quarter. In the second quarter of 2021, there were 10% more da Vinci systems installed globally than in Q2 of 2020. Assuming that the business will continue to deploy its products at a similar rate, it'll have a massive pool of future sales opportunities to draw from over the next decade.\nBut will it make investors richer?\nI'm of the view that Intuitive's stock will multiply in value well before 2029.\nOver the next seven years, a $1,000 investment made today could grow to reach $4,000 in value if the stock expands with a compound annual growth rate (CAGR) of 21.9%. Let's take a closer look at why the stock is likely to grow by at least that much on an annual basis for the next few years.\nFirst, Intuitive's stock has been rising rapidly at an even faster rate over the past seven years. Since August 2014, the stock has grown by 567.5%, giving it a CAGR of about 31.5%. While skeptics might argue that the such a strong performance is unlikely to be repeated on a consistent basis, there is little evidence to suggest that growth is slowing.\nEven when including for the sharp drop in income and earnings that occurred when hospitals stopped performing elective surgeries during the first peak of the pandemic, the past three years have seen the company's quarterly revenue rise by nearly 59%, with quarterly earnings before interest, taxes, depreciation, and amortization (EBITDA) increasing by just over 70% in the same period. Likewise, its quarterly free cash flow (FCF) has grown by slightly more than 84% in the last five years, so its financial strength has been steadily increasing over time.\n\nISRG Revenue (Quarterly) data by YCharts\nThus, Intuitive doesn't need to change its business model or optimize its operations to keep expanding. And that means its prospects for being a winning growth stock are secure.\nWhen's the right time to buy?\nIn my view, there's little doubt that this stock could juice a $1,000 investment today into $4,000 over the next seven years, even if growth does end up slowing slightly. Still, there remains the question of when to make a purchase.\nGiven the company's ongoing efforts to develop new surgical tools, expand its portfolio of eligible procedures, and deploy more machines internationally, there's a smattering of catalysts for Intuitive's stock between now and 2029. At the same time, there's little chance of a competitor stealing revenue from accessory sales and maintenance for the established base of installed systems.\nSo, there isn't much to hold investors back from buying the stock today.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":883084005,"gmtCreate":1631189693407,"gmtModify":1676530491480,"author":{"id":"3582595806100338","authorId":"3582595806100338","name":"Rteo","avatar":"https://static.tigerbbs.com/ba4c61a94c707cd25f18400b8cc52a4c","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"X4 ?","listText":"X4 ?","text":"X4 ?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/883084005","repostId":2166312201,"repostType":4,"repost":{"id":"2166312201","pubTimestamp":1631187660,"share":"https://www.laohu8.com/m/news/2166312201?lang=&edition=full","pubTime":"2021-09-09 19:41","market":"us","language":"en","title":"This Robotics Growth Stock Could Turn $1,000 Into $4,000 by 2029","url":"https://stock-news.laohu8.com/highlight/detail?id=2166312201","media":"Motley Fool","summary":"Doing business as usual will be more than enough to make this company a strong investment.","content":"<p>Doing business as usual will be more than enough to make this company a strong investment.</p>\n<p><b>Key Points</b></p>\n<ul>\n <li>Companies with regularly recurring revenue have an easier time posting consistent revenue growth.</li>\n <li>Making products that are platforms for complex tasks is one way to build a recurring revenue base.</li>\n <li>Surgical robots are likely to be in demand in the coming years, just like they have been for the past decade.</li>\n</ul>\n<p>You've probably heard that robots are the future for everything from manufacturing to retail distribution. But have you ever considered that they might be lucrative investments in the present?</p>\n<p><b>Intuitive Surgical</b>(NASDAQ:ISRG) sits at the intersection of high-tech robotics and healthcare, and that's <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the many reasons why it's an exciting growth stock. Still, with a market cap in excess of $123 billion, investors are right to be skeptical about the stock's prospects for triple-digit percentage growth. Could Intuitive Surgical be a powerhouse for your portfolio with a relatively small initial investment, or is this stock's growth story approaching stagnation? Let's investigate by taking a look at its business model to start.</p>\n<p><img src=\"https://static.tigerbbs.com/a92230e2013b2ec95bc9649c43631081\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: Getty Images.</p>\n<p><b>Big growth is more than feasible</b></p>\n<p>Overall, Intuitive Surgical is primed to experience consistent and significant growth because of how it makes its income.</p>\n<p>In case you aren't familiar, its main product is the da Vinci line of robotic surgical suites, which surgeons control from a station in the operating room. It also sells maintenance contracts and an ever-increasing selection of robotic surgical tools to use in conjunction with its da Vinci units. In total, these three product categories made the company $5.16 billion in trailing revenue, 77% of which is recurring.</p>\n<p>For investors seeking growth stocks, there's nothing sweeter than a rock-solid revenue base. Importantly, there are a few different things that contribute to Intuitive's aggressive expansion of that base.</p>\n<p>The most obvious is sales of its surgical suites, but that's just the start. Once a hospital has purchased a da Vinci unit and trained its surgeons, it's safe to say that it won't be buying a similar unit from competitors.</p>\n<p>So, when Intuitive develops new surgical tools to expand the range of procedures performable with the robot, existing customers are highly likely to be interested in expanding the capabilities of the platform they own. Likewise, the more a hospital utilizes its surgical robotics, the more it'll need maintenance and a steady supply of replacement parts.</p>\n<p>All of the above means that each newly installed surgical suite will render a significant amount of revenue over its lifetime, and the company is constantly installing more with each quarter. In the second quarter of 2021, there were 10% more da Vinci systems installed globally than in Q2 of 2020. Assuming that the business will continue to deploy its products at a similar rate, it'll have a massive pool of future sales opportunities to draw from over the next decade.</p>\n<p><b>But will it make investors richer?</b></p>\n<p>I'm of the view that Intuitive's stock will multiply in value well before 2029.</p>\n<p>Over the next seven years, a $1,000 investment made today could grow to reach $4,000 in value if the stock expands with a compound annual growth rate (CAGR) of 21.9%. Let's take a closer look at why the stock is likely to grow by at least that much on an annual basis for the next few years.</p>\n<p>First, Intuitive's stock has been rising rapidly at an even faster rate over the past seven years. Since August 2014, the stock has grown by 567.5%, giving it a CAGR of about 31.5%. While skeptics might argue that the such a strong performance is unlikely to be repeated on a consistent basis, there is little evidence to suggest that growth is slowing.</p>\n<p>Even when including for the sharp drop in income and earnings that occurred when hospitals stopped performing elective surgeries during the first peak of the pandemic, the past three years have seen the company's quarterly revenue rise by nearly 59%, with quarterly earnings before interest, taxes, depreciation, and amortization (EBITDA) increasing by just over 70% in the same period. Likewise, its quarterly free cash flow (FCF) has grown by slightly more than 84% in the last five years, so its financial strength has been steadily increasing over time.</p>\n<p><img src=\"https://static.tigerbbs.com/23c1a7a479389e7ae5416faa90fb0002\" tg-width=\"720\" tg-height=\"387\" referrerpolicy=\"no-referrer\"></p>\n<p>ISRG Revenue (Quarterly) data by YCharts</p>\n<p>Thus, Intuitive doesn't need to change its business model or optimize its operations to keep expanding. And that means its prospects for being a winning growth stock are secure.</p>\n<p><b>When's the right time to buy?</b></p>\n<p>In my view, there's little doubt that this stock could juice a $1,000 investment today into $4,000 over the next seven years, even if growth does end up slowing slightly. Still, there remains the question of when to make a purchase.</p>\n<p>Given the company's ongoing efforts to develop new surgical tools, expand its portfolio of eligible procedures, and deploy more machines internationally, there's a smattering of catalysts for Intuitive's stock between now and 2029. At the same time, there's little chance of a competitor stealing revenue from accessory sales and maintenance for the established base of installed systems.</p>\n<p>So, there isn't much to hold investors back from buying the stock today.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>This Robotics Growth Stock Could Turn $1,000 Into $4,000 by 2029</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThis Robotics Growth Stock Could Turn $1,000 Into $4,000 by 2029\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-09 19:41 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/09/09/this-robotics-growth-stock-could-turn-1000-into-40/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Doing business as usual will be more than enough to make this company a strong investment.\nKey Points\n\nCompanies with regularly recurring revenue have an easier time posting consistent revenue growth....</p>\n\n<a href=\"https://www.fool.com/investing/2021/09/09/this-robotics-growth-stock-could-turn-1000-into-40/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ISRG":"直觉外科公司"},"source_url":"https://www.fool.com/investing/2021/09/09/this-robotics-growth-stock-could-turn-1000-into-40/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2166312201","content_text":"Doing business as usual will be more than enough to make this company a strong investment.\nKey Points\n\nCompanies with regularly recurring revenue have an easier time posting consistent revenue growth.\nMaking products that are platforms for complex tasks is one way to build a recurring revenue base.\nSurgical robots are likely to be in demand in the coming years, just like they have been for the past decade.\n\nYou've probably heard that robots are the future for everything from manufacturing to retail distribution. But have you ever considered that they might be lucrative investments in the present?\nIntuitive Surgical(NASDAQ:ISRG) sits at the intersection of high-tech robotics and healthcare, and that's one of the many reasons why it's an exciting growth stock. Still, with a market cap in excess of $123 billion, investors are right to be skeptical about the stock's prospects for triple-digit percentage growth. Could Intuitive Surgical be a powerhouse for your portfolio with a relatively small initial investment, or is this stock's growth story approaching stagnation? Let's investigate by taking a look at its business model to start.\n\nImage source: Getty Images.\nBig growth is more than feasible\nOverall, Intuitive Surgical is primed to experience consistent and significant growth because of how it makes its income.\nIn case you aren't familiar, its main product is the da Vinci line of robotic surgical suites, which surgeons control from a station in the operating room. It also sells maintenance contracts and an ever-increasing selection of robotic surgical tools to use in conjunction with its da Vinci units. In total, these three product categories made the company $5.16 billion in trailing revenue, 77% of which is recurring.\nFor investors seeking growth stocks, there's nothing sweeter than a rock-solid revenue base. Importantly, there are a few different things that contribute to Intuitive's aggressive expansion of that base.\nThe most obvious is sales of its surgical suites, but that's just the start. Once a hospital has purchased a da Vinci unit and trained its surgeons, it's safe to say that it won't be buying a similar unit from competitors.\nSo, when Intuitive develops new surgical tools to expand the range of procedures performable with the robot, existing customers are highly likely to be interested in expanding the capabilities of the platform they own. Likewise, the more a hospital utilizes its surgical robotics, the more it'll need maintenance and a steady supply of replacement parts.\nAll of the above means that each newly installed surgical suite will render a significant amount of revenue over its lifetime, and the company is constantly installing more with each quarter. In the second quarter of 2021, there were 10% more da Vinci systems installed globally than in Q2 of 2020. Assuming that the business will continue to deploy its products at a similar rate, it'll have a massive pool of future sales opportunities to draw from over the next decade.\nBut will it make investors richer?\nI'm of the view that Intuitive's stock will multiply in value well before 2029.\nOver the next seven years, a $1,000 investment made today could grow to reach $4,000 in value if the stock expands with a compound annual growth rate (CAGR) of 21.9%. Let's take a closer look at why the stock is likely to grow by at least that much on an annual basis for the next few years.\nFirst, Intuitive's stock has been rising rapidly at an even faster rate over the past seven years. Since August 2014, the stock has grown by 567.5%, giving it a CAGR of about 31.5%. While skeptics might argue that the such a strong performance is unlikely to be repeated on a consistent basis, there is little evidence to suggest that growth is slowing.\nEven when including for the sharp drop in income and earnings that occurred when hospitals stopped performing elective surgeries during the first peak of the pandemic, the past three years have seen the company's quarterly revenue rise by nearly 59%, with quarterly earnings before interest, taxes, depreciation, and amortization (EBITDA) increasing by just over 70% in the same period. Likewise, its quarterly free cash flow (FCF) has grown by slightly more than 84% in the last five years, so its financial strength has been steadily increasing over time.\n\nISRG Revenue (Quarterly) data by YCharts\nThus, Intuitive doesn't need to change its business model or optimize its operations to keep expanding. And that means its prospects for being a winning growth stock are secure.\nWhen's the right time to buy?\nIn my view, there's little doubt that this stock could juice a $1,000 investment today into $4,000 over the next seven years, even if growth does end up slowing slightly. Still, there remains the question of when to make a purchase.\nGiven the company's ongoing efforts to develop new surgical tools, expand its portfolio of eligible procedures, and deploy more machines internationally, there's a smattering of catalysts for Intuitive's stock between now and 2029. At the same time, there's little chance of a competitor stealing revenue from accessory sales and maintenance for the established base of installed systems.\nSo, there isn't much to hold investors back from buying the stock today.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":883088437,"gmtCreate":1631189467029,"gmtModify":1676530491417,"author":{"id":"3570549774646276","authorId":"3570549774646276","name":"Andr3","avatar":"https://static.tigerbbs.com/c41ca7aea5e2b5f410896f8cdc5a940c","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"Like please","listText":"Like please","text":"Like please","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/883088437","repostId":2166312201,"repostType":4,"repost":{"id":"2166312201","pubTimestamp":1631187660,"share":"https://www.laohu8.com/m/news/2166312201?lang=&edition=full","pubTime":"2021-09-09 19:41","market":"us","language":"en","title":"This Robotics Growth Stock Could Turn $1,000 Into $4,000 by 2029","url":"https://stock-news.laohu8.com/highlight/detail?id=2166312201","media":"Motley Fool","summary":"Doing business as usual will be more than enough to make this company a strong investment.","content":"<p>Doing business as usual will be more than enough to make this company a strong investment.</p>\n<p><b>Key Points</b></p>\n<ul>\n <li>Companies with regularly recurring revenue have an easier time posting consistent revenue growth.</li>\n <li>Making products that are platforms for complex tasks is one way to build a recurring revenue base.</li>\n <li>Surgical robots are likely to be in demand in the coming years, just like they have been for the past decade.</li>\n</ul>\n<p>You've probably heard that robots are the future for everything from manufacturing to retail distribution. But have you ever considered that they might be lucrative investments in the present?</p>\n<p><b>Intuitive Surgical</b>(NASDAQ:ISRG) sits at the intersection of high-tech robotics and healthcare, and that's <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the many reasons why it's an exciting growth stock. Still, with a market cap in excess of $123 billion, investors are right to be skeptical about the stock's prospects for triple-digit percentage growth. Could Intuitive Surgical be a powerhouse for your portfolio with a relatively small initial investment, or is this stock's growth story approaching stagnation? Let's investigate by taking a look at its business model to start.</p>\n<p><img src=\"https://static.tigerbbs.com/a92230e2013b2ec95bc9649c43631081\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: Getty Images.</p>\n<p><b>Big growth is more than feasible</b></p>\n<p>Overall, Intuitive Surgical is primed to experience consistent and significant growth because of how it makes its income.</p>\n<p>In case you aren't familiar, its main product is the da Vinci line of robotic surgical suites, which surgeons control from a station in the operating room. It also sells maintenance contracts and an ever-increasing selection of robotic surgical tools to use in conjunction with its da Vinci units. In total, these three product categories made the company $5.16 billion in trailing revenue, 77% of which is recurring.</p>\n<p>For investors seeking growth stocks, there's nothing sweeter than a rock-solid revenue base. Importantly, there are a few different things that contribute to Intuitive's aggressive expansion of that base.</p>\n<p>The most obvious is sales of its surgical suites, but that's just the start. Once a hospital has purchased a da Vinci unit and trained its surgeons, it's safe to say that it won't be buying a similar unit from competitors.</p>\n<p>So, when Intuitive develops new surgical tools to expand the range of procedures performable with the robot, existing customers are highly likely to be interested in expanding the capabilities of the platform they own. Likewise, the more a hospital utilizes its surgical robotics, the more it'll need maintenance and a steady supply of replacement parts.</p>\n<p>All of the above means that each newly installed surgical suite will render a significant amount of revenue over its lifetime, and the company is constantly installing more with each quarter. In the second quarter of 2021, there were 10% more da Vinci systems installed globally than in Q2 of 2020. Assuming that the business will continue to deploy its products at a similar rate, it'll have a massive pool of future sales opportunities to draw from over the next decade.</p>\n<p><b>But will it make investors richer?</b></p>\n<p>I'm of the view that Intuitive's stock will multiply in value well before 2029.</p>\n<p>Over the next seven years, a $1,000 investment made today could grow to reach $4,000 in value if the stock expands with a compound annual growth rate (CAGR) of 21.9%. Let's take a closer look at why the stock is likely to grow by at least that much on an annual basis for the next few years.</p>\n<p>First, Intuitive's stock has been rising rapidly at an even faster rate over the past seven years. Since August 2014, the stock has grown by 567.5%, giving it a CAGR of about 31.5%. While skeptics might argue that the such a strong performance is unlikely to be repeated on a consistent basis, there is little evidence to suggest that growth is slowing.</p>\n<p>Even when including for the sharp drop in income and earnings that occurred when hospitals stopped performing elective surgeries during the first peak of the pandemic, the past three years have seen the company's quarterly revenue rise by nearly 59%, with quarterly earnings before interest, taxes, depreciation, and amortization (EBITDA) increasing by just over 70% in the same period. Likewise, its quarterly free cash flow (FCF) has grown by slightly more than 84% in the last five years, so its financial strength has been steadily increasing over time.</p>\n<p><img src=\"https://static.tigerbbs.com/23c1a7a479389e7ae5416faa90fb0002\" tg-width=\"720\" tg-height=\"387\" referrerpolicy=\"no-referrer\"></p>\n<p>ISRG Revenue (Quarterly) data by YCharts</p>\n<p>Thus, Intuitive doesn't need to change its business model or optimize its operations to keep expanding. And that means its prospects for being a winning growth stock are secure.</p>\n<p><b>When's the right time to buy?</b></p>\n<p>In my view, there's little doubt that this stock could juice a $1,000 investment today into $4,000 over the next seven years, even if growth does end up slowing slightly. Still, there remains the question of when to make a purchase.</p>\n<p>Given the company's ongoing efforts to develop new surgical tools, expand its portfolio of eligible procedures, and deploy more machines internationally, there's a smattering of catalysts for Intuitive's stock between now and 2029. At the same time, there's little chance of a competitor stealing revenue from accessory sales and maintenance for the established base of installed systems.</p>\n<p>So, there isn't much to hold investors back from buying the stock today.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>This Robotics Growth Stock Could Turn $1,000 Into $4,000 by 2029</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThis Robotics Growth Stock Could Turn $1,000 Into $4,000 by 2029\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-09 19:41 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/09/09/this-robotics-growth-stock-could-turn-1000-into-40/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Doing business as usual will be more than enough to make this company a strong investment.\nKey Points\n\nCompanies with regularly recurring revenue have an easier time posting consistent revenue growth....</p>\n\n<a href=\"https://www.fool.com/investing/2021/09/09/this-robotics-growth-stock-could-turn-1000-into-40/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ISRG":"直觉外科公司"},"source_url":"https://www.fool.com/investing/2021/09/09/this-robotics-growth-stock-could-turn-1000-into-40/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2166312201","content_text":"Doing business as usual will be more than enough to make this company a strong investment.\nKey Points\n\nCompanies with regularly recurring revenue have an easier time posting consistent revenue growth.\nMaking products that are platforms for complex tasks is one way to build a recurring revenue base.\nSurgical robots are likely to be in demand in the coming years, just like they have been for the past decade.\n\nYou've probably heard that robots are the future for everything from manufacturing to retail distribution. But have you ever considered that they might be lucrative investments in the present?\nIntuitive Surgical(NASDAQ:ISRG) sits at the intersection of high-tech robotics and healthcare, and that's one of the many reasons why it's an exciting growth stock. Still, with a market cap in excess of $123 billion, investors are right to be skeptical about the stock's prospects for triple-digit percentage growth. Could Intuitive Surgical be a powerhouse for your portfolio with a relatively small initial investment, or is this stock's growth story approaching stagnation? Let's investigate by taking a look at its business model to start.\n\nImage source: Getty Images.\nBig growth is more than feasible\nOverall, Intuitive Surgical is primed to experience consistent and significant growth because of how it makes its income.\nIn case you aren't familiar, its main product is the da Vinci line of robotic surgical suites, which surgeons control from a station in the operating room. It also sells maintenance contracts and an ever-increasing selection of robotic surgical tools to use in conjunction with its da Vinci units. In total, these three product categories made the company $5.16 billion in trailing revenue, 77% of which is recurring.\nFor investors seeking growth stocks, there's nothing sweeter than a rock-solid revenue base. Importantly, there are a few different things that contribute to Intuitive's aggressive expansion of that base.\nThe most obvious is sales of its surgical suites, but that's just the start. Once a hospital has purchased a da Vinci unit and trained its surgeons, it's safe to say that it won't be buying a similar unit from competitors.\nSo, when Intuitive develops new surgical tools to expand the range of procedures performable with the robot, existing customers are highly likely to be interested in expanding the capabilities of the platform they own. Likewise, the more a hospital utilizes its surgical robotics, the more it'll need maintenance and a steady supply of replacement parts.\nAll of the above means that each newly installed surgical suite will render a significant amount of revenue over its lifetime, and the company is constantly installing more with each quarter. In the second quarter of 2021, there were 10% more da Vinci systems installed globally than in Q2 of 2020. Assuming that the business will continue to deploy its products at a similar rate, it'll have a massive pool of future sales opportunities to draw from over the next decade.\nBut will it make investors richer?\nI'm of the view that Intuitive's stock will multiply in value well before 2029.\nOver the next seven years, a $1,000 investment made today could grow to reach $4,000 in value if the stock expands with a compound annual growth rate (CAGR) of 21.9%. Let's take a closer look at why the stock is likely to grow by at least that much on an annual basis for the next few years.\nFirst, Intuitive's stock has been rising rapidly at an even faster rate over the past seven years. Since August 2014, the stock has grown by 567.5%, giving it a CAGR of about 31.5%. While skeptics might argue that the such a strong performance is unlikely to be repeated on a consistent basis, there is little evidence to suggest that growth is slowing.\nEven when including for the sharp drop in income and earnings that occurred when hospitals stopped performing elective surgeries during the first peak of the pandemic, the past three years have seen the company's quarterly revenue rise by nearly 59%, with quarterly earnings before interest, taxes, depreciation, and amortization (EBITDA) increasing by just over 70% in the same period. Likewise, its quarterly free cash flow (FCF) has grown by slightly more than 84% in the last five years, so its financial strength has been steadily increasing over time.\n\nISRG Revenue (Quarterly) data by YCharts\nThus, Intuitive doesn't need to change its business model or optimize its operations to keep expanding. And that means its prospects for being a winning growth stock are secure.\nWhen's the right time to buy?\nIn my view, there's little doubt that this stock could juice a $1,000 investment today into $4,000 over the next seven years, even if growth does end up slowing slightly. Still, there remains the question of when to make a purchase.\nGiven the company's ongoing efforts to develop new surgical tools, expand its portfolio of eligible procedures, and deploy more machines internationally, there's a smattering of catalysts for Intuitive's stock between now and 2029. At the same time, there's little chance of a competitor stealing revenue from accessory sales and maintenance for the established base of installed systems.\nSo, there isn't much to hold investors back from buying the stock today.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5806462,"gmtCreate":1631189775174,"gmtModify":1663233617942,"authorId":3563941452424650,"author":{"id":3563941452424650,"authorId":3563941452424650,"name":"lyokel","avatar":"https://community-static.tradeup.com/news/a0bd3f0fc07966cf561519ba8ef67d7e","vip":1,"crmLevel":6,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":883088437,"type":1,"supId":5806386,"prevId":0,"content":"done","text":"done","html":"done"},{"id":5806386,"gmtCreate":1631189476993,"gmtModify":1663233614528,"authorId":3570549774646276,"author":{"id":3570549774646276,"authorId":3570549774646276,"name":"Andr3","avatar":"https://static.tigerbbs.com/c41ca7aea5e2b5f410896f8cdc5a940c","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":883088437,"type":1,"supId":0,"prevId":0,"content":"comment","text":"comment","html":"comment"}],"langContent":"EN"},{"id":883088602,"gmtCreate":1631189450706,"gmtModify":1676530491419,"author":{"id":"3585729801280242","authorId":"3585729801280242","name":"Boonseong","avatar":"https://static.tigerbbs.com/246facebf009ccbd87b47e3e304c37ef","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"[財迷]&nbsp;","listText":"[財迷]&nbsp;","text":"[財迷]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/883088602","repostId":2166312201,"repostType":4,"repost":{"id":"2166312201","pubTimestamp":1631187660,"share":"https://www.laohu8.com/m/news/2166312201?lang=&edition=full","pubTime":"2021-09-09 19:41","market":"us","language":"en","title":"This Robotics Growth Stock Could Turn $1,000 Into $4,000 by 2029","url":"https://stock-news.laohu8.com/highlight/detail?id=2166312201","media":"Motley Fool","summary":"Doing business as usual will be more than enough to make this company a strong investment.","content":"<p>Doing business as usual will be more than enough to make this company a strong investment.</p>\n<p><b>Key Points</b></p>\n<ul>\n <li>Companies with regularly recurring revenue have an easier time posting consistent revenue growth.</li>\n <li>Making products that are platforms for complex tasks is one way to build a recurring revenue base.</li>\n <li>Surgical robots are likely to be in demand in the coming years, just like they have been for the past decade.</li>\n</ul>\n<p>You've probably heard that robots are the future for everything from manufacturing to retail distribution. But have you ever considered that they might be lucrative investments in the present?</p>\n<p><b>Intuitive Surgical</b>(NASDAQ:ISRG) sits at the intersection of high-tech robotics and healthcare, and that's <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the many reasons why it's an exciting growth stock. Still, with a market cap in excess of $123 billion, investors are right to be skeptical about the stock's prospects for triple-digit percentage growth. Could Intuitive Surgical be a powerhouse for your portfolio with a relatively small initial investment, or is this stock's growth story approaching stagnation? Let's investigate by taking a look at its business model to start.</p>\n<p><img src=\"https://static.tigerbbs.com/a92230e2013b2ec95bc9649c43631081\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: Getty Images.</p>\n<p><b>Big growth is more than feasible</b></p>\n<p>Overall, Intuitive Surgical is primed to experience consistent and significant growth because of how it makes its income.</p>\n<p>In case you aren't familiar, its main product is the da Vinci line of robotic surgical suites, which surgeons control from a station in the operating room. It also sells maintenance contracts and an ever-increasing selection of robotic surgical tools to use in conjunction with its da Vinci units. In total, these three product categories made the company $5.16 billion in trailing revenue, 77% of which is recurring.</p>\n<p>For investors seeking growth stocks, there's nothing sweeter than a rock-solid revenue base. Importantly, there are a few different things that contribute to Intuitive's aggressive expansion of that base.</p>\n<p>The most obvious is sales of its surgical suites, but that's just the start. Once a hospital has purchased a da Vinci unit and trained its surgeons, it's safe to say that it won't be buying a similar unit from competitors.</p>\n<p>So, when Intuitive develops new surgical tools to expand the range of procedures performable with the robot, existing customers are highly likely to be interested in expanding the capabilities of the platform they own. Likewise, the more a hospital utilizes its surgical robotics, the more it'll need maintenance and a steady supply of replacement parts.</p>\n<p>All of the above means that each newly installed surgical suite will render a significant amount of revenue over its lifetime, and the company is constantly installing more with each quarter. In the second quarter of 2021, there were 10% more da Vinci systems installed globally than in Q2 of 2020. Assuming that the business will continue to deploy its products at a similar rate, it'll have a massive pool of future sales opportunities to draw from over the next decade.</p>\n<p><b>But will it make investors richer?</b></p>\n<p>I'm of the view that Intuitive's stock will multiply in value well before 2029.</p>\n<p>Over the next seven years, a $1,000 investment made today could grow to reach $4,000 in value if the stock expands with a compound annual growth rate (CAGR) of 21.9%. Let's take a closer look at why the stock is likely to grow by at least that much on an annual basis for the next few years.</p>\n<p>First, Intuitive's stock has been rising rapidly at an even faster rate over the past seven years. Since August 2014, the stock has grown by 567.5%, giving it a CAGR of about 31.5%. While skeptics might argue that the such a strong performance is unlikely to be repeated on a consistent basis, there is little evidence to suggest that growth is slowing.</p>\n<p>Even when including for the sharp drop in income and earnings that occurred when hospitals stopped performing elective surgeries during the first peak of the pandemic, the past three years have seen the company's quarterly revenue rise by nearly 59%, with quarterly earnings before interest, taxes, depreciation, and amortization (EBITDA) increasing by just over 70% in the same period. Likewise, its quarterly free cash flow (FCF) has grown by slightly more than 84% in the last five years, so its financial strength has been steadily increasing over time.</p>\n<p><img src=\"https://static.tigerbbs.com/23c1a7a479389e7ae5416faa90fb0002\" tg-width=\"720\" tg-height=\"387\" referrerpolicy=\"no-referrer\"></p>\n<p>ISRG Revenue (Quarterly) data by YCharts</p>\n<p>Thus, Intuitive doesn't need to change its business model or optimize its operations to keep expanding. And that means its prospects for being a winning growth stock are secure.</p>\n<p><b>When's the right time to buy?</b></p>\n<p>In my view, there's little doubt that this stock could juice a $1,000 investment today into $4,000 over the next seven years, even if growth does end up slowing slightly. Still, there remains the question of when to make a purchase.</p>\n<p>Given the company's ongoing efforts to develop new surgical tools, expand its portfolio of eligible procedures, and deploy more machines internationally, there's a smattering of catalysts for Intuitive's stock between now and 2029. At the same time, there's little chance of a competitor stealing revenue from accessory sales and maintenance for the established base of installed systems.</p>\n<p>So, there isn't much to hold investors back from buying the stock today.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>This Robotics Growth Stock Could Turn $1,000 Into $4,000 by 2029</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThis Robotics Growth Stock Could Turn $1,000 Into $4,000 by 2029\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-09 19:41 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/09/09/this-robotics-growth-stock-could-turn-1000-into-40/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Doing business as usual will be more than enough to make this company a strong investment.\nKey Points\n\nCompanies with regularly recurring revenue have an easier time posting consistent revenue growth....</p>\n\n<a href=\"https://www.fool.com/investing/2021/09/09/this-robotics-growth-stock-could-turn-1000-into-40/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ISRG":"直觉外科公司"},"source_url":"https://www.fool.com/investing/2021/09/09/this-robotics-growth-stock-could-turn-1000-into-40/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2166312201","content_text":"Doing business as usual will be more than enough to make this company a strong investment.\nKey Points\n\nCompanies with regularly recurring revenue have an easier time posting consistent revenue growth.\nMaking products that are platforms for complex tasks is one way to build a recurring revenue base.\nSurgical robots are likely to be in demand in the coming years, just like they have been for the past decade.\n\nYou've probably heard that robots are the future for everything from manufacturing to retail distribution. But have you ever considered that they might be lucrative investments in the present?\nIntuitive Surgical(NASDAQ:ISRG) sits at the intersection of high-tech robotics and healthcare, and that's one of the many reasons why it's an exciting growth stock. Still, with a market cap in excess of $123 billion, investors are right to be skeptical about the stock's prospects for triple-digit percentage growth. Could Intuitive Surgical be a powerhouse for your portfolio with a relatively small initial investment, or is this stock's growth story approaching stagnation? Let's investigate by taking a look at its business model to start.\n\nImage source: Getty Images.\nBig growth is more than feasible\nOverall, Intuitive Surgical is primed to experience consistent and significant growth because of how it makes its income.\nIn case you aren't familiar, its main product is the da Vinci line of robotic surgical suites, which surgeons control from a station in the operating room. It also sells maintenance contracts and an ever-increasing selection of robotic surgical tools to use in conjunction with its da Vinci units. In total, these three product categories made the company $5.16 billion in trailing revenue, 77% of which is recurring.\nFor investors seeking growth stocks, there's nothing sweeter than a rock-solid revenue base. Importantly, there are a few different things that contribute to Intuitive's aggressive expansion of that base.\nThe most obvious is sales of its surgical suites, but that's just the start. Once a hospital has purchased a da Vinci unit and trained its surgeons, it's safe to say that it won't be buying a similar unit from competitors.\nSo, when Intuitive develops new surgical tools to expand the range of procedures performable with the robot, existing customers are highly likely to be interested in expanding the capabilities of the platform they own. Likewise, the more a hospital utilizes its surgical robotics, the more it'll need maintenance and a steady supply of replacement parts.\nAll of the above means that each newly installed surgical suite will render a significant amount of revenue over its lifetime, and the company is constantly installing more with each quarter. In the second quarter of 2021, there were 10% more da Vinci systems installed globally than in Q2 of 2020. Assuming that the business will continue to deploy its products at a similar rate, it'll have a massive pool of future sales opportunities to draw from over the next decade.\nBut will it make investors richer?\nI'm of the view that Intuitive's stock will multiply in value well before 2029.\nOver the next seven years, a $1,000 investment made today could grow to reach $4,000 in value if the stock expands with a compound annual growth rate (CAGR) of 21.9%. Let's take a closer look at why the stock is likely to grow by at least that much on an annual basis for the next few years.\nFirst, Intuitive's stock has been rising rapidly at an even faster rate over the past seven years. Since August 2014, the stock has grown by 567.5%, giving it a CAGR of about 31.5%. While skeptics might argue that the such a strong performance is unlikely to be repeated on a consistent basis, there is little evidence to suggest that growth is slowing.\nEven when including for the sharp drop in income and earnings that occurred when hospitals stopped performing elective surgeries during the first peak of the pandemic, the past three years have seen the company's quarterly revenue rise by nearly 59%, with quarterly earnings before interest, taxes, depreciation, and amortization (EBITDA) increasing by just over 70% in the same period. Likewise, its quarterly free cash flow (FCF) has grown by slightly more than 84% in the last five years, so its financial strength has been steadily increasing over time.\n\nISRG Revenue (Quarterly) data by YCharts\nThus, Intuitive doesn't need to change its business model or optimize its operations to keep expanding. And that means its prospects for being a winning growth stock are secure.\nWhen's the right time to buy?\nIn my view, there's little doubt that this stock could juice a $1,000 investment today into $4,000 over the next seven years, even if growth does end up slowing slightly. Still, there remains the question of when to make a purchase.\nGiven the company's ongoing efforts to develop new surgical tools, expand its portfolio of eligible procedures, and deploy more machines internationally, there's a smattering of catalysts for Intuitive's stock between now and 2029. At the same time, there's little chance of a competitor stealing revenue from accessory sales and maintenance for the established base of installed systems.\nSo, there isn't much to hold investors back from buying the stock today.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5806428,"gmtCreate":1631189671686,"gmtModify":1663233618043,"authorId":3582595806100338,"author":{"id":3582595806100338,"authorId":3582595806100338,"name":"Rteo","avatar":"https://static.tigerbbs.com/ba4c61a94c707cd25f18400b8cc52a4c","vip":1,"currentWearingBadge":{"badgeId":"1026c425416b44e0aac28c11a0848493-2","templateUuid":"1026c425416b44e0aac28c11a0848493","name":"Senior Tiger","description":"Join the tiger community for 1000 days","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.01.22","individualDisplayEnabled":0,"individualDisplaySort":0,"categoryType":1001},"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":883088602,"type":1,"supId":0,"prevId":0,"content":"?","text":"?","html":"?"}],"langContent":"CN"},{"id":883081414,"gmtCreate":1631189379438,"gmtModify":1676530491400,"author":{"id":"3575378956741249","authorId":"3575378956741249","name":"Kiattt","avatar":"https://community-static.tradeup.com/news/e6d09fa1316db5994a40917a273216eb","vip":1,"hat":"https://static.tigerbbs.com/f84859c65fc2d7681e28f6b8e9b0535a","crmLevel":6,"crmLevelSwitch":1},"htmlText":"Like&nbsp;","listText":"Like&nbsp;","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/883081414","repostId":2166312201,"repostType":4,"repost":{"id":"2166312201","pubTimestamp":1631187660,"share":"https://www.laohu8.com/m/news/2166312201?lang=&edition=full","pubTime":"2021-09-09 19:41","market":"us","language":"en","title":"This Robotics Growth Stock Could Turn $1,000 Into $4,000 by 2029","url":"https://stock-news.laohu8.com/highlight/detail?id=2166312201","media":"Motley Fool","summary":"Doing business as usual will be more than enough to make this company a strong investment.","content":"<p>Doing business as usual will be more than enough to make this company a strong investment.</p>\n<p><b>Key Points</b></p>\n<ul>\n <li>Companies with regularly recurring revenue have an easier time posting consistent revenue growth.</li>\n <li>Making products that are platforms for complex tasks is one way to build a recurring revenue base.</li>\n <li>Surgical robots are likely to be in demand in the coming years, just like they have been for the past decade.</li>\n</ul>\n<p>You've probably heard that robots are the future for everything from manufacturing to retail distribution. But have you ever considered that they might be lucrative investments in the present?</p>\n<p><b>Intuitive Surgical</b>(NASDAQ:ISRG) sits at the intersection of high-tech robotics and healthcare, and that's <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the many reasons why it's an exciting growth stock. Still, with a market cap in excess of $123 billion, investors are right to be skeptical about the stock's prospects for triple-digit percentage growth. Could Intuitive Surgical be a powerhouse for your portfolio with a relatively small initial investment, or is this stock's growth story approaching stagnation? Let's investigate by taking a look at its business model to start.</p>\n<p><img src=\"https://static.tigerbbs.com/a92230e2013b2ec95bc9649c43631081\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: Getty Images.</p>\n<p><b>Big growth is more than feasible</b></p>\n<p>Overall, Intuitive Surgical is primed to experience consistent and significant growth because of how it makes its income.</p>\n<p>In case you aren't familiar, its main product is the da Vinci line of robotic surgical suites, which surgeons control from a station in the operating room. It also sells maintenance contracts and an ever-increasing selection of robotic surgical tools to use in conjunction with its da Vinci units. In total, these three product categories made the company $5.16 billion in trailing revenue, 77% of which is recurring.</p>\n<p>For investors seeking growth stocks, there's nothing sweeter than a rock-solid revenue base. Importantly, there are a few different things that contribute to Intuitive's aggressive expansion of that base.</p>\n<p>The most obvious is sales of its surgical suites, but that's just the start. Once a hospital has purchased a da Vinci unit and trained its surgeons, it's safe to say that it won't be buying a similar unit from competitors.</p>\n<p>So, when Intuitive develops new surgical tools to expand the range of procedures performable with the robot, existing customers are highly likely to be interested in expanding the capabilities of the platform they own. Likewise, the more a hospital utilizes its surgical robotics, the more it'll need maintenance and a steady supply of replacement parts.</p>\n<p>All of the above means that each newly installed surgical suite will render a significant amount of revenue over its lifetime, and the company is constantly installing more with each quarter. In the second quarter of 2021, there were 10% more da Vinci systems installed globally than in Q2 of 2020. Assuming that the business will continue to deploy its products at a similar rate, it'll have a massive pool of future sales opportunities to draw from over the next decade.</p>\n<p><b>But will it make investors richer?</b></p>\n<p>I'm of the view that Intuitive's stock will multiply in value well before 2029.</p>\n<p>Over the next seven years, a $1,000 investment made today could grow to reach $4,000 in value if the stock expands with a compound annual growth rate (CAGR) of 21.9%. Let's take a closer look at why the stock is likely to grow by at least that much on an annual basis for the next few years.</p>\n<p>First, Intuitive's stock has been rising rapidly at an even faster rate over the past seven years. Since August 2014, the stock has grown by 567.5%, giving it a CAGR of about 31.5%. While skeptics might argue that the such a strong performance is unlikely to be repeated on a consistent basis, there is little evidence to suggest that growth is slowing.</p>\n<p>Even when including for the sharp drop in income and earnings that occurred when hospitals stopped performing elective surgeries during the first peak of the pandemic, the past three years have seen the company's quarterly revenue rise by nearly 59%, with quarterly earnings before interest, taxes, depreciation, and amortization (EBITDA) increasing by just over 70% in the same period. Likewise, its quarterly free cash flow (FCF) has grown by slightly more than 84% in the last five years, so its financial strength has been steadily increasing over time.</p>\n<p><img src=\"https://static.tigerbbs.com/23c1a7a479389e7ae5416faa90fb0002\" tg-width=\"720\" tg-height=\"387\" referrerpolicy=\"no-referrer\"></p>\n<p>ISRG Revenue (Quarterly) data by YCharts</p>\n<p>Thus, Intuitive doesn't need to change its business model or optimize its operations to keep expanding. And that means its prospects for being a winning growth stock are secure.</p>\n<p><b>When's the right time to buy?</b></p>\n<p>In my view, there's little doubt that this stock could juice a $1,000 investment today into $4,000 over the next seven years, even if growth does end up slowing slightly. Still, there remains the question of when to make a purchase.</p>\n<p>Given the company's ongoing efforts to develop new surgical tools, expand its portfolio of eligible procedures, and deploy more machines internationally, there's a smattering of catalysts for Intuitive's stock between now and 2029. At the same time, there's little chance of a competitor stealing revenue from accessory sales and maintenance for the established base of installed systems.</p>\n<p>So, there isn't much to hold investors back from buying the stock today.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>This Robotics Growth Stock Could Turn $1,000 Into $4,000 by 2029</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThis Robotics Growth Stock Could Turn $1,000 Into $4,000 by 2029\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-09 19:41 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/09/09/this-robotics-growth-stock-could-turn-1000-into-40/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Doing business as usual will be more than enough to make this company a strong investment.\nKey Points\n\nCompanies with regularly recurring revenue have an easier time posting consistent revenue growth....</p>\n\n<a href=\"https://www.fool.com/investing/2021/09/09/this-robotics-growth-stock-could-turn-1000-into-40/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ISRG":"直觉外科公司"},"source_url":"https://www.fool.com/investing/2021/09/09/this-robotics-growth-stock-could-turn-1000-into-40/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2166312201","content_text":"Doing business as usual will be more than enough to make this company a strong investment.\nKey Points\n\nCompanies with regularly recurring revenue have an easier time posting consistent revenue growth.\nMaking products that are platforms for complex tasks is one way to build a recurring revenue base.\nSurgical robots are likely to be in demand in the coming years, just like they have been for the past decade.\n\nYou've probably heard that robots are the future for everything from manufacturing to retail distribution. But have you ever considered that they might be lucrative investments in the present?\nIntuitive Surgical(NASDAQ:ISRG) sits at the intersection of high-tech robotics and healthcare, and that's one of the many reasons why it's an exciting growth stock. Still, with a market cap in excess of $123 billion, investors are right to be skeptical about the stock's prospects for triple-digit percentage growth. Could Intuitive Surgical be a powerhouse for your portfolio with a relatively small initial investment, or is this stock's growth story approaching stagnation? Let's investigate by taking a look at its business model to start.\n\nImage source: Getty Images.\nBig growth is more than feasible\nOverall, Intuitive Surgical is primed to experience consistent and significant growth because of how it makes its income.\nIn case you aren't familiar, its main product is the da Vinci line of robotic surgical suites, which surgeons control from a station in the operating room. It also sells maintenance contracts and an ever-increasing selection of robotic surgical tools to use in conjunction with its da Vinci units. In total, these three product categories made the company $5.16 billion in trailing revenue, 77% of which is recurring.\nFor investors seeking growth stocks, there's nothing sweeter than a rock-solid revenue base. Importantly, there are a few different things that contribute to Intuitive's aggressive expansion of that base.\nThe most obvious is sales of its surgical suites, but that's just the start. Once a hospital has purchased a da Vinci unit and trained its surgeons, it's safe to say that it won't be buying a similar unit from competitors.\nSo, when Intuitive develops new surgical tools to expand the range of procedures performable with the robot, existing customers are highly likely to be interested in expanding the capabilities of the platform they own. Likewise, the more a hospital utilizes its surgical robotics, the more it'll need maintenance and a steady supply of replacement parts.\nAll of the above means that each newly installed surgical suite will render a significant amount of revenue over its lifetime, and the company is constantly installing more with each quarter. In the second quarter of 2021, there were 10% more da Vinci systems installed globally than in Q2 of 2020. Assuming that the business will continue to deploy its products at a similar rate, it'll have a massive pool of future sales opportunities to draw from over the next decade.\nBut will it make investors richer?\nI'm of the view that Intuitive's stock will multiply in value well before 2029.\nOver the next seven years, a $1,000 investment made today could grow to reach $4,000 in value if the stock expands with a compound annual growth rate (CAGR) of 21.9%. Let's take a closer look at why the stock is likely to grow by at least that much on an annual basis for the next few years.\nFirst, Intuitive's stock has been rising rapidly at an even faster rate over the past seven years. Since August 2014, the stock has grown by 567.5%, giving it a CAGR of about 31.5%. While skeptics might argue that the such a strong performance is unlikely to be repeated on a consistent basis, there is little evidence to suggest that growth is slowing.\nEven when including for the sharp drop in income and earnings that occurred when hospitals stopped performing elective surgeries during the first peak of the pandemic, the past three years have seen the company's quarterly revenue rise by nearly 59%, with quarterly earnings before interest, taxes, depreciation, and amortization (EBITDA) increasing by just over 70% in the same period. Likewise, its quarterly free cash flow (FCF) has grown by slightly more than 84% in the last five years, so its financial strength has been steadily increasing over time.\n\nISRG Revenue (Quarterly) data by YCharts\nThus, Intuitive doesn't need to change its business model or optimize its operations to keep expanding. And that means its prospects for being a winning growth stock are secure.\nWhen's the right time to buy?\nIn my view, there's little doubt that this stock could juice a $1,000 investment today into $4,000 over the next seven years, even if growth does end up slowing slightly. Still, there remains the question of when to make a purchase.\nGiven the company's ongoing efforts to develop new surgical tools, expand its portfolio of eligible procedures, and deploy more machines internationally, there's a smattering of catalysts for Intuitive's stock between now and 2029. At the same time, there's little chance of a competitor stealing revenue from accessory sales and maintenance for the established base of installed systems.\nSo, there isn't much to hold investors back from buying the stock today.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":883081519,"gmtCreate":1631189374331,"gmtModify":1676530491392,"author":{"id":"3582016561552186","authorId":"3582016561552186","name":"KMK","avatar":"https://static.tigerbbs.com/ef525a9485b7272e73ab442de514d467","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"Plz like","listText":"Plz like","text":"Plz like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/883081519","repostId":2166312201,"repostType":4,"repost":{"id":"2166312201","pubTimestamp":1631187660,"share":"https://www.laohu8.com/m/news/2166312201?lang=&edition=full","pubTime":"2021-09-09 19:41","market":"us","language":"en","title":"This Robotics Growth Stock Could Turn $1,000 Into $4,000 by 2029","url":"https://stock-news.laohu8.com/highlight/detail?id=2166312201","media":"Motley Fool","summary":"Doing business as usual will be more than enough to make this company a strong investment.","content":"<p>Doing business as usual will be more than enough to make this company a strong investment.</p>\n<p><b>Key Points</b></p>\n<ul>\n <li>Companies with regularly recurring revenue have an easier time posting consistent revenue growth.</li>\n <li>Making products that are platforms for complex tasks is one way to build a recurring revenue base.</li>\n <li>Surgical robots are likely to be in demand in the coming years, just like they have been for the past decade.</li>\n</ul>\n<p>You've probably heard that robots are the future for everything from manufacturing to retail distribution. But have you ever considered that they might be lucrative investments in the present?</p>\n<p><b>Intuitive Surgical</b>(NASDAQ:ISRG) sits at the intersection of high-tech robotics and healthcare, and that's <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the many reasons why it's an exciting growth stock. Still, with a market cap in excess of $123 billion, investors are right to be skeptical about the stock's prospects for triple-digit percentage growth. Could Intuitive Surgical be a powerhouse for your portfolio with a relatively small initial investment, or is this stock's growth story approaching stagnation? Let's investigate by taking a look at its business model to start.</p>\n<p><img src=\"https://static.tigerbbs.com/a92230e2013b2ec95bc9649c43631081\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: Getty Images.</p>\n<p><b>Big growth is more than feasible</b></p>\n<p>Overall, Intuitive Surgical is primed to experience consistent and significant growth because of how it makes its income.</p>\n<p>In case you aren't familiar, its main product is the da Vinci line of robotic surgical suites, which surgeons control from a station in the operating room. It also sells maintenance contracts and an ever-increasing selection of robotic surgical tools to use in conjunction with its da Vinci units. In total, these three product categories made the company $5.16 billion in trailing revenue, 77% of which is recurring.</p>\n<p>For investors seeking growth stocks, there's nothing sweeter than a rock-solid revenue base. Importantly, there are a few different things that contribute to Intuitive's aggressive expansion of that base.</p>\n<p>The most obvious is sales of its surgical suites, but that's just the start. Once a hospital has purchased a da Vinci unit and trained its surgeons, it's safe to say that it won't be buying a similar unit from competitors.</p>\n<p>So, when Intuitive develops new surgical tools to expand the range of procedures performable with the robot, existing customers are highly likely to be interested in expanding the capabilities of the platform they own. Likewise, the more a hospital utilizes its surgical robotics, the more it'll need maintenance and a steady supply of replacement parts.</p>\n<p>All of the above means that each newly installed surgical suite will render a significant amount of revenue over its lifetime, and the company is constantly installing more with each quarter. In the second quarter of 2021, there were 10% more da Vinci systems installed globally than in Q2 of 2020. Assuming that the business will continue to deploy its products at a similar rate, it'll have a massive pool of future sales opportunities to draw from over the next decade.</p>\n<p><b>But will it make investors richer?</b></p>\n<p>I'm of the view that Intuitive's stock will multiply in value well before 2029.</p>\n<p>Over the next seven years, a $1,000 investment made today could grow to reach $4,000 in value if the stock expands with a compound annual growth rate (CAGR) of 21.9%. Let's take a closer look at why the stock is likely to grow by at least that much on an annual basis for the next few years.</p>\n<p>First, Intuitive's stock has been rising rapidly at an even faster rate over the past seven years. Since August 2014, the stock has grown by 567.5%, giving it a CAGR of about 31.5%. While skeptics might argue that the such a strong performance is unlikely to be repeated on a consistent basis, there is little evidence to suggest that growth is slowing.</p>\n<p>Even when including for the sharp drop in income and earnings that occurred when hospitals stopped performing elective surgeries during the first peak of the pandemic, the past three years have seen the company's quarterly revenue rise by nearly 59%, with quarterly earnings before interest, taxes, depreciation, and amortization (EBITDA) increasing by just over 70% in the same period. Likewise, its quarterly free cash flow (FCF) has grown by slightly more than 84% in the last five years, so its financial strength has been steadily increasing over time.</p>\n<p><img src=\"https://static.tigerbbs.com/23c1a7a479389e7ae5416faa90fb0002\" tg-width=\"720\" tg-height=\"387\" referrerpolicy=\"no-referrer\"></p>\n<p>ISRG Revenue (Quarterly) data by YCharts</p>\n<p>Thus, Intuitive doesn't need to change its business model or optimize its operations to keep expanding. And that means its prospects for being a winning growth stock are secure.</p>\n<p><b>When's the right time to buy?</b></p>\n<p>In my view, there's little doubt that this stock could juice a $1,000 investment today into $4,000 over the next seven years, even if growth does end up slowing slightly. Still, there remains the question of when to make a purchase.</p>\n<p>Given the company's ongoing efforts to develop new surgical tools, expand its portfolio of eligible procedures, and deploy more machines internationally, there's a smattering of catalysts for Intuitive's stock between now and 2029. At the same time, there's little chance of a competitor stealing revenue from accessory sales and maintenance for the established base of installed systems.</p>\n<p>So, there isn't much to hold investors back from buying the stock today.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>This Robotics Growth Stock Could Turn $1,000 Into $4,000 by 2029</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThis Robotics Growth Stock Could Turn $1,000 Into $4,000 by 2029\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-09 19:41 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/09/09/this-robotics-growth-stock-could-turn-1000-into-40/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Doing business as usual will be more than enough to make this company a strong investment.\nKey Points\n\nCompanies with regularly recurring revenue have an easier time posting consistent revenue growth....</p>\n\n<a href=\"https://www.fool.com/investing/2021/09/09/this-robotics-growth-stock-could-turn-1000-into-40/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ISRG":"直觉外科公司"},"source_url":"https://www.fool.com/investing/2021/09/09/this-robotics-growth-stock-could-turn-1000-into-40/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2166312201","content_text":"Doing business as usual will be more than enough to make this company a strong investment.\nKey Points\n\nCompanies with regularly recurring revenue have an easier time posting consistent revenue growth.\nMaking products that are platforms for complex tasks is one way to build a recurring revenue base.\nSurgical robots are likely to be in demand in the coming years, just like they have been for the past decade.\n\nYou've probably heard that robots are the future for everything from manufacturing to retail distribution. But have you ever considered that they might be lucrative investments in the present?\nIntuitive Surgical(NASDAQ:ISRG) sits at the intersection of high-tech robotics and healthcare, and that's one of the many reasons why it's an exciting growth stock. Still, with a market cap in excess of $123 billion, investors are right to be skeptical about the stock's prospects for triple-digit percentage growth. Could Intuitive Surgical be a powerhouse for your portfolio with a relatively small initial investment, or is this stock's growth story approaching stagnation? Let's investigate by taking a look at its business model to start.\n\nImage source: Getty Images.\nBig growth is more than feasible\nOverall, Intuitive Surgical is primed to experience consistent and significant growth because of how it makes its income.\nIn case you aren't familiar, its main product is the da Vinci line of robotic surgical suites, which surgeons control from a station in the operating room. It also sells maintenance contracts and an ever-increasing selection of robotic surgical tools to use in conjunction with its da Vinci units. In total, these three product categories made the company $5.16 billion in trailing revenue, 77% of which is recurring.\nFor investors seeking growth stocks, there's nothing sweeter than a rock-solid revenue base. Importantly, there are a few different things that contribute to Intuitive's aggressive expansion of that base.\nThe most obvious is sales of its surgical suites, but that's just the start. Once a hospital has purchased a da Vinci unit and trained its surgeons, it's safe to say that it won't be buying a similar unit from competitors.\nSo, when Intuitive develops new surgical tools to expand the range of procedures performable with the robot, existing customers are highly likely to be interested in expanding the capabilities of the platform they own. Likewise, the more a hospital utilizes its surgical robotics, the more it'll need maintenance and a steady supply of replacement parts.\nAll of the above means that each newly installed surgical suite will render a significant amount of revenue over its lifetime, and the company is constantly installing more with each quarter. In the second quarter of 2021, there were 10% more da Vinci systems installed globally than in Q2 of 2020. Assuming that the business will continue to deploy its products at a similar rate, it'll have a massive pool of future sales opportunities to draw from over the next decade.\nBut will it make investors richer?\nI'm of the view that Intuitive's stock will multiply in value well before 2029.\nOver the next seven years, a $1,000 investment made today could grow to reach $4,000 in value if the stock expands with a compound annual growth rate (CAGR) of 21.9%. Let's take a closer look at why the stock is likely to grow by at least that much on an annual basis for the next few years.\nFirst, Intuitive's stock has been rising rapidly at an even faster rate over the past seven years. Since August 2014, the stock has grown by 567.5%, giving it a CAGR of about 31.5%. While skeptics might argue that the such a strong performance is unlikely to be repeated on a consistent basis, there is little evidence to suggest that growth is slowing.\nEven when including for the sharp drop in income and earnings that occurred when hospitals stopped performing elective surgeries during the first peak of the pandemic, the past three years have seen the company's quarterly revenue rise by nearly 59%, with quarterly earnings before interest, taxes, depreciation, and amortization (EBITDA) increasing by just over 70% in the same period. Likewise, its quarterly free cash flow (FCF) has grown by slightly more than 84% in the last five years, so its financial strength has been steadily increasing over time.\n\nISRG Revenue (Quarterly) data by YCharts\nThus, Intuitive doesn't need to change its business model or optimize its operations to keep expanding. And that means its prospects for being a winning growth stock are secure.\nWhen's the right time to buy?\nIn my view, there's little doubt that this stock could juice a $1,000 investment today into $4,000 over the next seven years, even if growth does end up slowing slightly. Still, there remains the question of when to make a purchase.\nGiven the company's ongoing efforts to develop new surgical tools, expand its portfolio of eligible procedures, and deploy more machines internationally, there's a smattering of catalysts for Intuitive's stock between now and 2029. At the same time, there's little chance of a competitor stealing revenue from accessory sales and maintenance for the established base of installed systems.\nSo, there isn't much to hold investors back from buying the stock today.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":883081922,"gmtCreate":1631189274466,"gmtModify":1676530491383,"author":{"id":"3559770113710833","authorId":"3559770113710833","name":"SillyOldBear","avatar":"https://static.tigerbbs.com/ef207140107fde8983f710c746a5b404","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"Like pls","listText":"Like pls","text":"Like pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/883081922","repostId":2166312201,"repostType":4,"repost":{"id":"2166312201","pubTimestamp":1631187660,"share":"https://www.laohu8.com/m/news/2166312201?lang=&edition=full","pubTime":"2021-09-09 19:41","market":"us","language":"en","title":"This Robotics Growth Stock Could Turn $1,000 Into $4,000 by 2029","url":"https://stock-news.laohu8.com/highlight/detail?id=2166312201","media":"Motley Fool","summary":"Doing business as usual will be more than enough to make this company a strong investment.","content":"<p>Doing business as usual will be more than enough to make this company a strong investment.</p>\n<p><b>Key Points</b></p>\n<ul>\n <li>Companies with regularly recurring revenue have an easier time posting consistent revenue growth.</li>\n <li>Making products that are platforms for complex tasks is one way to build a recurring revenue base.</li>\n <li>Surgical robots are likely to be in demand in the coming years, just like they have been for the past decade.</li>\n</ul>\n<p>You've probably heard that robots are the future for everything from manufacturing to retail distribution. But have you ever considered that they might be lucrative investments in the present?</p>\n<p><b>Intuitive Surgical</b>(NASDAQ:ISRG) sits at the intersection of high-tech robotics and healthcare, and that's <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the many reasons why it's an exciting growth stock. Still, with a market cap in excess of $123 billion, investors are right to be skeptical about the stock's prospects for triple-digit percentage growth. Could Intuitive Surgical be a powerhouse for your portfolio with a relatively small initial investment, or is this stock's growth story approaching stagnation? Let's investigate by taking a look at its business model to start.</p>\n<p><img src=\"https://static.tigerbbs.com/a92230e2013b2ec95bc9649c43631081\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: Getty Images.</p>\n<p><b>Big growth is more than feasible</b></p>\n<p>Overall, Intuitive Surgical is primed to experience consistent and significant growth because of how it makes its income.</p>\n<p>In case you aren't familiar, its main product is the da Vinci line of robotic surgical suites, which surgeons control from a station in the operating room. It also sells maintenance contracts and an ever-increasing selection of robotic surgical tools to use in conjunction with its da Vinci units. In total, these three product categories made the company $5.16 billion in trailing revenue, 77% of which is recurring.</p>\n<p>For investors seeking growth stocks, there's nothing sweeter than a rock-solid revenue base. Importantly, there are a few different things that contribute to Intuitive's aggressive expansion of that base.</p>\n<p>The most obvious is sales of its surgical suites, but that's just the start. Once a hospital has purchased a da Vinci unit and trained its surgeons, it's safe to say that it won't be buying a similar unit from competitors.</p>\n<p>So, when Intuitive develops new surgical tools to expand the range of procedures performable with the robot, existing customers are highly likely to be interested in expanding the capabilities of the platform they own. Likewise, the more a hospital utilizes its surgical robotics, the more it'll need maintenance and a steady supply of replacement parts.</p>\n<p>All of the above means that each newly installed surgical suite will render a significant amount of revenue over its lifetime, and the company is constantly installing more with each quarter. In the second quarter of 2021, there were 10% more da Vinci systems installed globally than in Q2 of 2020. Assuming that the business will continue to deploy its products at a similar rate, it'll have a massive pool of future sales opportunities to draw from over the next decade.</p>\n<p><b>But will it make investors richer?</b></p>\n<p>I'm of the view that Intuitive's stock will multiply in value well before 2029.</p>\n<p>Over the next seven years, a $1,000 investment made today could grow to reach $4,000 in value if the stock expands with a compound annual growth rate (CAGR) of 21.9%. Let's take a closer look at why the stock is likely to grow by at least that much on an annual basis for the next few years.</p>\n<p>First, Intuitive's stock has been rising rapidly at an even faster rate over the past seven years. Since August 2014, the stock has grown by 567.5%, giving it a CAGR of about 31.5%. While skeptics might argue that the such a strong performance is unlikely to be repeated on a consistent basis, there is little evidence to suggest that growth is slowing.</p>\n<p>Even when including for the sharp drop in income and earnings that occurred when hospitals stopped performing elective surgeries during the first peak of the pandemic, the past three years have seen the company's quarterly revenue rise by nearly 59%, with quarterly earnings before interest, taxes, depreciation, and amortization (EBITDA) increasing by just over 70% in the same period. Likewise, its quarterly free cash flow (FCF) has grown by slightly more than 84% in the last five years, so its financial strength has been steadily increasing over time.</p>\n<p><img src=\"https://static.tigerbbs.com/23c1a7a479389e7ae5416faa90fb0002\" tg-width=\"720\" tg-height=\"387\" referrerpolicy=\"no-referrer\"></p>\n<p>ISRG Revenue (Quarterly) data by YCharts</p>\n<p>Thus, Intuitive doesn't need to change its business model or optimize its operations to keep expanding. And that means its prospects for being a winning growth stock are secure.</p>\n<p><b>When's the right time to buy?</b></p>\n<p>In my view, there's little doubt that this stock could juice a $1,000 investment today into $4,000 over the next seven years, even if growth does end up slowing slightly. Still, there remains the question of when to make a purchase.</p>\n<p>Given the company's ongoing efforts to develop new surgical tools, expand its portfolio of eligible procedures, and deploy more machines internationally, there's a smattering of catalysts for Intuitive's stock between now and 2029. At the same time, there's little chance of a competitor stealing revenue from accessory sales and maintenance for the established base of installed systems.</p>\n<p>So, there isn't much to hold investors back from buying the stock today.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>This Robotics Growth Stock Could Turn $1,000 Into $4,000 by 2029</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThis Robotics Growth Stock Could Turn $1,000 Into $4,000 by 2029\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-09 19:41 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/09/09/this-robotics-growth-stock-could-turn-1000-into-40/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Doing business as usual will be more than enough to make this company a strong investment.\nKey Points\n\nCompanies with regularly recurring revenue have an easier time posting consistent revenue growth....</p>\n\n<a href=\"https://www.fool.com/investing/2021/09/09/this-robotics-growth-stock-could-turn-1000-into-40/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ISRG":"直觉外科公司"},"source_url":"https://www.fool.com/investing/2021/09/09/this-robotics-growth-stock-could-turn-1000-into-40/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2166312201","content_text":"Doing business as usual will be more than enough to make this company a strong investment.\nKey Points\n\nCompanies with regularly recurring revenue have an easier time posting consistent revenue growth.\nMaking products that are platforms for complex tasks is one way to build a recurring revenue base.\nSurgical robots are likely to be in demand in the coming years, just like they have been for the past decade.\n\nYou've probably heard that robots are the future for everything from manufacturing to retail distribution. But have you ever considered that they might be lucrative investments in the present?\nIntuitive Surgical(NASDAQ:ISRG) sits at the intersection of high-tech robotics and healthcare, and that's one of the many reasons why it's an exciting growth stock. Still, with a market cap in excess of $123 billion, investors are right to be skeptical about the stock's prospects for triple-digit percentage growth. Could Intuitive Surgical be a powerhouse for your portfolio with a relatively small initial investment, or is this stock's growth story approaching stagnation? Let's investigate by taking a look at its business model to start.\n\nImage source: Getty Images.\nBig growth is more than feasible\nOverall, Intuitive Surgical is primed to experience consistent and significant growth because of how it makes its income.\nIn case you aren't familiar, its main product is the da Vinci line of robotic surgical suites, which surgeons control from a station in the operating room. It also sells maintenance contracts and an ever-increasing selection of robotic surgical tools to use in conjunction with its da Vinci units. In total, these three product categories made the company $5.16 billion in trailing revenue, 77% of which is recurring.\nFor investors seeking growth stocks, there's nothing sweeter than a rock-solid revenue base. Importantly, there are a few different things that contribute to Intuitive's aggressive expansion of that base.\nThe most obvious is sales of its surgical suites, but that's just the start. Once a hospital has purchased a da Vinci unit and trained its surgeons, it's safe to say that it won't be buying a similar unit from competitors.\nSo, when Intuitive develops new surgical tools to expand the range of procedures performable with the robot, existing customers are highly likely to be interested in expanding the capabilities of the platform they own. Likewise, the more a hospital utilizes its surgical robotics, the more it'll need maintenance and a steady supply of replacement parts.\nAll of the above means that each newly installed surgical suite will render a significant amount of revenue over its lifetime, and the company is constantly installing more with each quarter. In the second quarter of 2021, there were 10% more da Vinci systems installed globally than in Q2 of 2020. Assuming that the business will continue to deploy its products at a similar rate, it'll have a massive pool of future sales opportunities to draw from over the next decade.\nBut will it make investors richer?\nI'm of the view that Intuitive's stock will multiply in value well before 2029.\nOver the next seven years, a $1,000 investment made today could grow to reach $4,000 in value if the stock expands with a compound annual growth rate (CAGR) of 21.9%. Let's take a closer look at why the stock is likely to grow by at least that much on an annual basis for the next few years.\nFirst, Intuitive's stock has been rising rapidly at an even faster rate over the past seven years. Since August 2014, the stock has grown by 567.5%, giving it a CAGR of about 31.5%. While skeptics might argue that the such a strong performance is unlikely to be repeated on a consistent basis, there is little evidence to suggest that growth is slowing.\nEven when including for the sharp drop in income and earnings that occurred when hospitals stopped performing elective surgeries during the first peak of the pandemic, the past three years have seen the company's quarterly revenue rise by nearly 59%, with quarterly earnings before interest, taxes, depreciation, and amortization (EBITDA) increasing by just over 70% in the same period. Likewise, its quarterly free cash flow (FCF) has grown by slightly more than 84% in the last five years, so its financial strength has been steadily increasing over time.\n\nISRG Revenue (Quarterly) data by YCharts\nThus, Intuitive doesn't need to change its business model or optimize its operations to keep expanding. And that means its prospects for being a winning growth stock are secure.\nWhen's the right time to buy?\nIn my view, there's little doubt that this stock could juice a $1,000 investment today into $4,000 over the next seven years, even if growth does end up slowing slightly. Still, there remains the question of when to make a purchase.\nGiven the company's ongoing efforts to develop new surgical tools, expand its portfolio of eligible procedures, and deploy more machines internationally, there's a smattering of catalysts for Intuitive's stock between now and 2029. At the same time, there's little chance of a competitor stealing revenue from accessory sales and maintenance for the established base of installed systems.\nSo, there isn't much to hold investors back from buying the stock today.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5806370,"gmtCreate":1631189345172,"gmtModify":1663233614530,"authorId":3575378956741249,"author":{"id":3575378956741249,"authorId":3575378956741249,"name":"Kiattt","avatar":"https://community-static.tradeup.com/news/e6d09fa1316db5994a40917a273216eb","vip":1,"currentWearingBadge":{"badgeId":"44212b71d0be4ec88898348dbe882e03-1","templateUuid":"44212b71d0be4ec88898348dbe882e03","name":"Boss Tiger","description":"The transaction amount of the securities account reaches $100,000","bigImgUrl":"https://static.tigerbbs.com/c8dfc27c1ee0e25db1c93e9d0b641101","smallImgUrl":"https://static.tigerbbs.com/f43908c142f8a33c78f5bdf0e2897488","grayImgUrl":"https://static.tigerbbs.com/82165ff19cb8a786e8919f92acee5213","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.08.26","exceedPercentage":"60.27%","individualDisplayEnabled":0,"individualDisplaySort":0,"categoryType":1101},"crmLevel":6,"crmLevelSwitch":1,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":883081922,"type":1,"supId":0,"prevId":0,"content":"<u>K</u>","text":"<u>K</u>","html":"<u>K</u>"}],"langContent":"EN"},{"id":883089403,"gmtCreate":1631189094702,"gmtModify":1676530491350,"author":{"id":"3582769468410601","authorId":"3582769468410601","name":"clare288","avatar":"https://static.tigerbbs.com/2302ca3cd94dcb0acc98aa0cd7d3438b","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"Wow","listText":"Wow","text":"Wow","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/883089403","repostId":2166312201,"repostType":4,"repost":{"id":"2166312201","pubTimestamp":1631187660,"share":"https://www.laohu8.com/m/news/2166312201?lang=&edition=full","pubTime":"2021-09-09 19:41","market":"us","language":"en","title":"This Robotics Growth Stock Could Turn $1,000 Into $4,000 by 2029","url":"https://stock-news.laohu8.com/highlight/detail?id=2166312201","media":"Motley Fool","summary":"Doing business as usual will be more than enough to make this company a strong investment.","content":"<p>Doing business as usual will be more than enough to make this company a strong investment.</p>\n<p><b>Key Points</b></p>\n<ul>\n <li>Companies with regularly recurring revenue have an easier time posting consistent revenue growth.</li>\n <li>Making products that are platforms for complex tasks is one way to build a recurring revenue base.</li>\n <li>Surgical robots are likely to be in demand in the coming years, just like they have been for the past decade.</li>\n</ul>\n<p>You've probably heard that robots are the future for everything from manufacturing to retail distribution. But have you ever considered that they might be lucrative investments in the present?</p>\n<p><b>Intuitive Surgical</b>(NASDAQ:ISRG) sits at the intersection of high-tech robotics and healthcare, and that's <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the many reasons why it's an exciting growth stock. Still, with a market cap in excess of $123 billion, investors are right to be skeptical about the stock's prospects for triple-digit percentage growth. Could Intuitive Surgical be a powerhouse for your portfolio with a relatively small initial investment, or is this stock's growth story approaching stagnation? Let's investigate by taking a look at its business model to start.</p>\n<p><img src=\"https://static.tigerbbs.com/a92230e2013b2ec95bc9649c43631081\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: Getty Images.</p>\n<p><b>Big growth is more than feasible</b></p>\n<p>Overall, Intuitive Surgical is primed to experience consistent and significant growth because of how it makes its income.</p>\n<p>In case you aren't familiar, its main product is the da Vinci line of robotic surgical suites, which surgeons control from a station in the operating room. It also sells maintenance contracts and an ever-increasing selection of robotic surgical tools to use in conjunction with its da Vinci units. In total, these three product categories made the company $5.16 billion in trailing revenue, 77% of which is recurring.</p>\n<p>For investors seeking growth stocks, there's nothing sweeter than a rock-solid revenue base. Importantly, there are a few different things that contribute to Intuitive's aggressive expansion of that base.</p>\n<p>The most obvious is sales of its surgical suites, but that's just the start. Once a hospital has purchased a da Vinci unit and trained its surgeons, it's safe to say that it won't be buying a similar unit from competitors.</p>\n<p>So, when Intuitive develops new surgical tools to expand the range of procedures performable with the robot, existing customers are highly likely to be interested in expanding the capabilities of the platform they own. Likewise, the more a hospital utilizes its surgical robotics, the more it'll need maintenance and a steady supply of replacement parts.</p>\n<p>All of the above means that each newly installed surgical suite will render a significant amount of revenue over its lifetime, and the company is constantly installing more with each quarter. In the second quarter of 2021, there were 10% more da Vinci systems installed globally than in Q2 of 2020. Assuming that the business will continue to deploy its products at a similar rate, it'll have a massive pool of future sales opportunities to draw from over the next decade.</p>\n<p><b>But will it make investors richer?</b></p>\n<p>I'm of the view that Intuitive's stock will multiply in value well before 2029.</p>\n<p>Over the next seven years, a $1,000 investment made today could grow to reach $4,000 in value if the stock expands with a compound annual growth rate (CAGR) of 21.9%. Let's take a closer look at why the stock is likely to grow by at least that much on an annual basis for the next few years.</p>\n<p>First, Intuitive's stock has been rising rapidly at an even faster rate over the past seven years. Since August 2014, the stock has grown by 567.5%, giving it a CAGR of about 31.5%. While skeptics might argue that the such a strong performance is unlikely to be repeated on a consistent basis, there is little evidence to suggest that growth is slowing.</p>\n<p>Even when including for the sharp drop in income and earnings that occurred when hospitals stopped performing elective surgeries during the first peak of the pandemic, the past three years have seen the company's quarterly revenue rise by nearly 59%, with quarterly earnings before interest, taxes, depreciation, and amortization (EBITDA) increasing by just over 70% in the same period. Likewise, its quarterly free cash flow (FCF) has grown by slightly more than 84% in the last five years, so its financial strength has been steadily increasing over time.</p>\n<p><img src=\"https://static.tigerbbs.com/23c1a7a479389e7ae5416faa90fb0002\" tg-width=\"720\" tg-height=\"387\" referrerpolicy=\"no-referrer\"></p>\n<p>ISRG Revenue (Quarterly) data by YCharts</p>\n<p>Thus, Intuitive doesn't need to change its business model or optimize its operations to keep expanding. And that means its prospects for being a winning growth stock are secure.</p>\n<p><b>When's the right time to buy?</b></p>\n<p>In my view, there's little doubt that this stock could juice a $1,000 investment today into $4,000 over the next seven years, even if growth does end up slowing slightly. Still, there remains the question of when to make a purchase.</p>\n<p>Given the company's ongoing efforts to develop new surgical tools, expand its portfolio of eligible procedures, and deploy more machines internationally, there's a smattering of catalysts for Intuitive's stock between now and 2029. At the same time, there's little chance of a competitor stealing revenue from accessory sales and maintenance for the established base of installed systems.</p>\n<p>So, there isn't much to hold investors back from buying the stock today.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>This Robotics Growth Stock Could Turn $1,000 Into $4,000 by 2029</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThis Robotics Growth Stock Could Turn $1,000 Into $4,000 by 2029\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-09 19:41 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/09/09/this-robotics-growth-stock-could-turn-1000-into-40/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Doing business as usual will be more than enough to make this company a strong investment.\nKey Points\n\nCompanies with regularly recurring revenue have an easier time posting consistent revenue growth....</p>\n\n<a href=\"https://www.fool.com/investing/2021/09/09/this-robotics-growth-stock-could-turn-1000-into-40/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ISRG":"直觉外科公司"},"source_url":"https://www.fool.com/investing/2021/09/09/this-robotics-growth-stock-could-turn-1000-into-40/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2166312201","content_text":"Doing business as usual will be more than enough to make this company a strong investment.\nKey Points\n\nCompanies with regularly recurring revenue have an easier time posting consistent revenue growth.\nMaking products that are platforms for complex tasks is one way to build a recurring revenue base.\nSurgical robots are likely to be in demand in the coming years, just like they have been for the past decade.\n\nYou've probably heard that robots are the future for everything from manufacturing to retail distribution. But have you ever considered that they might be lucrative investments in the present?\nIntuitive Surgical(NASDAQ:ISRG) sits at the intersection of high-tech robotics and healthcare, and that's one of the many reasons why it's an exciting growth stock. Still, with a market cap in excess of $123 billion, investors are right to be skeptical about the stock's prospects for triple-digit percentage growth. Could Intuitive Surgical be a powerhouse for your portfolio with a relatively small initial investment, or is this stock's growth story approaching stagnation? Let's investigate by taking a look at its business model to start.\n\nImage source: Getty Images.\nBig growth is more than feasible\nOverall, Intuitive Surgical is primed to experience consistent and significant growth because of how it makes its income.\nIn case you aren't familiar, its main product is the da Vinci line of robotic surgical suites, which surgeons control from a station in the operating room. It also sells maintenance contracts and an ever-increasing selection of robotic surgical tools to use in conjunction with its da Vinci units. In total, these three product categories made the company $5.16 billion in trailing revenue, 77% of which is recurring.\nFor investors seeking growth stocks, there's nothing sweeter than a rock-solid revenue base. Importantly, there are a few different things that contribute to Intuitive's aggressive expansion of that base.\nThe most obvious is sales of its surgical suites, but that's just the start. Once a hospital has purchased a da Vinci unit and trained its surgeons, it's safe to say that it won't be buying a similar unit from competitors.\nSo, when Intuitive develops new surgical tools to expand the range of procedures performable with the robot, existing customers are highly likely to be interested in expanding the capabilities of the platform they own. Likewise, the more a hospital utilizes its surgical robotics, the more it'll need maintenance and a steady supply of replacement parts.\nAll of the above means that each newly installed surgical suite will render a significant amount of revenue over its lifetime, and the company is constantly installing more with each quarter. In the second quarter of 2021, there were 10% more da Vinci systems installed globally than in Q2 of 2020. Assuming that the business will continue to deploy its products at a similar rate, it'll have a massive pool of future sales opportunities to draw from over the next decade.\nBut will it make investors richer?\nI'm of the view that Intuitive's stock will multiply in value well before 2029.\nOver the next seven years, a $1,000 investment made today could grow to reach $4,000 in value if the stock expands with a compound annual growth rate (CAGR) of 21.9%. Let's take a closer look at why the stock is likely to grow by at least that much on an annual basis for the next few years.\nFirst, Intuitive's stock has been rising rapidly at an even faster rate over the past seven years. Since August 2014, the stock has grown by 567.5%, giving it a CAGR of about 31.5%. While skeptics might argue that the such a strong performance is unlikely to be repeated on a consistent basis, there is little evidence to suggest that growth is slowing.\nEven when including for the sharp drop in income and earnings that occurred when hospitals stopped performing elective surgeries during the first peak of the pandemic, the past three years have seen the company's quarterly revenue rise by nearly 59%, with quarterly earnings before interest, taxes, depreciation, and amortization (EBITDA) increasing by just over 70% in the same period. Likewise, its quarterly free cash flow (FCF) has grown by slightly more than 84% in the last five years, so its financial strength has been steadily increasing over time.\n\nISRG Revenue (Quarterly) data by YCharts\nThus, Intuitive doesn't need to change its business model or optimize its operations to keep expanding. And that means its prospects for being a winning growth stock are secure.\nWhen's the right time to buy?\nIn my view, there's little doubt that this stock could juice a $1,000 investment today into $4,000 over the next seven years, even if growth does end up slowing slightly. Still, there remains the question of when to make a purchase.\nGiven the company's ongoing efforts to develop new surgical tools, expand its portfolio of eligible procedures, and deploy more machines internationally, there's a smattering of catalysts for Intuitive's stock between now and 2029. At the same time, there's little chance of a competitor stealing revenue from accessory sales and maintenance for the established base of installed systems.\nSo, there isn't much to hold investors back from buying the stock today.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5806325,"gmtCreate":1631189146587,"gmtModify":1663233615834,"authorId":3581046107767827,"author":{"id":3581046107767827,"authorId":3581046107767827,"name":"Vonz","avatar":"https://static.tigerbbs.com/5a1cb72de358038a377e7053d898bb82","vip":1,"crmLevel":5,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":883089403,"type":1,"supId":0,"prevId":0,"content":"<u>oo</u>","text":"<u>oo</u>","html":"<u>oo</u>"},{"id":5806338,"gmtCreate":1631189215439,"gmtModify":1663233615248,"authorId":3577764785081065,"author":{"id":3577764785081065,"authorId":3577764785081065,"name":"sncx00","avatar":"https://static.tigerbbs.com/76058ac62e6ab115952491be37a1ad4d","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":883089403,"type":1,"supId":5806325,"prevId":0,"content":"<u>oo</u>","text":"<u>oo</u>","html":"<u>oo</u>"}],"langContent":"EN"},{"id":883080507,"gmtCreate":1631188966209,"gmtModify":1676530491340,"author":{"id":"3581585794734271","authorId":"3581585794734271","name":"thuiching","avatar":"https://static.tigerbbs.com/9dc8e63d946079f8f710c092c90f6aa4","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/883080507","repostId":2166312201,"repostType":4,"repost":{"id":"2166312201","pubTimestamp":1631187660,"share":"https://www.laohu8.com/m/news/2166312201?lang=&edition=full","pubTime":"2021-09-09 19:41","market":"us","language":"en","title":"This Robotics Growth Stock Could Turn $1,000 Into $4,000 by 2029","url":"https://stock-news.laohu8.com/highlight/detail?id=2166312201","media":"Motley Fool","summary":"Doing business as usual will be more than enough to make this company a strong investment.","content":"<p>Doing business as usual will be more than enough to make this company a strong investment.</p>\n<p><b>Key Points</b></p>\n<ul>\n <li>Companies with regularly recurring revenue have an easier time posting consistent revenue growth.</li>\n <li>Making products that are platforms for complex tasks is one way to build a recurring revenue base.</li>\n <li>Surgical robots are likely to be in demand in the coming years, just like they have been for the past decade.</li>\n</ul>\n<p>You've probably heard that robots are the future for everything from manufacturing to retail distribution. But have you ever considered that they might be lucrative investments in the present?</p>\n<p><b>Intuitive Surgical</b>(NASDAQ:ISRG) sits at the intersection of high-tech robotics and healthcare, and that's <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the many reasons why it's an exciting growth stock. Still, with a market cap in excess of $123 billion, investors are right to be skeptical about the stock's prospects for triple-digit percentage growth. Could Intuitive Surgical be a powerhouse for your portfolio with a relatively small initial investment, or is this stock's growth story approaching stagnation? Let's investigate by taking a look at its business model to start.</p>\n<p><img src=\"https://static.tigerbbs.com/a92230e2013b2ec95bc9649c43631081\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: Getty Images.</p>\n<p><b>Big growth is more than feasible</b></p>\n<p>Overall, Intuitive Surgical is primed to experience consistent and significant growth because of how it makes its income.</p>\n<p>In case you aren't familiar, its main product is the da Vinci line of robotic surgical suites, which surgeons control from a station in the operating room. It also sells maintenance contracts and an ever-increasing selection of robotic surgical tools to use in conjunction with its da Vinci units. In total, these three product categories made the company $5.16 billion in trailing revenue, 77% of which is recurring.</p>\n<p>For investors seeking growth stocks, there's nothing sweeter than a rock-solid revenue base. Importantly, there are a few different things that contribute to Intuitive's aggressive expansion of that base.</p>\n<p>The most obvious is sales of its surgical suites, but that's just the start. Once a hospital has purchased a da Vinci unit and trained its surgeons, it's safe to say that it won't be buying a similar unit from competitors.</p>\n<p>So, when Intuitive develops new surgical tools to expand the range of procedures performable with the robot, existing customers are highly likely to be interested in expanding the capabilities of the platform they own. Likewise, the more a hospital utilizes its surgical robotics, the more it'll need maintenance and a steady supply of replacement parts.</p>\n<p>All of the above means that each newly installed surgical suite will render a significant amount of revenue over its lifetime, and the company is constantly installing more with each quarter. In the second quarter of 2021, there were 10% more da Vinci systems installed globally than in Q2 of 2020. Assuming that the business will continue to deploy its products at a similar rate, it'll have a massive pool of future sales opportunities to draw from over the next decade.</p>\n<p><b>But will it make investors richer?</b></p>\n<p>I'm of the view that Intuitive's stock will multiply in value well before 2029.</p>\n<p>Over the next seven years, a $1,000 investment made today could grow to reach $4,000 in value if the stock expands with a compound annual growth rate (CAGR) of 21.9%. Let's take a closer look at why the stock is likely to grow by at least that much on an annual basis for the next few years.</p>\n<p>First, Intuitive's stock has been rising rapidly at an even faster rate over the past seven years. Since August 2014, the stock has grown by 567.5%, giving it a CAGR of about 31.5%. While skeptics might argue that the such a strong performance is unlikely to be repeated on a consistent basis, there is little evidence to suggest that growth is slowing.</p>\n<p>Even when including for the sharp drop in income and earnings that occurred when hospitals stopped performing elective surgeries during the first peak of the pandemic, the past three years have seen the company's quarterly revenue rise by nearly 59%, with quarterly earnings before interest, taxes, depreciation, and amortization (EBITDA) increasing by just over 70% in the same period. Likewise, its quarterly free cash flow (FCF) has grown by slightly more than 84% in the last five years, so its financial strength has been steadily increasing over time.</p>\n<p><img src=\"https://static.tigerbbs.com/23c1a7a479389e7ae5416faa90fb0002\" tg-width=\"720\" tg-height=\"387\" referrerpolicy=\"no-referrer\"></p>\n<p>ISRG Revenue (Quarterly) data by YCharts</p>\n<p>Thus, Intuitive doesn't need to change its business model or optimize its operations to keep expanding. And that means its prospects for being a winning growth stock are secure.</p>\n<p><b>When's the right time to buy?</b></p>\n<p>In my view, there's little doubt that this stock could juice a $1,000 investment today into $4,000 over the next seven years, even if growth does end up slowing slightly. Still, there remains the question of when to make a purchase.</p>\n<p>Given the company's ongoing efforts to develop new surgical tools, expand its portfolio of eligible procedures, and deploy more machines internationally, there's a smattering of catalysts for Intuitive's stock between now and 2029. At the same time, there's little chance of a competitor stealing revenue from accessory sales and maintenance for the established base of installed systems.</p>\n<p>So, there isn't much to hold investors back from buying the stock today.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>This Robotics Growth Stock Could Turn $1,000 Into $4,000 by 2029</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThis Robotics Growth Stock Could Turn $1,000 Into $4,000 by 2029\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-09 19:41 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/09/09/this-robotics-growth-stock-could-turn-1000-into-40/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Doing business as usual will be more than enough to make this company a strong investment.\nKey Points\n\nCompanies with regularly recurring revenue have an easier time posting consistent revenue growth....</p>\n\n<a href=\"https://www.fool.com/investing/2021/09/09/this-robotics-growth-stock-could-turn-1000-into-40/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ISRG":"直觉外科公司"},"source_url":"https://www.fool.com/investing/2021/09/09/this-robotics-growth-stock-could-turn-1000-into-40/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2166312201","content_text":"Doing business as usual will be more than enough to make this company a strong investment.\nKey Points\n\nCompanies with regularly recurring revenue have an easier time posting consistent revenue growth.\nMaking products that are platforms for complex tasks is one way to build a recurring revenue base.\nSurgical robots are likely to be in demand in the coming years, just like they have been for the past decade.\n\nYou've probably heard that robots are the future for everything from manufacturing to retail distribution. But have you ever considered that they might be lucrative investments in the present?\nIntuitive Surgical(NASDAQ:ISRG) sits at the intersection of high-tech robotics and healthcare, and that's one of the many reasons why it's an exciting growth stock. Still, with a market cap in excess of $123 billion, investors are right to be skeptical about the stock's prospects for triple-digit percentage growth. Could Intuitive Surgical be a powerhouse for your portfolio with a relatively small initial investment, or is this stock's growth story approaching stagnation? Let's investigate by taking a look at its business model to start.\n\nImage source: Getty Images.\nBig growth is more than feasible\nOverall, Intuitive Surgical is primed to experience consistent and significant growth because of how it makes its income.\nIn case you aren't familiar, its main product is the da Vinci line of robotic surgical suites, which surgeons control from a station in the operating room. It also sells maintenance contracts and an ever-increasing selection of robotic surgical tools to use in conjunction with its da Vinci units. In total, these three product categories made the company $5.16 billion in trailing revenue, 77% of which is recurring.\nFor investors seeking growth stocks, there's nothing sweeter than a rock-solid revenue base. Importantly, there are a few different things that contribute to Intuitive's aggressive expansion of that base.\nThe most obvious is sales of its surgical suites, but that's just the start. Once a hospital has purchased a da Vinci unit and trained its surgeons, it's safe to say that it won't be buying a similar unit from competitors.\nSo, when Intuitive develops new surgical tools to expand the range of procedures performable with the robot, existing customers are highly likely to be interested in expanding the capabilities of the platform they own. Likewise, the more a hospital utilizes its surgical robotics, the more it'll need maintenance and a steady supply of replacement parts.\nAll of the above means that each newly installed surgical suite will render a significant amount of revenue over its lifetime, and the company is constantly installing more with each quarter. In the second quarter of 2021, there were 10% more da Vinci systems installed globally than in Q2 of 2020. Assuming that the business will continue to deploy its products at a similar rate, it'll have a massive pool of future sales opportunities to draw from over the next decade.\nBut will it make investors richer?\nI'm of the view that Intuitive's stock will multiply in value well before 2029.\nOver the next seven years, a $1,000 investment made today could grow to reach $4,000 in value if the stock expands with a compound annual growth rate (CAGR) of 21.9%. Let's take a closer look at why the stock is likely to grow by at least that much on an annual basis for the next few years.\nFirst, Intuitive's stock has been rising rapidly at an even faster rate over the past seven years. Since August 2014, the stock has grown by 567.5%, giving it a CAGR of about 31.5%. While skeptics might argue that the such a strong performance is unlikely to be repeated on a consistent basis, there is little evidence to suggest that growth is slowing.\nEven when including for the sharp drop in income and earnings that occurred when hospitals stopped performing elective surgeries during the first peak of the pandemic, the past three years have seen the company's quarterly revenue rise by nearly 59%, with quarterly earnings before interest, taxes, depreciation, and amortization (EBITDA) increasing by just over 70% in the same period. Likewise, its quarterly free cash flow (FCF) has grown by slightly more than 84% in the last five years, so its financial strength has been steadily increasing over time.\n\nISRG Revenue (Quarterly) data by YCharts\nThus, Intuitive doesn't need to change its business model or optimize its operations to keep expanding. And that means its prospects for being a winning growth stock are secure.\nWhen's the right time to buy?\nIn my view, there's little doubt that this stock could juice a $1,000 investment today into $4,000 over the next seven years, even if growth does end up slowing slightly. Still, there remains the question of when to make a purchase.\nGiven the company's ongoing efforts to develop new surgical tools, expand its portfolio of eligible procedures, and deploy more machines internationally, there's a smattering of catalysts for Intuitive's stock between now and 2029. At the same time, there's little chance of a competitor stealing revenue from accessory sales and maintenance for the established base of installed systems.\nSo, there isn't much to hold investors back from buying the stock today.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5806274,"gmtCreate":1631189004408,"gmtModify":1663233615329,"authorId":3554886109685293,"author":{"id":3554886109685293,"authorId":3554886109685293,"name":"Expert126","avatar":"https://static.tigerbbs.com/2d4304f2ec7fabd9d599a3ba8b2a17e0","vip":1,"crmLevel":3,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":883080507,"type":1,"supId":0,"prevId":0,"content":"<u>ok</u>","text":"<u>ok</u>","html":"<u>ok</u>"}],"langContent":"EN"},{"id":883080894,"gmtCreate":1631188922318,"gmtModify":1676530491315,"author":{"id":"3577131990335289","authorId":"3577131990335289","name":"Saintrade","avatar":"https://static.tigerbbs.com/0586ed865bb515fc4dd23fea4fa2590d","vip":1,"crmLevel":4,"crmLevelSwitch":1},"htmlText":"Like and comments ty&nbsp;","listText":"Like and comments ty&nbsp;","text":"Like and comments ty","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/883080894","repostId":2166312201,"repostType":4,"repost":{"id":"2166312201","pubTimestamp":1631187660,"share":"https://www.laohu8.com/m/news/2166312201?lang=&edition=full","pubTime":"2021-09-09 19:41","market":"us","language":"en","title":"This Robotics Growth Stock Could Turn $1,000 Into $4,000 by 2029","url":"https://stock-news.laohu8.com/highlight/detail?id=2166312201","media":"Motley Fool","summary":"Doing business as usual will be more than enough to make this company a strong investment.","content":"<p>Doing business as usual will be more than enough to make this company a strong investment.</p>\n<p><b>Key Points</b></p>\n<ul>\n <li>Companies with regularly recurring revenue have an easier time posting consistent revenue growth.</li>\n <li>Making products that are platforms for complex tasks is one way to build a recurring revenue base.</li>\n <li>Surgical robots are likely to be in demand in the coming years, just like they have been for the past decade.</li>\n</ul>\n<p>You've probably heard that robots are the future for everything from manufacturing to retail distribution. But have you ever considered that they might be lucrative investments in the present?</p>\n<p><b>Intuitive Surgical</b>(NASDAQ:ISRG) sits at the intersection of high-tech robotics and healthcare, and that's <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the many reasons why it's an exciting growth stock. Still, with a market cap in excess of $123 billion, investors are right to be skeptical about the stock's prospects for triple-digit percentage growth. Could Intuitive Surgical be a powerhouse for your portfolio with a relatively small initial investment, or is this stock's growth story approaching stagnation? Let's investigate by taking a look at its business model to start.</p>\n<p><img src=\"https://static.tigerbbs.com/a92230e2013b2ec95bc9649c43631081\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: Getty Images.</p>\n<p><b>Big growth is more than feasible</b></p>\n<p>Overall, Intuitive Surgical is primed to experience consistent and significant growth because of how it makes its income.</p>\n<p>In case you aren't familiar, its main product is the da Vinci line of robotic surgical suites, which surgeons control from a station in the operating room. It also sells maintenance contracts and an ever-increasing selection of robotic surgical tools to use in conjunction with its da Vinci units. In total, these three product categories made the company $5.16 billion in trailing revenue, 77% of which is recurring.</p>\n<p>For investors seeking growth stocks, there's nothing sweeter than a rock-solid revenue base. Importantly, there are a few different things that contribute to Intuitive's aggressive expansion of that base.</p>\n<p>The most obvious is sales of its surgical suites, but that's just the start. Once a hospital has purchased a da Vinci unit and trained its surgeons, it's safe to say that it won't be buying a similar unit from competitors.</p>\n<p>So, when Intuitive develops new surgical tools to expand the range of procedures performable with the robot, existing customers are highly likely to be interested in expanding the capabilities of the platform they own. Likewise, the more a hospital utilizes its surgical robotics, the more it'll need maintenance and a steady supply of replacement parts.</p>\n<p>All of the above means that each newly installed surgical suite will render a significant amount of revenue over its lifetime, and the company is constantly installing more with each quarter. In the second quarter of 2021, there were 10% more da Vinci systems installed globally than in Q2 of 2020. Assuming that the business will continue to deploy its products at a similar rate, it'll have a massive pool of future sales opportunities to draw from over the next decade.</p>\n<p><b>But will it make investors richer?</b></p>\n<p>I'm of the view that Intuitive's stock will multiply in value well before 2029.</p>\n<p>Over the next seven years, a $1,000 investment made today could grow to reach $4,000 in value if the stock expands with a compound annual growth rate (CAGR) of 21.9%. Let's take a closer look at why the stock is likely to grow by at least that much on an annual basis for the next few years.</p>\n<p>First, Intuitive's stock has been rising rapidly at an even faster rate over the past seven years. Since August 2014, the stock has grown by 567.5%, giving it a CAGR of about 31.5%. While skeptics might argue that the such a strong performance is unlikely to be repeated on a consistent basis, there is little evidence to suggest that growth is slowing.</p>\n<p>Even when including for the sharp drop in income and earnings that occurred when hospitals stopped performing elective surgeries during the first peak of the pandemic, the past three years have seen the company's quarterly revenue rise by nearly 59%, with quarterly earnings before interest, taxes, depreciation, and amortization (EBITDA) increasing by just over 70% in the same period. Likewise, its quarterly free cash flow (FCF) has grown by slightly more than 84% in the last five years, so its financial strength has been steadily increasing over time.</p>\n<p><img src=\"https://static.tigerbbs.com/23c1a7a479389e7ae5416faa90fb0002\" tg-width=\"720\" tg-height=\"387\" referrerpolicy=\"no-referrer\"></p>\n<p>ISRG Revenue (Quarterly) data by YCharts</p>\n<p>Thus, Intuitive doesn't need to change its business model or optimize its operations to keep expanding. And that means its prospects for being a winning growth stock are secure.</p>\n<p><b>When's the right time to buy?</b></p>\n<p>In my view, there's little doubt that this stock could juice a $1,000 investment today into $4,000 over the next seven years, even if growth does end up slowing slightly. Still, there remains the question of when to make a purchase.</p>\n<p>Given the company's ongoing efforts to develop new surgical tools, expand its portfolio of eligible procedures, and deploy more machines internationally, there's a smattering of catalysts for Intuitive's stock between now and 2029. At the same time, there's little chance of a competitor stealing revenue from accessory sales and maintenance for the established base of installed systems.</p>\n<p>So, there isn't much to hold investors back from buying the stock today.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>This Robotics Growth Stock Could Turn $1,000 Into $4,000 by 2029</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThis Robotics Growth Stock Could Turn $1,000 Into $4,000 by 2029\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-09 19:41 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/09/09/this-robotics-growth-stock-could-turn-1000-into-40/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Doing business as usual will be more than enough to make this company a strong investment.\nKey Points\n\nCompanies with regularly recurring revenue have an easier time posting consistent revenue growth....</p>\n\n<a href=\"https://www.fool.com/investing/2021/09/09/this-robotics-growth-stock-could-turn-1000-into-40/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ISRG":"直觉外科公司"},"source_url":"https://www.fool.com/investing/2021/09/09/this-robotics-growth-stock-could-turn-1000-into-40/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2166312201","content_text":"Doing business as usual will be more than enough to make this company a strong investment.\nKey Points\n\nCompanies with regularly recurring revenue have an easier time posting consistent revenue growth.\nMaking products that are platforms for complex tasks is one way to build a recurring revenue base.\nSurgical robots are likely to be in demand in the coming years, just like they have been for the past decade.\n\nYou've probably heard that robots are the future for everything from manufacturing to retail distribution. But have you ever considered that they might be lucrative investments in the present?\nIntuitive Surgical(NASDAQ:ISRG) sits at the intersection of high-tech robotics and healthcare, and that's one of the many reasons why it's an exciting growth stock. Still, with a market cap in excess of $123 billion, investors are right to be skeptical about the stock's prospects for triple-digit percentage growth. Could Intuitive Surgical be a powerhouse for your portfolio with a relatively small initial investment, or is this stock's growth story approaching stagnation? Let's investigate by taking a look at its business model to start.\n\nImage source: Getty Images.\nBig growth is more than feasible\nOverall, Intuitive Surgical is primed to experience consistent and significant growth because of how it makes its income.\nIn case you aren't familiar, its main product is the da Vinci line of robotic surgical suites, which surgeons control from a station in the operating room. It also sells maintenance contracts and an ever-increasing selection of robotic surgical tools to use in conjunction with its da Vinci units. In total, these three product categories made the company $5.16 billion in trailing revenue, 77% of which is recurring.\nFor investors seeking growth stocks, there's nothing sweeter than a rock-solid revenue base. Importantly, there are a few different things that contribute to Intuitive's aggressive expansion of that base.\nThe most obvious is sales of its surgical suites, but that's just the start. Once a hospital has purchased a da Vinci unit and trained its surgeons, it's safe to say that it won't be buying a similar unit from competitors.\nSo, when Intuitive develops new surgical tools to expand the range of procedures performable with the robot, existing customers are highly likely to be interested in expanding the capabilities of the platform they own. Likewise, the more a hospital utilizes its surgical robotics, the more it'll need maintenance and a steady supply of replacement parts.\nAll of the above means that each newly installed surgical suite will render a significant amount of revenue over its lifetime, and the company is constantly installing more with each quarter. In the second quarter of 2021, there were 10% more da Vinci systems installed globally than in Q2 of 2020. Assuming that the business will continue to deploy its products at a similar rate, it'll have a massive pool of future sales opportunities to draw from over the next decade.\nBut will it make investors richer?\nI'm of the view that Intuitive's stock will multiply in value well before 2029.\nOver the next seven years, a $1,000 investment made today could grow to reach $4,000 in value if the stock expands with a compound annual growth rate (CAGR) of 21.9%. Let's take a closer look at why the stock is likely to grow by at least that much on an annual basis for the next few years.\nFirst, Intuitive's stock has been rising rapidly at an even faster rate over the past seven years. Since August 2014, the stock has grown by 567.5%, giving it a CAGR of about 31.5%. While skeptics might argue that the such a strong performance is unlikely to be repeated on a consistent basis, there is little evidence to suggest that growth is slowing.\nEven when including for the sharp drop in income and earnings that occurred when hospitals stopped performing elective surgeries during the first peak of the pandemic, the past three years have seen the company's quarterly revenue rise by nearly 59%, with quarterly earnings before interest, taxes, depreciation, and amortization (EBITDA) increasing by just over 70% in the same period. Likewise, its quarterly free cash flow (FCF) has grown by slightly more than 84% in the last five years, so its financial strength has been steadily increasing over time.\n\nISRG Revenue (Quarterly) data by YCharts\nThus, Intuitive doesn't need to change its business model or optimize its operations to keep expanding. And that means its prospects for being a winning growth stock are secure.\nWhen's the right time to buy?\nIn my view, there's little doubt that this stock could juice a $1,000 investment today into $4,000 over the next seven years, even if growth does end up slowing slightly. Still, there remains the question of when to make a purchase.\nGiven the company's ongoing efforts to develop new surgical tools, expand its portfolio of eligible procedures, and deploy more machines internationally, there's a smattering of catalysts for Intuitive's stock between now and 2029. At the same time, there's little chance of a competitor stealing revenue from accessory sales and maintenance for the established base of installed systems.\nSo, there isn't much to hold investors back from buying the stock today.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5806256,"gmtCreate":1631188928311,"gmtModify":1663233615832,"authorId":3577131990335289,"author":{"id":3577131990335289,"authorId":3577131990335289,"name":"Saintrade","avatar":"https://static.tigerbbs.com/0586ed865bb515fc4dd23fea4fa2590d","vip":1,"crmLevel":4,"crmLevelSwitch":1,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":883080894,"type":1,"supId":0,"prevId":0,"content":"Ok","text":"Ok","html":"Ok"}],"langContent":"EN"},{"id":883017796,"gmtCreate":1631188820315,"gmtModify":1676530491306,"author":{"id":"3584067862408237","authorId":"3584067862408237","name":"StaceyLiew","avatar":"https://static.tigerbbs.com/0d96094b3b57d3cc339a5fa471709239","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"Comment and like","listText":"Comment and like","text":"Comment and like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":10,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/883017796","repostId":2166312201,"repostType":4,"repost":{"id":"2166312201","pubTimestamp":1631187660,"share":"https://www.laohu8.com/m/news/2166312201?lang=&edition=full","pubTime":"2021-09-09 19:41","market":"us","language":"en","title":"This Robotics Growth Stock Could Turn $1,000 Into $4,000 by 2029","url":"https://stock-news.laohu8.com/highlight/detail?id=2166312201","media":"Motley Fool","summary":"Doing business as usual will be more than enough to make this company a strong investment.","content":"<p>Doing business as usual will be more than enough to make this company a strong investment.</p>\n<p><b>Key Points</b></p>\n<ul>\n <li>Companies with regularly recurring revenue have an easier time posting consistent revenue growth.</li>\n <li>Making products that are platforms for complex tasks is one way to build a recurring revenue base.</li>\n <li>Surgical robots are likely to be in demand in the coming years, just like they have been for the past decade.</li>\n</ul>\n<p>You've probably heard that robots are the future for everything from manufacturing to retail distribution. But have you ever considered that they might be lucrative investments in the present?</p>\n<p><b>Intuitive Surgical</b>(NASDAQ:ISRG) sits at the intersection of high-tech robotics and healthcare, and that's <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the many reasons why it's an exciting growth stock. Still, with a market cap in excess of $123 billion, investors are right to be skeptical about the stock's prospects for triple-digit percentage growth. Could Intuitive Surgical be a powerhouse for your portfolio with a relatively small initial investment, or is this stock's growth story approaching stagnation? Let's investigate by taking a look at its business model to start.</p>\n<p><img src=\"https://static.tigerbbs.com/a92230e2013b2ec95bc9649c43631081\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: Getty Images.</p>\n<p><b>Big growth is more than feasible</b></p>\n<p>Overall, Intuitive Surgical is primed to experience consistent and significant growth because of how it makes its income.</p>\n<p>In case you aren't familiar, its main product is the da Vinci line of robotic surgical suites, which surgeons control from a station in the operating room. It also sells maintenance contracts and an ever-increasing selection of robotic surgical tools to use in conjunction with its da Vinci units. In total, these three product categories made the company $5.16 billion in trailing revenue, 77% of which is recurring.</p>\n<p>For investors seeking growth stocks, there's nothing sweeter than a rock-solid revenue base. Importantly, there are a few different things that contribute to Intuitive's aggressive expansion of that base.</p>\n<p>The most obvious is sales of its surgical suites, but that's just the start. Once a hospital has purchased a da Vinci unit and trained its surgeons, it's safe to say that it won't be buying a similar unit from competitors.</p>\n<p>So, when Intuitive develops new surgical tools to expand the range of procedures performable with the robot, existing customers are highly likely to be interested in expanding the capabilities of the platform they own. Likewise, the more a hospital utilizes its surgical robotics, the more it'll need maintenance and a steady supply of replacement parts.</p>\n<p>All of the above means that each newly installed surgical suite will render a significant amount of revenue over its lifetime, and the company is constantly installing more with each quarter. In the second quarter of 2021, there were 10% more da Vinci systems installed globally than in Q2 of 2020. Assuming that the business will continue to deploy its products at a similar rate, it'll have a massive pool of future sales opportunities to draw from over the next decade.</p>\n<p><b>But will it make investors richer?</b></p>\n<p>I'm of the view that Intuitive's stock will multiply in value well before 2029.</p>\n<p>Over the next seven years, a $1,000 investment made today could grow to reach $4,000 in value if the stock expands with a compound annual growth rate (CAGR) of 21.9%. Let's take a closer look at why the stock is likely to grow by at least that much on an annual basis for the next few years.</p>\n<p>First, Intuitive's stock has been rising rapidly at an even faster rate over the past seven years. Since August 2014, the stock has grown by 567.5%, giving it a CAGR of about 31.5%. While skeptics might argue that the such a strong performance is unlikely to be repeated on a consistent basis, there is little evidence to suggest that growth is slowing.</p>\n<p>Even when including for the sharp drop in income and earnings that occurred when hospitals stopped performing elective surgeries during the first peak of the pandemic, the past three years have seen the company's quarterly revenue rise by nearly 59%, with quarterly earnings before interest, taxes, depreciation, and amortization (EBITDA) increasing by just over 70% in the same period. Likewise, its quarterly free cash flow (FCF) has grown by slightly more than 84% in the last five years, so its financial strength has been steadily increasing over time.</p>\n<p><img src=\"https://static.tigerbbs.com/23c1a7a479389e7ae5416faa90fb0002\" tg-width=\"720\" tg-height=\"387\" referrerpolicy=\"no-referrer\"></p>\n<p>ISRG Revenue (Quarterly) data by YCharts</p>\n<p>Thus, Intuitive doesn't need to change its business model or optimize its operations to keep expanding. And that means its prospects for being a winning growth stock are secure.</p>\n<p><b>When's the right time to buy?</b></p>\n<p>In my view, there's little doubt that this stock could juice a $1,000 investment today into $4,000 over the next seven years, even if growth does end up slowing slightly. Still, there remains the question of when to make a purchase.</p>\n<p>Given the company's ongoing efforts to develop new surgical tools, expand its portfolio of eligible procedures, and deploy more machines internationally, there's a smattering of catalysts for Intuitive's stock between now and 2029. At the same time, there's little chance of a competitor stealing revenue from accessory sales and maintenance for the established base of installed systems.</p>\n<p>So, there isn't much to hold investors back from buying the stock today.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>This Robotics Growth Stock Could Turn $1,000 Into $4,000 by 2029</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThis Robotics Growth Stock Could Turn $1,000 Into $4,000 by 2029\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-09 19:41 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/09/09/this-robotics-growth-stock-could-turn-1000-into-40/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Doing business as usual will be more than enough to make this company a strong investment.\nKey Points\n\nCompanies with regularly recurring revenue have an easier time posting consistent revenue growth....</p>\n\n<a href=\"https://www.fool.com/investing/2021/09/09/this-robotics-growth-stock-could-turn-1000-into-40/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ISRG":"直觉外科公司"},"source_url":"https://www.fool.com/investing/2021/09/09/this-robotics-growth-stock-could-turn-1000-into-40/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2166312201","content_text":"Doing business as usual will be more than enough to make this company a strong investment.\nKey Points\n\nCompanies with regularly recurring revenue have an easier time posting consistent revenue growth.\nMaking products that are platforms for complex tasks is one way to build a recurring revenue base.\nSurgical robots are likely to be in demand in the coming years, just like they have been for the past decade.\n\nYou've probably heard that robots are the future for everything from manufacturing to retail distribution. But have you ever considered that they might be lucrative investments in the present?\nIntuitive Surgical(NASDAQ:ISRG) sits at the intersection of high-tech robotics and healthcare, and that's one of the many reasons why it's an exciting growth stock. Still, with a market cap in excess of $123 billion, investors are right to be skeptical about the stock's prospects for triple-digit percentage growth. Could Intuitive Surgical be a powerhouse for your portfolio with a relatively small initial investment, or is this stock's growth story approaching stagnation? Let's investigate by taking a look at its business model to start.\n\nImage source: Getty Images.\nBig growth is more than feasible\nOverall, Intuitive Surgical is primed to experience consistent and significant growth because of how it makes its income.\nIn case you aren't familiar, its main product is the da Vinci line of robotic surgical suites, which surgeons control from a station in the operating room. It also sells maintenance contracts and an ever-increasing selection of robotic surgical tools to use in conjunction with its da Vinci units. In total, these three product categories made the company $5.16 billion in trailing revenue, 77% of which is recurring.\nFor investors seeking growth stocks, there's nothing sweeter than a rock-solid revenue base. Importantly, there are a few different things that contribute to Intuitive's aggressive expansion of that base.\nThe most obvious is sales of its surgical suites, but that's just the start. Once a hospital has purchased a da Vinci unit and trained its surgeons, it's safe to say that it won't be buying a similar unit from competitors.\nSo, when Intuitive develops new surgical tools to expand the range of procedures performable with the robot, existing customers are highly likely to be interested in expanding the capabilities of the platform they own. Likewise, the more a hospital utilizes its surgical robotics, the more it'll need maintenance and a steady supply of replacement parts.\nAll of the above means that each newly installed surgical suite will render a significant amount of revenue over its lifetime, and the company is constantly installing more with each quarter. In the second quarter of 2021, there were 10% more da Vinci systems installed globally than in Q2 of 2020. Assuming that the business will continue to deploy its products at a similar rate, it'll have a massive pool of future sales opportunities to draw from over the next decade.\nBut will it make investors richer?\nI'm of the view that Intuitive's stock will multiply in value well before 2029.\nOver the next seven years, a $1,000 investment made today could grow to reach $4,000 in value if the stock expands with a compound annual growth rate (CAGR) of 21.9%. Let's take a closer look at why the stock is likely to grow by at least that much on an annual basis for the next few years.\nFirst, Intuitive's stock has been rising rapidly at an even faster rate over the past seven years. Since August 2014, the stock has grown by 567.5%, giving it a CAGR of about 31.5%. While skeptics might argue that the such a strong performance is unlikely to be repeated on a consistent basis, there is little evidence to suggest that growth is slowing.\nEven when including for the sharp drop in income and earnings that occurred when hospitals stopped performing elective surgeries during the first peak of the pandemic, the past three years have seen the company's quarterly revenue rise by nearly 59%, with quarterly earnings before interest, taxes, depreciation, and amortization (EBITDA) increasing by just over 70% in the same period. Likewise, its quarterly free cash flow (FCF) has grown by slightly more than 84% in the last five years, so its financial strength has been steadily increasing over time.\n\nISRG Revenue (Quarterly) data by YCharts\nThus, Intuitive doesn't need to change its business model or optimize its operations to keep expanding. And that means its prospects for being a winning growth stock are secure.\nWhen's the right time to buy?\nIn my view, there's little doubt that this stock could juice a $1,000 investment today into $4,000 over the next seven years, even if growth does end up slowing slightly. Still, there remains the question of when to make a purchase.\nGiven the company's ongoing efforts to develop new surgical tools, expand its portfolio of eligible procedures, and deploy more machines internationally, there's a smattering of catalysts for Intuitive's stock between now and 2029. At the same time, there's little chance of a competitor stealing revenue from accessory sales and maintenance for the established base of installed systems.\nSo, there isn't much to hold investors back from buying the stock today.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5806226,"gmtCreate":1631188851596,"gmtModify":1663233618139,"authorId":3572249185724220,"author":{"id":3572249185724220,"authorId":3572249185724220,"name":"xoxoll","avatar":"https://static.tigerbbs.com/8ed65c2962af2a6fbd414f4d6fe9e378","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":883017796,"type":1,"supId":0,"prevId":0,"content":"Ok","text":"Ok","html":"Ok"},{"id":5806306,"gmtCreate":1631189068198,"gmtModify":1631890275563,"authorId":3584067862408237,"author":{"id":3584067862408237,"authorId":3584067862408237,"name":"StaceyLiew","avatar":"https://static.tigerbbs.com/0d96094b3b57d3cc339a5fa471709239","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":883017796,"type":1,"supId":5806226,"prevId":0,"content":"[强]","text":"[强]","html":"[强]"}],"langContent":"EN"},{"id":883017873,"gmtCreate":1631188793092,"gmtModify":1676530491289,"author":{"id":"3572249185724220","authorId":"3572249185724220","name":"xoxoll","avatar":"https://static.tigerbbs.com/8ed65c2962af2a6fbd414f4d6fe9e378","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"Help me like&nbsp;","listText":"Help me like&nbsp;","text":"Help me like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/883017873","repostId":2166312201,"repostType":4,"repost":{"id":"2166312201","pubTimestamp":1631187660,"share":"https://www.laohu8.com/m/news/2166312201?lang=&edition=full","pubTime":"2021-09-09 19:41","market":"us","language":"en","title":"This Robotics Growth Stock Could Turn $1,000 Into $4,000 by 2029","url":"https://stock-news.laohu8.com/highlight/detail?id=2166312201","media":"Motley Fool","summary":"Doing business as usual will be more than enough to make this company a strong investment.","content":"<p>Doing business as usual will be more than enough to make this company a strong investment.</p>\n<p><b>Key Points</b></p>\n<ul>\n <li>Companies with regularly recurring revenue have an easier time posting consistent revenue growth.</li>\n <li>Making products that are platforms for complex tasks is one way to build a recurring revenue base.</li>\n <li>Surgical robots are likely to be in demand in the coming years, just like they have been for the past decade.</li>\n</ul>\n<p>You've probably heard that robots are the future for everything from manufacturing to retail distribution. But have you ever considered that they might be lucrative investments in the present?</p>\n<p><b>Intuitive Surgical</b>(NASDAQ:ISRG) sits at the intersection of high-tech robotics and healthcare, and that's <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the many reasons why it's an exciting growth stock. Still, with a market cap in excess of $123 billion, investors are right to be skeptical about the stock's prospects for triple-digit percentage growth. Could Intuitive Surgical be a powerhouse for your portfolio with a relatively small initial investment, or is this stock's growth story approaching stagnation? Let's investigate by taking a look at its business model to start.</p>\n<p><img src=\"https://static.tigerbbs.com/a92230e2013b2ec95bc9649c43631081\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: Getty Images.</p>\n<p><b>Big growth is more than feasible</b></p>\n<p>Overall, Intuitive Surgical is primed to experience consistent and significant growth because of how it makes its income.</p>\n<p>In case you aren't familiar, its main product is the da Vinci line of robotic surgical suites, which surgeons control from a station in the operating room. It also sells maintenance contracts and an ever-increasing selection of robotic surgical tools to use in conjunction with its da Vinci units. In total, these three product categories made the company $5.16 billion in trailing revenue, 77% of which is recurring.</p>\n<p>For investors seeking growth stocks, there's nothing sweeter than a rock-solid revenue base. Importantly, there are a few different things that contribute to Intuitive's aggressive expansion of that base.</p>\n<p>The most obvious is sales of its surgical suites, but that's just the start. Once a hospital has purchased a da Vinci unit and trained its surgeons, it's safe to say that it won't be buying a similar unit from competitors.</p>\n<p>So, when Intuitive develops new surgical tools to expand the range of procedures performable with the robot, existing customers are highly likely to be interested in expanding the capabilities of the platform they own. Likewise, the more a hospital utilizes its surgical robotics, the more it'll need maintenance and a steady supply of replacement parts.</p>\n<p>All of the above means that each newly installed surgical suite will render a significant amount of revenue over its lifetime, and the company is constantly installing more with each quarter. In the second quarter of 2021, there were 10% more da Vinci systems installed globally than in Q2 of 2020. Assuming that the business will continue to deploy its products at a similar rate, it'll have a massive pool of future sales opportunities to draw from over the next decade.</p>\n<p><b>But will it make investors richer?</b></p>\n<p>I'm of the view that Intuitive's stock will multiply in value well before 2029.</p>\n<p>Over the next seven years, a $1,000 investment made today could grow to reach $4,000 in value if the stock expands with a compound annual growth rate (CAGR) of 21.9%. Let's take a closer look at why the stock is likely to grow by at least that much on an annual basis for the next few years.</p>\n<p>First, Intuitive's stock has been rising rapidly at an even faster rate over the past seven years. Since August 2014, the stock has grown by 567.5%, giving it a CAGR of about 31.5%. While skeptics might argue that the such a strong performance is unlikely to be repeated on a consistent basis, there is little evidence to suggest that growth is slowing.</p>\n<p>Even when including for the sharp drop in income and earnings that occurred when hospitals stopped performing elective surgeries during the first peak of the pandemic, the past three years have seen the company's quarterly revenue rise by nearly 59%, with quarterly earnings before interest, taxes, depreciation, and amortization (EBITDA) increasing by just over 70% in the same period. Likewise, its quarterly free cash flow (FCF) has grown by slightly more than 84% in the last five years, so its financial strength has been steadily increasing over time.</p>\n<p><img src=\"https://static.tigerbbs.com/23c1a7a479389e7ae5416faa90fb0002\" tg-width=\"720\" tg-height=\"387\" referrerpolicy=\"no-referrer\"></p>\n<p>ISRG Revenue (Quarterly) data by YCharts</p>\n<p>Thus, Intuitive doesn't need to change its business model or optimize its operations to keep expanding. And that means its prospects for being a winning growth stock are secure.</p>\n<p><b>When's the right time to buy?</b></p>\n<p>In my view, there's little doubt that this stock could juice a $1,000 investment today into $4,000 over the next seven years, even if growth does end up slowing slightly. Still, there remains the question of when to make a purchase.</p>\n<p>Given the company's ongoing efforts to develop new surgical tools, expand its portfolio of eligible procedures, and deploy more machines internationally, there's a smattering of catalysts for Intuitive's stock between now and 2029. At the same time, there's little chance of a competitor stealing revenue from accessory sales and maintenance for the established base of installed systems.</p>\n<p>So, there isn't much to hold investors back from buying the stock today.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>This Robotics Growth Stock Could Turn $1,000 Into $4,000 by 2029</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThis Robotics Growth Stock Could Turn $1,000 Into $4,000 by 2029\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-09 19:41 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/09/09/this-robotics-growth-stock-could-turn-1000-into-40/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Doing business as usual will be more than enough to make this company a strong investment.\nKey Points\n\nCompanies with regularly recurring revenue have an easier time posting consistent revenue growth....</p>\n\n<a href=\"https://www.fool.com/investing/2021/09/09/this-robotics-growth-stock-could-turn-1000-into-40/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ISRG":"直觉外科公司"},"source_url":"https://www.fool.com/investing/2021/09/09/this-robotics-growth-stock-could-turn-1000-into-40/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2166312201","content_text":"Doing business as usual will be more than enough to make this company a strong investment.\nKey Points\n\nCompanies with regularly recurring revenue have an easier time posting consistent revenue growth.\nMaking products that are platforms for complex tasks is one way to build a recurring revenue base.\nSurgical robots are likely to be in demand in the coming years, just like they have been for the past decade.\n\nYou've probably heard that robots are the future for everything from manufacturing to retail distribution. But have you ever considered that they might be lucrative investments in the present?\nIntuitive Surgical(NASDAQ:ISRG) sits at the intersection of high-tech robotics and healthcare, and that's one of the many reasons why it's an exciting growth stock. Still, with a market cap in excess of $123 billion, investors are right to be skeptical about the stock's prospects for triple-digit percentage growth. Could Intuitive Surgical be a powerhouse for your portfolio with a relatively small initial investment, or is this stock's growth story approaching stagnation? Let's investigate by taking a look at its business model to start.\n\nImage source: Getty Images.\nBig growth is more than feasible\nOverall, Intuitive Surgical is primed to experience consistent and significant growth because of how it makes its income.\nIn case you aren't familiar, its main product is the da Vinci line of robotic surgical suites, which surgeons control from a station in the operating room. It also sells maintenance contracts and an ever-increasing selection of robotic surgical tools to use in conjunction with its da Vinci units. In total, these three product categories made the company $5.16 billion in trailing revenue, 77% of which is recurring.\nFor investors seeking growth stocks, there's nothing sweeter than a rock-solid revenue base. Importantly, there are a few different things that contribute to Intuitive's aggressive expansion of that base.\nThe most obvious is sales of its surgical suites, but that's just the start. Once a hospital has purchased a da Vinci unit and trained its surgeons, it's safe to say that it won't be buying a similar unit from competitors.\nSo, when Intuitive develops new surgical tools to expand the range of procedures performable with the robot, existing customers are highly likely to be interested in expanding the capabilities of the platform they own. Likewise, the more a hospital utilizes its surgical robotics, the more it'll need maintenance and a steady supply of replacement parts.\nAll of the above means that each newly installed surgical suite will render a significant amount of revenue over its lifetime, and the company is constantly installing more with each quarter. In the second quarter of 2021, there were 10% more da Vinci systems installed globally than in Q2 of 2020. Assuming that the business will continue to deploy its products at a similar rate, it'll have a massive pool of future sales opportunities to draw from over the next decade.\nBut will it make investors richer?\nI'm of the view that Intuitive's stock will multiply in value well before 2029.\nOver the next seven years, a $1,000 investment made today could grow to reach $4,000 in value if the stock expands with a compound annual growth rate (CAGR) of 21.9%. Let's take a closer look at why the stock is likely to grow by at least that much on an annual basis for the next few years.\nFirst, Intuitive's stock has been rising rapidly at an even faster rate over the past seven years. Since August 2014, the stock has grown by 567.5%, giving it a CAGR of about 31.5%. While skeptics might argue that the such a strong performance is unlikely to be repeated on a consistent basis, there is little evidence to suggest that growth is slowing.\nEven when including for the sharp drop in income and earnings that occurred when hospitals stopped performing elective surgeries during the first peak of the pandemic, the past three years have seen the company's quarterly revenue rise by nearly 59%, with quarterly earnings before interest, taxes, depreciation, and amortization (EBITDA) increasing by just over 70% in the same period. Likewise, its quarterly free cash flow (FCF) has grown by slightly more than 84% in the last five years, so its financial strength has been steadily increasing over time.\n\nISRG Revenue (Quarterly) data by YCharts\nThus, Intuitive doesn't need to change its business model or optimize its operations to keep expanding. And that means its prospects for being a winning growth stock are secure.\nWhen's the right time to buy?\nIn my view, there's little doubt that this stock could juice a $1,000 investment today into $4,000 over the next seven years, even if growth does end up slowing slightly. Still, there remains the question of when to make a purchase.\nGiven the company's ongoing efforts to develop new surgical tools, expand its portfolio of eligible procedures, and deploy more machines internationally, there's a smattering of catalysts for Intuitive's stock between now and 2029. At the same time, there's little chance of a competitor stealing revenue from accessory sales and maintenance for the established base of installed systems.\nSo, there isn't much to hold investors back from buying the stock today.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5806265,"gmtCreate":1631188956343,"gmtModify":1663233615327,"authorId":3581585794734271,"author":{"id":3581585794734271,"authorId":3581585794734271,"name":"thuiching","avatar":"https://static.tigerbbs.com/9dc8e63d946079f8f710c092c90f6aa4","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":883017873,"type":1,"supId":0,"prevId":0,"content":"[微笑]","text":"[微笑]","html":"[微笑]"}],"langContent":"EN"},{"id":883014211,"gmtCreate":1631188710533,"gmtModify":1676530491271,"author":{"id":"3561534918172425","authorId":"3561534918172425","name":"Jrrr92","avatar":"https://static.tigerbbs.com/3713f77c17599af04b8943281769ec65","vip":1,"crmLevel":5,"crmLevelSwitch":0},"htmlText":"Good","listText":"Good","text":"Good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/883014211","repostId":2166312201,"repostType":4,"repost":{"id":"2166312201","pubTimestamp":1631187660,"share":"https://www.laohu8.com/m/news/2166312201?lang=&edition=full","pubTime":"2021-09-09 19:41","market":"us","language":"en","title":"This Robotics Growth Stock Could Turn $1,000 Into $4,000 by 2029","url":"https://stock-news.laohu8.com/highlight/detail?id=2166312201","media":"Motley Fool","summary":"Doing business as usual will be more than enough to make this company a strong investment.","content":"<p>Doing business as usual will be more than enough to make this company a strong investment.</p>\n<p><b>Key Points</b></p>\n<ul>\n <li>Companies with regularly recurring revenue have an easier time posting consistent revenue growth.</li>\n <li>Making products that are platforms for complex tasks is one way to build a recurring revenue base.</li>\n <li>Surgical robots are likely to be in demand in the coming years, just like they have been for the past decade.</li>\n</ul>\n<p>You've probably heard that robots are the future for everything from manufacturing to retail distribution. But have you ever considered that they might be lucrative investments in the present?</p>\n<p><b>Intuitive Surgical</b>(NASDAQ:ISRG) sits at the intersection of high-tech robotics and healthcare, and that's <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the many reasons why it's an exciting growth stock. Still, with a market cap in excess of $123 billion, investors are right to be skeptical about the stock's prospects for triple-digit percentage growth. Could Intuitive Surgical be a powerhouse for your portfolio with a relatively small initial investment, or is this stock's growth story approaching stagnation? Let's investigate by taking a look at its business model to start.</p>\n<p><img src=\"https://static.tigerbbs.com/a92230e2013b2ec95bc9649c43631081\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"></p>\n<p>Image source: Getty Images.</p>\n<p><b>Big growth is more than feasible</b></p>\n<p>Overall, Intuitive Surgical is primed to experience consistent and significant growth because of how it makes its income.</p>\n<p>In case you aren't familiar, its main product is the da Vinci line of robotic surgical suites, which surgeons control from a station in the operating room. It also sells maintenance contracts and an ever-increasing selection of robotic surgical tools to use in conjunction with its da Vinci units. In total, these three product categories made the company $5.16 billion in trailing revenue, 77% of which is recurring.</p>\n<p>For investors seeking growth stocks, there's nothing sweeter than a rock-solid revenue base. Importantly, there are a few different things that contribute to Intuitive's aggressive expansion of that base.</p>\n<p>The most obvious is sales of its surgical suites, but that's just the start. Once a hospital has purchased a da Vinci unit and trained its surgeons, it's safe to say that it won't be buying a similar unit from competitors.</p>\n<p>So, when Intuitive develops new surgical tools to expand the range of procedures performable with the robot, existing customers are highly likely to be interested in expanding the capabilities of the platform they own. Likewise, the more a hospital utilizes its surgical robotics, the more it'll need maintenance and a steady supply of replacement parts.</p>\n<p>All of the above means that each newly installed surgical suite will render a significant amount of revenue over its lifetime, and the company is constantly installing more with each quarter. In the second quarter of 2021, there were 10% more da Vinci systems installed globally than in Q2 of 2020. Assuming that the business will continue to deploy its products at a similar rate, it'll have a massive pool of future sales opportunities to draw from over the next decade.</p>\n<p><b>But will it make investors richer?</b></p>\n<p>I'm of the view that Intuitive's stock will multiply in value well before 2029.</p>\n<p>Over the next seven years, a $1,000 investment made today could grow to reach $4,000 in value if the stock expands with a compound annual growth rate (CAGR) of 21.9%. Let's take a closer look at why the stock is likely to grow by at least that much on an annual basis for the next few years.</p>\n<p>First, Intuitive's stock has been rising rapidly at an even faster rate over the past seven years. Since August 2014, the stock has grown by 567.5%, giving it a CAGR of about 31.5%. While skeptics might argue that the such a strong performance is unlikely to be repeated on a consistent basis, there is little evidence to suggest that growth is slowing.</p>\n<p>Even when including for the sharp drop in income and earnings that occurred when hospitals stopped performing elective surgeries during the first peak of the pandemic, the past three years have seen the company's quarterly revenue rise by nearly 59%, with quarterly earnings before interest, taxes, depreciation, and amortization (EBITDA) increasing by just over 70% in the same period. Likewise, its quarterly free cash flow (FCF) has grown by slightly more than 84% in the last five years, so its financial strength has been steadily increasing over time.</p>\n<p><img src=\"https://static.tigerbbs.com/23c1a7a479389e7ae5416faa90fb0002\" tg-width=\"720\" tg-height=\"387\" referrerpolicy=\"no-referrer\"></p>\n<p>ISRG Revenue (Quarterly) data by YCharts</p>\n<p>Thus, Intuitive doesn't need to change its business model or optimize its operations to keep expanding. And that means its prospects for being a winning growth stock are secure.</p>\n<p><b>When's the right time to buy?</b></p>\n<p>In my view, there's little doubt that this stock could juice a $1,000 investment today into $4,000 over the next seven years, even if growth does end up slowing slightly. Still, there remains the question of when to make a purchase.</p>\n<p>Given the company's ongoing efforts to develop new surgical tools, expand its portfolio of eligible procedures, and deploy more machines internationally, there's a smattering of catalysts for Intuitive's stock between now and 2029. At the same time, there's little chance of a competitor stealing revenue from accessory sales and maintenance for the established base of installed systems.</p>\n<p>So, there isn't much to hold investors back from buying the stock today.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>This Robotics Growth Stock Could Turn $1,000 Into $4,000 by 2029</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThis Robotics Growth Stock Could Turn $1,000 Into $4,000 by 2029\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-09-09 19:41 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/09/09/this-robotics-growth-stock-could-turn-1000-into-40/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Doing business as usual will be more than enough to make this company a strong investment.\nKey Points\n\nCompanies with regularly recurring revenue have an easier time posting consistent revenue growth....</p>\n\n<a href=\"https://www.fool.com/investing/2021/09/09/this-robotics-growth-stock-could-turn-1000-into-40/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ISRG":"直觉外科公司"},"source_url":"https://www.fool.com/investing/2021/09/09/this-robotics-growth-stock-could-turn-1000-into-40/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2166312201","content_text":"Doing business as usual will be more than enough to make this company a strong investment.\nKey Points\n\nCompanies with regularly recurring revenue have an easier time posting consistent revenue growth.\nMaking products that are platforms for complex tasks is one way to build a recurring revenue base.\nSurgical robots are likely to be in demand in the coming years, just like they have been for the past decade.\n\nYou've probably heard that robots are the future for everything from manufacturing to retail distribution. But have you ever considered that they might be lucrative investments in the present?\nIntuitive Surgical(NASDAQ:ISRG) sits at the intersection of high-tech robotics and healthcare, and that's one of the many reasons why it's an exciting growth stock. Still, with a market cap in excess of $123 billion, investors are right to be skeptical about the stock's prospects for triple-digit percentage growth. Could Intuitive Surgical be a powerhouse for your portfolio with a relatively small initial investment, or is this stock's growth story approaching stagnation? Let's investigate by taking a look at its business model to start.\n\nImage source: Getty Images.\nBig growth is more than feasible\nOverall, Intuitive Surgical is primed to experience consistent and significant growth because of how it makes its income.\nIn case you aren't familiar, its main product is the da Vinci line of robotic surgical suites, which surgeons control from a station in the operating room. It also sells maintenance contracts and an ever-increasing selection of robotic surgical tools to use in conjunction with its da Vinci units. In total, these three product categories made the company $5.16 billion in trailing revenue, 77% of which is recurring.\nFor investors seeking growth stocks, there's nothing sweeter than a rock-solid revenue base. Importantly, there are a few different things that contribute to Intuitive's aggressive expansion of that base.\nThe most obvious is sales of its surgical suites, but that's just the start. Once a hospital has purchased a da Vinci unit and trained its surgeons, it's safe to say that it won't be buying a similar unit from competitors.\nSo, when Intuitive develops new surgical tools to expand the range of procedures performable with the robot, existing customers are highly likely to be interested in expanding the capabilities of the platform they own. Likewise, the more a hospital utilizes its surgical robotics, the more it'll need maintenance and a steady supply of replacement parts.\nAll of the above means that each newly installed surgical suite will render a significant amount of revenue over its lifetime, and the company is constantly installing more with each quarter. In the second quarter of 2021, there were 10% more da Vinci systems installed globally than in Q2 of 2020. Assuming that the business will continue to deploy its products at a similar rate, it'll have a massive pool of future sales opportunities to draw from over the next decade.\nBut will it make investors richer?\nI'm of the view that Intuitive's stock will multiply in value well before 2029.\nOver the next seven years, a $1,000 investment made today could grow to reach $4,000 in value if the stock expands with a compound annual growth rate (CAGR) of 21.9%. Let's take a closer look at why the stock is likely to grow by at least that much on an annual basis for the next few years.\nFirst, Intuitive's stock has been rising rapidly at an even faster rate over the past seven years. Since August 2014, the stock has grown by 567.5%, giving it a CAGR of about 31.5%. While skeptics might argue that the such a strong performance is unlikely to be repeated on a consistent basis, there is little evidence to suggest that growth is slowing.\nEven when including for the sharp drop in income and earnings that occurred when hospitals stopped performing elective surgeries during the first peak of the pandemic, the past three years have seen the company's quarterly revenue rise by nearly 59%, with quarterly earnings before interest, taxes, depreciation, and amortization (EBITDA) increasing by just over 70% in the same period. Likewise, its quarterly free cash flow (FCF) has grown by slightly more than 84% in the last five years, so its financial strength has been steadily increasing over time.\n\nISRG Revenue (Quarterly) data by YCharts\nThus, Intuitive doesn't need to change its business model or optimize its operations to keep expanding. And that means its prospects for being a winning growth stock are secure.\nWhen's the right time to buy?\nIn my view, there's little doubt that this stock could juice a $1,000 investment today into $4,000 over the next seven years, even if growth does end up slowing slightly. Still, there remains the question of when to make a purchase.\nGiven the company's ongoing efforts to develop new surgical tools, expand its portfolio of eligible procedures, and deploy more machines internationally, there's a smattering of catalysts for Intuitive's stock between now and 2029. At the same time, there's little chance of a competitor stealing revenue from accessory sales and maintenance for the established base of installed systems.\nSo, there isn't much to hold investors back from buying the stock today.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5806209,"gmtCreate":1631188789243,"gmtModify":1663233617528,"authorId":3572053070508728,"author":{"id":3572053070508728,"authorId":3572053070508728,"name":"Darrs21","avatar":"https://static.tigerbbs.com/4369b2898eb8897a14eac55da66c4ba5","vip":1,"currentWearingBadge":{"badgeId":"7a9f168ff73447fe856ed6c938b61789-1","templateUuid":"7a9f168ff73447fe856ed6c938b61789","name":"Knowledgeable Investor","description":"Traded more than 10 stocks","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","individualDisplayEnabled":0,"individualDisplaySort":0,"categoryType":1102},"crmLevel":5,"crmLevelSwitch":1,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":883014211,"type":1,"supId":0,"prevId":0,"content":"<u>K</u>","text":"<u>K</u>","html":"<u>K</u>"}],"langContent":"EN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":68,"commentSize":28,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}